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Abstract 
Approximately 30% of elderly stroke survivors develop post-stroke dementia 
(PSD). The mechanisms underlying this cognitive decline following stroke are 
unclear. Vascular pathology is associated with the frontal lobe, damage to 
which may result in executive dysfunction; a common clinical outcome of PSD. 
Previous pathological studies in PSD subjects have found that pyramidal 
neurons in the CA1 region of the hippocampus were particularly vulnerable, 
with atrophy of these cells associated with cognitive impairment. In this study 
we test the hypothesis that similar changes in pyramidal neurons in the three 
prefrontal circuits which control executive function may be related to executive 
dysfunction. The three circuits are; the dorsolateral prefrontal cortex (dlPFC), 
anterior cingulate cortex (ACC) and the orbitofrontal cortex (OFC). 
Histological and immunohistochemical staining with three dimensional 
morphometric analysis and quantitative image analysis was carried out in fixed 
paraffin-embedded prefrontal brain sections from the MRC funded CogFAST 
study (a long-term prospective study designed to investigate delayed dementia 
after stroke) as well as frontal brain tissue from aged-matched controls and 
pathologically defined dementia groups: vascular dementia (VaD), Alzheimer’s 
disease (AD), and those with mixed Alzheimer’s disease and vascular dementia 
(mixed).  
Pyramidal neuron volumes were significantly reduced in PSD, VaD, mixed, and 
AD when compared to aged-controls and post-stroke non demented (PSND) 
subjects in layer III, with layer V following a similar pattern. The neuronal 
changes in PSD correlated with global and executive function scores and were 
associated with markers for mitochondrial function, though did not correlate with 
tau or amyloid burden. Neuronal volumes in the ACC and the OFC did not 
significantly vary between groups; however pyramidal neurons within the OFC 
were significantly smaller in all groups (controls and disease) when compared to 
controls in dlPFC and ACC. There were no significant changes in pyramidal 
neuron densities between PSND and PSD in any of the three frontal regions. 
Analysis of the interneuronal densities revealed no significant differences 
between inhibitory neurons in PSND and PSD subjects. Pyramidal neuron 
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volume changes did not appear to be associated with white matter (WM) 
pathology in post-stroke subjects. These findings suggest that pyramidal 
neuronal volume loss in the dlPFC is associated with cognitive decline in post-
stroke and ageing-related dementia.  
The lack of relationship between AD type pathology, WM pathology, or 
interneuronal changes suggests dysfunction of the pyramidal neurons in the 
dlPFC play an important role in the development of executive dysfunction in 
PSD. 
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Chapter 1. Introduction 
 Normal ageing and dementia 
Over 35 million people worldwide are living with dementia at an estimated cost 
of $604billion per year (Wimo et al. 2013) putting  a significant strain on the 
economy (Leal et al. 2006). With older age as the single most significant risk 
factor for developing dementia, an ageing population is only set to exacerbate 
the problem. Improved healthcare, wealth, and more sanitary living conditions 
indicate people are living longer and will add to the burden of dementia.  
Pathological features of dementia are acquired gradually during normal ageing. 
Neuronal loss, cortical atrophy, and white matter lesions all occur in individuals, 
who do not appear cognitively impaired (Brockmann et al. 2013; Marner et al. 
2003; de Leeuw et al. 2001; Apaydin et al. 2002; Opris and Casanova 2014), 
with the hallmarks of specific neurodegenerative diseases such amyloid β and 
hyperphosphorylated tau, principal markers of AD, having been reported in 
abundance in otherwise healthy, cognitively normal adults. This suggests that 
the brain may have a threshold level which must be surpassed before the 
pathological burden or additional factors affect the cognitive status of 
individuals. Risk factors have also been reported in non-demented aged-
controls, such as reduced cerebral blood flow, vascular basement membrane 
thickening, amyloid deposits on vasculature, and impairment of the blood brain 
barrier (BBB) (Farkas and Luiten 2001; Chen et al. 2011; Kalaria 1996). Some 
of these vascular changes are consistent with the presence of white matter 
changes identified as white matter hyperintensities (WMH) on T2-weighted  MRI 
imaging techniques, with up to 100% of those ages 71-80 years of age showing 
some degree of change  (Christiansen et al. 1994; de Leeuw et al. 2001). In 
addition to vascular pathology, it is not uncommon for cognitively normal elderly 
healthy individuals to display some form of Alzheimer type pathology with no 
apparent accompanying cognitive dysfunction (Braak and Braak 1991). Indeed 
Snowdon et al (Snowdon et al. 1997) found that 40% of those exhibiting 
Alzheimer pathology above the threshold required for disease diagnosis, 
remained cognitive intact.  
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 Cognitive reserve hypothesis 
One reason for the mismatch between clinical diagnosis and pathological brain 
changes has been attributed to individual cognitive reserves (Barulli and Stern 
2013). This theory suggests that individuals may be equally vulnerable to 
pathological damage but, some may have an increased brain reserve to hold off 
dementia (Stern et al. 1994). If an individual dies before their respective 
pathology reaches the reserve threshold then they will remain cognitively intact. 
However, it is difficult to measure one’s cognitive reserve in order to test this 
theory. Whether this theory plays a role in ageing or not, it is not surprising that 
elderly individuals with several comorbidities i.e. more than one risk factor, 
succumb to dementia due to the combined stress that such pathologies will 
place on any hypothetical cognitive reserve (Allan et al. 2011) .  
 Ageing and stroke  
The risk of stroke increases greatly with age (Pendlebury and Rothwell 2009; E. 
J. Burton et al. 2004) with one third of ischaemic stroke sufferers over the age 
of 80 (Ly and Maquet 2014), and the Framingham study reporting a 1 in 6 
lifetime risk of suffering a stroke (Seshadri et al. 2006). Ischaemic stroke is 
responsible for two thirds of morbidity and mortality which results from stroke 
(Ly and Maquet 2014), accounting for 10-12% of deaths in industrialised 
countries with around 88% attributed to those over 88 years of age (Bonita 
1992). Indeed this trend appears to be increasing with the prevalence of stroke 
in over 75-year olds rising form 9% to 13% between 1994, and 2006 
(Scarborough et al. 2009). 
Around 80% of strokes are ischaemic and almost all are caused by some type 
of arterial occlusion, resulting in a reduced flow of blood, nutrients, and oxygen 
(Kalaria and Ballard 2001). The sudden lack of oxygen and nutrients leads to 
neuronal death, in the affected area, through a combination of hypoxia, 
hypoglycemia, and glutamate excitotoxicity (Larsen et al. 2006), as part of the 
ischemic stroke cascade which can continue for a long time after the initial 
stroke has resolved itself (Dirnagl et al. 1999). Due to this oxidative damage 
mitochondria within the cell begin to break down and release apoptotic factors, 
which result in cell death (Sanchez-Gomez et al. 2003). Though this series of 
events can occur in all tissue deprived of oxygen, neurons are also susceptible 
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to hypoxia due to their high metabolic turnover (Magistretti 2006; Magistretti and 
Pellerin 1999).  
The infarct area resulting from an ischaemic stroke consists of a central core, 
which may involve the cortex and/or the WM, of complete infarction which is 
devoid of functioning components such as neurons, axons, and 
oligodendrocytes. Surrounding the core is the hypo-perfused penumbra region. 
This area may in time recover some function as the vasculature recovers 
(Nedergaard and Dirnagl 2005). Focal ischaemia, as that seen in the ocular 
occlusions present in stroke tend to result in death for all cells at the epicenter 
of the infarct with both neurons and glial cells equally affected. In the penumbra 
cells may be metabolically active, but do not appear mechanistically capable of 
sending out electrical signals (Nedergaard and Dirnagl 2005). The fate of these 
neurons and glial cells may decide whether an individual recovers from a stroke 
or declines into delayed post-stroke dementia. However, once blood flow has 
been restored there may be a period of stability before the stroke subject begins 
to develop cognitive dysfunction (Leys et al. 2005). 
 
 Stroke and dementia 
Post-stroke dementia (PSD) is defined as any type of dementia occurring after 
stroke, regardless of the underlying pathological cause, including VaD and AD 
(Leys et al. 2005). It has been estimated that 20% of those over the age of 65 
will suffer a stroke, incidentally resulting in a nine-fold increase in the risk of 
dementia when compared to those who have not suffered a stroke (Kalaria and 
Ballard 2001), with Savva et al’s (Savva et al. 2010) systematic review of 
sixteen post-stroke epidemiological studies concluding that a history of stroke 
doubles the risk of dementia in an older population. The risk of cognitive decline 
after stroke also increases with age (Moroney and Desmond 1997). Delayed 
cognitive decline, developing a minimum of 3 months post-stroke, has been 
reported in 35.2% of post-stroke patients compared to 3.8% incidence in 
controls (Tatemichi et al. 1994) with around 30% of PSD cases show mixed 
CVD and AD type pathology (Pohjasvaara et al. 1998) and around 10% 
displaying some form of dementia before first stroke (Pendlebury and Rothwell 
2009). Though PSD does not necessarily have to be vascular based (Leys et al. 
2005), vascular risk factors have been cited to increase risk for dementia after 
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stroke, with the presence of microscopic infarcts contributing to dementia 
(Pascual et al. 2010; Firbank et al. 2012; E. Burton et al. 2003) and silent 
infarcts having been shown to be independent predictors for developing PSD 
(Desmond et al. 2000; Henon et al. 2001; Tatemichi 1990). Those who go on to 
develop dementia have an increased risk of further stroke, suggesting a 
relationship between the development of dementia and an underlying CVD 
(Moroney et al. 1997). The importance of stroke alone in the development of 
PSD has been highlighted. The size, number, and location of lesions appeared 
to be more significant than the underlying vascular risk factors. Strategic 
infarcts, i.e. stroke locations which result in dementia regardless of any other 
lesion or factor (Leys et al. 2005) are associated with PSD. The inferomesial 
temporal and mesial frontal locations have been suggested as sites where 
infarcts may result in significant cognitive decline (Leys et al. 2005). Leys et al 
suggest that vascular lesions have a more prominent role in the development of 
PSD when a patient is too young to have developed the conventional hallmarks 
of Alzheimer pathology (Pasquier and Leys 1997). In addition, a number of non-
stroke based risk factors were also identified including low education 
attainment, race, diabetes, medial and temporal lobe atrophy, arterial fibrillation, 
and leukoaraiosis (Pendlebury and Rothwell 2009). In addition, milder forms of 
cognitive impairment also exist following stroke, with reports of executive 
function and attention deficits apparent in stroke survivors without cognitive 
impairment (Stephens et al. 2004). 
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Figure 1-1 showing the hypothetical model of the ultimate effects of sustained vascular influecnes 
during ageing that lead to AD type changes, CAA, and VaD. AD = Alzheimer’s disease, CAA = 
cerebral amyloid angiopathy, and VaD = vascular dementia adapted from (Kalaria 2002; Roman 
2002a). Images adapted from (Okamoto et al. 2012; Gamblin et al. 2003; Johnson et al. 2012) 
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 Cerebral Atrophy, metabolism, and stroke 
Subjects with global cerebral atrophy are at increased risk for the development 
of post-stroke dementia (Leys et al. 2005), with medial temporal atrophy most 
common in those suffering dementia previous to stroke. The presence of medial 
temporal atrophy in those with PSD may suggest pre-clinical AD which is 
exacerbated or exposed by the stroke (Tang et al. 2004), though medial 
temporal atrophy has been noted in vascular dementia (VaD) (Jobst et al. 1998; 
Laakso et al. 1996; Fein et al. 2000). Elderly stroke sufferers who remain 
dementia free but have temporal atrophy develop slower mental speeds and 
visuospatial tasks. Executive function remained intact in these cases, 
suggesting no involvement of the frontal lobes (Leys et al. 1998; Henon, 
Godefroy, et al. 1996). Glucose metabolism was shown to decrease in the 
frontal lobe in cases with suspected vascular pathology (Haight et al. 2013) and 
the  temporal lobes of those suffering AD suggesting decreased neuronal 
function in areas shown to exhibit atrophy (Pascual et al. 2010; Jagust et al. 
1991). 
 Dementia and cerebrovascular disease (CVD) 
Cerebrovascular disease (CVD) plays an important role in the development of 
dementia with the risk of CVD increasing with age in association with cognitive 
decline (Kalaria and Ballard 2001). The brain accounts for around 2% of the 
body mass, yet requires over 20% of the body’s total blood and oxygen (Kalaria 
2010). This makes the brain extremely vulnerable to changes in the vasculature 
which could affect this supply. Mounting evidence from pathological, 
neuroimaging and clinical studies indicates a strong link between CVD and the 
onset of VaD. VaD is the second most common form of age-related dementia, 
accounting for between 36% and 67% of cases (Roman 2002a). This vascular 
pathology results in ischaemic damage and hypoperfusion which acts to deprive 
neurons and glial cells of oxygen and trophic factors, resulting in their damage 
or death (Zlokovic 2011; Majno and Joris 1995; Dirnagl et al. 1999; Nedergaard 
and Dirnagl 2005). Clinical features can develop insidiously over a period of 
years with pathology either developing as cognitive impairment in later in life or 
detected at autopsy, so any long standing changes may mask the original 
underlying causes (Farrall and Wardlaw 2009), or can appear as a sudden 
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stepwise decline as a result of more severe infarcts having an instant impact of 
cognition (Roman et al. 2002).   
 Large and small vessel disease 
Cerebrovascular disease can be conveniently grouped into two distinct 
categories: Large vessel disease (LVD) and small vessel disease (SVD) 
(Kalaria 2012).  
 Large vessel disease  
LVD involves the major arteries feeding the brain such as the carotid or the 
circle of Willis. These large vessels can be affected by atherosclerosis, 
haemorrhage, thrombotic occlusion, and embolism (up to 50% of ischaemic 
strokes) which lead to blockage of major arterial territories causing large 
macroinfarcts which are visible upon gross inspection of the brain  (Kalaria 
2012; Kalaria et al. 2004). LVD can result in large volumes of tissue loss, 
associated with high mortality death, and/or cognitive impairment (Nedergaard 
and Dirnagl 2005) as a result of delayed neuronal death. In addition, blockage 
of the internal carotid and/or circle of Willis can also lead to multi-infarct 
dementia, accounting for 15% of VaD cases (Brun 1994)  
 Small vessel disease  
Pathological changes in small vessels are thought to lead to decreases in blood 
flow, microinfarcts and diffuse white matter changes, which have been identified 
as substrates for cognitive impairment. The frontal lobe is more vulnerable to 
vascular pathology and SVD than the temporal (E. Burton et al. 2003; 
Deramecourt et al. 2012). Severe SVD can result in vascular dementia (VaD) 
(Jellinger 2013). SVD may result in a more insidious, progressing pathology 
than the step-wise decline associated with large vessel infarcts/strokes, in 
which each new event results in a marked decrease in cognitive faculties 
(Kalaria et al. 2004). The most common lesions associated with SVD are vessel 
wall modifications, such as arteriolosclerosis and CAA, with the frontal lobe 
more heavily affected (Deramecourt et al. 2012). These pathologies are thought 
to promote replacement of the vascular smooth muscle with collagen reducing 
the structural integrity of the vessel that are causal in lacunar and micro infarcts 
[lesions under 2cm (Kalaria 2012)]. Arteriolosclerosis is the result of hyalinosis 
and degradation of smooth muscle cells, followed by the continuing concentric 
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accumulation of collagen and fibroblasts and ultimately a decrease of the vessel 
lumen. This decreased lumen may result in restricted blood flow, creating a 
chronic ischaemic environment in the surrounding tissue. This occurs most 
commonly in the small vessels of the WM as well as cortical grey matter 
(Craggs et al. 2013; Lammie 2000). Craggs et al reported an increase in the 
sclerotic index of vessels of deep and cortical WM in cases with SVD and 
CADASIL (a condition characterised by SVD) when compared to cognitively 
normal controls (Craggs et al. 2013). These changes affect the ability of the 
vessel to dilate and contract resulting in potential haemodynamic irregularity 
and loss of auto-regulation through disruption of the perivascular nerve plexi 
(Craggs et al. 2013; Kalaria 2010), and may lead to subsequent pathologies 
such as microinfarcts detectable at MRI (E. Burton et al. 2003; E. J. Burton et 
al. 2004; Firbank et al. 2012). 
Microinfarcts (a minuscule area of necrosis resulting from sudden insufficiency 
of arterial or venous blood supply) are found in both cortical and subcortical 
regions, most probably signifying underlying microvascular pathology. 
Microinfarcts are associated with cognitive impairment and their presence 
predicts a poor outcome in elderly individuals with CVD independent of 
Alzheimer’s pathology (Vinters et al. 2000; Ballard et al. 2000; Kalaria et al. 
2004). Another outcome of an occlusion are lacunar infarcts which are 
indicative of severe ischaemic damage resulting in a small area of necrosis 
leaving behind a cavity (lacuna). Combined, microinfarcts and lacunar infarcts 
are associated with over 50% of VaD cases (Esiri et al. 1999; Kalaria et al. 
2004). Strategic infarcts refer to perfusion loss in a specific, cognitively 
important area of the brain, which may result in severe cognitive impairment 
relative to a similar sized infarct affecting a less critical part of the brain as 
mentioned earlier (Roman 2002b). 
 Neuroimaging studies 
Neuroimaging studies have correlated changes in the white matter with 
cognitive dysfunction. Additionally frontal lesions have been associated with 
executive dysfunction (E. Burton et al. 2003). White matter hyperintensities 
(WMH) on T2 weighted MRI have long been associated as a pathological 
substrate of SVD and VaD (Kalaria and Ballard 1999; Tang et al. 2004; O'Brien 
et al. 2003) with WMH more prominent in the frontal lobe. The inefficient 
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vasculature leading to a chronic hypoxic state is thought to result in a loss of 
myelin and damage to the axonal tracts forming the cortico-cortico and cortico-
subcortical connections within the brain (Kalaria and Ihara 2013). This hypoxic 
state is also thought to damage oligodendrocytes, cells which are responsible 
for repairing the myelin sheath. These cells are activated after mild to moderate 
ischaemic injury, however the prolonged hypoxic state is thought to lead to 
damage of the oligodendrocyte’s precursor cells which no longer retain he 
ability to compensate for the myelin loss resulting in long term WM damage 
(Ihara et al. 2010).  
 The blood brain barrier 
Gradual damage to the cerebral endothelium, which makes up the blood brain 
barrier (BBB) as a result of small vessel pathology may compromise the 
protective nature of the network of capillaries. The BBB plays a key role in the 
neurovascular unit and helps maintain an optimal environment for neurons and 
other cells to function. Breakdown of the vessel walls may result in the 
unregulated movement of macromolecules and fluid across the barrier into the 
brain with several studies linking the breakdown of the BBB to the development 
of cognitive impairment (Alafuzoff et al. 1983; Elovaara et al. 1987; Blennow et 
al. 1995; Wada 1998) with VaD suffers more affected than those of AD 
suggesting a vascular link to cognitive decline. This is further supported by the 
correlation between WML and BBB permeability (Skoog et al. 1998; Wardlaw et 
al. 2003; Farrall and Wardlaw 2009). However, BBB dysfunction has been 
linked to amyloid levels in the cerebral spinal fluid, with those developing 
dementia having a higher CSF to serum albumin ratio than those without 
(Skoog et al. 1998; Blennow et al. 1990; Hampel et al. 1995). These studies 
suggest BBB dysfunction may be associated with both AD and VaD in elderly 
demented subjects, suggesting reduced selectivity of the permeability of the 
BBB. This increased permeability may result in increased flow of potentially 
harmful substrate entering the brain, disrupting neurons and other cells. The 
increase in CSF amyloid may signal the beginnings of the much-heralded 
amyloid cascade (Kalaria 2010; J. A. Hardy and Higgins 1992). 
 Cerebral amyloid Angiopathy 
The insidious buildup of amyloid β (Aβ) (a protein associated with AD and 
ageing) in the vessel walls is known as cerebral amyloid angiopathy (CAA) 
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(Grinberg and Thal 2010; Attems et al. 2011). Amyloid is transported through 
the perivascular space as a clearance mechanism. A breakdown in this 
mechanism may result in a buildup of Aβ-40, and to a lesser extent 42, within 
the vessels basement membrane causing CAA (Weller et al. 2009; Kalaria 
1992). The accumulation of Aβ within the vasculature may lead to degeneration 
of the vessel wall, lowering perfusion and resulting in micro infarctions and 
haemorrhage (Kalimo et al. 2002; Knudsen et al. 2001). 
 
 Alzheimer’s disease (AD) 
AD is the most common form of dementia, affecting around 10% of the 
population over the age of 75 (Jellinger 2002; Jorm and Jolley 1998). Clinically, 
AD is characterised by short term memory loss, impairments to spatial memory, 
which continue to deteriorate as the  disease progresses (Thind and Sabbagh 
2007). Memory loss results in pathology localized in the medial temporal, 
hippocampal areas. As the disease advances, involvement of the frontal lobes 
(Braak and Braak 1991) can result in executive dysfunction (Braak and Braak 
1996; Braak et al. 1998; Braak and Braak 1998). At post-mortem the major 
pathological hallmarks of AD are amyloid-beta (Aβ) plaques, neurofibrillary 
tangles (NFTs), neuropil threads, and neuritic plaques (Braak and Braak 1991; 
Khachaturian 1985; J. A. Hardy and Higgins 1992). 
One of the primary features of AD are extracellular cortical amyloid β plagues 
(Aβ), formed mainly of cortical Aβ42 (Montine et al. 2012) and to a lesser extent 
Aβ40 peptides. Amyloid β formed by the cleavage of APP by proteolytic 
enzymes α, β, and γ secretase. However Aβ-40 and 42 are more likely to be 
formed when APP is cleaved by the β or the γ secretases at (Donmez et al. 
2010). It has been shown that increasing the activation of ADAM 10, the gene 
encoding alpha secretase, can reduce the level of Aβ produced due to 
alternative cleavage of the APP (Donmez et al. 2010). In addition, mutations 
within presenilin 1 and 2, a sub-protein of γ-secretase have been associated 
with increased amyloid production in familial AD (J. Hardy 1997). Age-related 
vascular pathology is thought to contribute the decrease in clearance of amyloid 
β (Kalaria 2010) resulting aggregation of the proteins, developing originally in 
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the neocortex and hippocampus before spreading to other areas of the brain in 
a well characterized manner as the disease progresses (Thal et al. 2002).   
Several gene mutations have been associated with the production of amyloid. It 
has been shown that mutations within the gene coding for presenilin, part of the 
γ-secretase complex, are correlated with increased Aβ42 production, whilst 
specific mutations in the APP gene itself have been found to aid the subsequent 
folding capabilities of the Aβ peptides produced through its cleavage. Though 
these mutations point towards a strong argument for the role of amyloid in AD it 
must be stated that familial cases of AD, such as those which present with 
mutations, represent only around 0.1% of all AD cases (Ertekin-Taner 2010). 
The majority of AD sufferers belong to a group known as sporadic AD. Whilst a 
range of specific gene mutations and SNPs have been reported in studies such 
as GWAS (Ertekin-Taner 2010) by far the most important risk factor in 
developing AD is age, though there exists a range of factors which may 
predispose an individual to developing AD.  
Apolipoprotein (APO) E is a class of apolipoprotein essential for the catabolism 
of triglyceride rich lipoproteins. ApoE exists in 3 isoforms: Apo E2, E3, and E4. 
Those expressing one or two alleles of the apolipoprotein epsilon 4 have a 
significantly increased risk of developing AD (Walter 2012; Kalaria 2002), 
however, this is not a prerequisite for developing AD as 40% of AD suffers do 
not possess the APOE ε4 allele at all.   
The second neuropathological hallmark of AD is the presence of intracellular 
neurofibrillary tangles (NFTs) which consist of large entanglements of 
hyperphosphorylated tau protein (Goedert 1996; Alonso et al. 2008). Under 
normal conditions tau is a soluble microtubule-associated protein, with its role in 
stabilising the structure of cells, primarily aiding the stability of axonal 
microtubules. As part of its role all tau within a system is in a continuous flux 
between phosphorylation and non-phosphorylation (Iqbal et al. 2010; Alonso et 
al. 2008). In AD the tau protein becomes hyperphosphorylated leading to the 
formation of neurofibrillary tangles consisting of paired and single filaments 
within individual neurons. These large tangles are thought to either possess 
neurotoxic (gain-of-function) properties, damaging the neuron from within, or 
mechanistically disrupting the neuron by physically taking up large amount of 
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internal space (Mandelkow and Mandelkow 1998). Tau may also interact with 
amyloid in the form of neuritic plaques, Aβ plaques surrounded by degenerating 
axons and dendrites containing hyperphosphorylated tau (Nelson et al. 2012; 
Montine et al. 2012).  
The amyloid cascade hypothesis, a theory tying the two pathologies together, 
places amyloid burden at the core of AD progression, leading to NFT formation, 
has been a key focus for research (J. A. Hardy and Higgins 1992; Lamb 1997; 
Joseph et al. 2001). However, support for the theory is slowly beginning to 
wane. Braak et al showed that severity of clinical AD did not correlate with the 
amyloid pathology seen at post-mortem with high amyloid pathology also being 
reported in the brains of cognitively normal elderly individuals. The relationship 
between amyloid and tau has also been questioned, with each pathological 
substrate progressing differently (Ohm et al. 1995; Braak and Braak 1991).  
CAA as mentioned previously is associated with up to 98% of AD patients 
(Jellinger 2002). Affected vessels present with thickened walls, with some 
presenting with microaneurysms and fibroid necrosis (Masson et al. 2000; 
Jellinger 2002). It is believed to be produced by the smooth muscle cells, which 
synthesis Aβ-40 intracellulary. This protein then aggregates extracellularly into 
fibrils which result degeneration of the smooth muscle cell. This degeneration 
results in haemodyamic changes and rupturing of the blood vessels (Coria and 
Rubio 1996; Alonzo et al. 1998). 
AD is also associated with reduced cholinergic neurotransmission, nicotinic 
acetylcholine receptors, and synaptic loss (Masliah 1995, 1998; Maelicke 2001; 
Crow et al. 1984; E. K. Perry et al. 1981), and cortical, ventricular, and white 
matter atrophy (Firbank et al. 2007; E. Burton et al. 2003; Chan et al. 2001). 
Neuronal or synaptic loss is thought to be the ultimate cause of the cognitive 
decline in AD though it is uncertain whether plaques and/or tangles are the 
cause of this loss or are just a by-product of an underlying pathology, such as 
CVD (Breteler 2000; Mann et al. 1988; Skoog et al. 1999; Maelicke 2001) . 
Primarily, research into preventative treatments for AD has focused on Aβ 
aggregate clearance mechanisms. However, attempts to develop suitable 
treatment against Aβ accumulation have been unsuccessful (Karran et al. 
2011). Treatments focused on alleviating the symptoms of AD have been 
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relatively more successful. Current drugs target the cholinergic and 
glutamatergic neurotransmission pathways, which have been shown to improve 
symptoms, though the neuroprotective role of such interventions is debatable 
(Mangialasche et al. 2010; Takeda et al. 2006; Bullock 2002). It is possible that 
current drug targets for the treatment of AD are focused on the end product of 
the disease and that in order to prevent disease progression, earlier 
interventions are needed. With this aim, early detection of AD may be helpful. 
Imaging with positron emission tomography (PET) with Pittsburgh Compound-B 
has linked amyloid β deposition with decreased glucose metabolism in the 
brain, providing a reliable imaging technique for detection of AD (Klunk et al. 
2004). Perhaps more promisingly, Mapstone et al have developed a method for 
detecting AD 2-3 years before symptoms appear by the analysis of blood-borne 
phospholipids as a biomarker (Mapstone et al. 2014). However, without current 
treatments the usefulness of such early detection remains limited. 
 
 Mixed dementia  
Mixed dementia is the diagnosis of two disease states both contributing to 
cognitive decline in an individual, in which the absence of one of the diseases 
would still result in dementia. The most common form of mixed dementia 
consists of AD and VaD (Kalaria and Ballard 1999). Indeed, 60-90% of those 
who exhibit clinical AD are found to have some form of CVD at post mortem 
(Kalaria 2002) and 60% of older patients with AD present with incomplete white 
matter infarctions (Roman et al. 2002) suggesting an underlying vascular 
component. 
Historically a clinical diagnosis of ‘pure’ VaD is only established in subjects with 
cerebrovascular pathology and dementia in the absence of other dementia type 
pathologies (Erkinjuntti 1994). However, neuropathological examination of 
those thought to be suffering from AD have shown extensive CVD pathology, 
which thought to dramatically exacerbate dementia symptoms (Kalaria and 
Ballard 1999; Kalaria 2002, 2010). It is now widely acknowledged that due to 
the overlap of the two pathologies that the number of mixed VaD/AD cases is 
hugely underestimated (Leys et al. 2005; Skoog et al. 1999; Kalaria and Ballard 
1999; Pascual et al. 2010). Additionally, a study conducted by Hulette et al 
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found the incidence of ‘pure’ VaD to be very uncommon (Hulette et al. 1997), 
with between 30-50% of mixed cases incorrectly diagnosed as VaD (Gold et al. 
1997). It has also been shown that AD pathology occurs more often in subjects 
with CVD than in a normal ageing population, with some VaD subjects bearing 
other AD pathology such as cholinergic neuronal deficits (Kalaria and Ballard 
1999) suggesting a shared aetiology between the two pathologies. Conversely, 
clinically diagnosed VaD subjects, at post-mortem, are frequently found to show 
AD type pathology (Kalaria 2002; Kalaria et al. 2004). Studies have also found 
amyloid accumulation around vessels correlating with hypoperfusion suggesting 
CVD may trigger AD type pathology (Sojkova et al. 2008; Huang et al. 2012). A 
causal link between AD pathology and VaD has been gleamed from Tg mouse 
studies. These studies suggest auto-regulation of the vasculature fails with 
amyloid accumulation, with vascular changes appearing in advance of 
neurodegeneration or Aβ deposits (Iadecola 2004). This interplay between CVD 
and AD pathologies is also evident in the number of risk factors shared between 
the two pathologies, including hypertension, atrial fibrillation, and coronary 
artery disease (Kalaria 2002; Gorelick 2004) which suggests a CVD link 
between the two diseases (Table 1-1). The Nun study, a continuing longitudinal 
study examining the onset of AD in a cohort of 678 Roman Catholics nuns, 
revealed that well characterised individuals who were clinically diagnosed with 
AD performed worse on cognitive tests when displaying higher volumes of 
lacunar infarcts, whilst presenting with fewer NFTs, suggesting synergistic 
involvement of vascular pathology in AD suffers (Snowdon et al. 1997). In 
addition to shared risk factors, stroke has been shown to aggravate AD 
pathology (Kalaria 2002; Kokmen et al. 1996; Henon, Durieu, et al. 1996), with 
the ischaemic event potentially exacerbating already underlying AD pathology 
(Kalaria 2002; Cumming and Brodtmann 2011). It has been suggested that 
reduced glucose metabolism, resulting in increased activation of the glycogen 
synthase kinase-3beta pathway, along with down regulation of the O-
GlcNAcylation may suggest a viable, vascular mechanism for the abnormal 
hyperphosphorylation of tau in AD and other naturopathies (Deng et al. 2009). 
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Table 1-1 showing the shared risk factors of AD and VaD. Adapted from (Kling et 
al. 2013; Gorelick 2004) 
Shared Risk factors between AD 
and VaD 
Age 
Low education 
Hypertension/hypotension 
Hypercholesterolaemia 
hyperhomocysteinaemia 
Hyperlipidaemia 
Carotid-artery wall thickness 
APOEe4 allele 
Diabetes mellitus 
Traumatic brain injury 
Smoking 
Obesity 
Stroke 
Atrial fibrillation 
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 The prefrontal cortex 
The prefrontal cortex contains three separate, yet interconnecting circuits 
responsible for specific aspects of memory, executive function, and social 
behaviour: the dorsolateral prefrontal cortex (dlPFC), the anterior cingulate 
cortex (ACC), and the orbitofrontal cortex (OFC) (Figure 1-4). Two other 
circuits: the motor circuit and the oculomotor circuit also make up the frontal 
cortex circuitry; though have little or no impact on executive functions (Tekin 
and Cummings 2002). These executive functions allow the organism to interact 
adaptively with environmental cues and stimuli. Each circuit takes its name from 
either its region of origin (i.e. the dorsolateral prefrontal cortex), or its primary 
function (i.e. motor circuit) (Lichter and Cummings 2001; Tekin and Cummings 
2002). 
Each of the three frontal circuits shares a similar cortico-subcortical framework, 
originating in the PFC before projecting to respective aspects of the striatum 
before reaching the globus pallidus and substantia nigra, pen-ultimately 
connecting to the thalamus before the circuit is completed by reverting back the 
PFC (Figure 1-2)(Tekin and Cummings 2002). Though several regions are 
shared between circuits the general connection remains separate throughout 
the majority of the circuit, a quality necessary for performance of individual 
processes and tasks. Much of what is known about the function of these circuits 
is through loss of function studies. 
 The prefrontal cortex and disease 
Essentially the role of each circuit is to connect the evolutionary younger 
prefrontal cortex with the more ancient subcortical areas such as the limbic 
system. These connections are crucial for working memory, processing for 
tasks and problem solving. By utilising the executive functionality of the PFC 
against the memories stored in the limbic system it allows for the brain to 
employ previous experiences against newer stimuli. Studies into the 
significance of lesions located in specific areas have helped elucidate the roles 
each of these circuits play. When measuring attention, working memory and 
visual processing functions via the Wisconsin Card shuffling test (WCST) 
patients with lesions in the dlPFC performed worse than those with lesions in 
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the OFC or indeed those with no lesions (Grafman et al. 1990) suggesting the 
dlPFC has a greater involvement in performing such tasks when compared to 
the OFC. Indeed several other studies have found deficits in WCST in dlPFC 
lesioned individuals compared to non-lesioned controls (Barcelo and Knight 
2002; Eslinger and Grattan 1993; Bornstein and Sigman 1986). When verbal 
dexterity is tested through use of the Phonemic Verbal Fluency test in which 
individuals must say as many words beginning with a given letter, or within a 
specific category as they can, it was found that those with frontal lobe lesions 
produced fewer words than those without (Bornstein and Sigman 1986; Butler 
et al. 1993), and those with lesions in the left frontal hemisphere performed 
worse still (Stuss et al. 1998; Baldo et al. 2001) revealing a lack of ability to 
utilise stored information in regards to a current task. A similar trend was found 
in individuals tested using the Stroop colour word interference test with those 
suffering left-side frontal lesions performing worse than controls or right-side 
lesion suffers (Perret 1974; Stuss et al. 2001).  
 Cortical architecture and pyramidal neurons 
Cortical grey matter is divided into different layers with each containing a 
specific subset and distribution of neurons, glia, and other cells (Mountcastle 
1997). The prefrontal cortex is divided into 6 layers with layer I (one) originating 
near the pial surface running through to VI adjacent to the WM. Though each 
area, the dlPFC, OFC, and ACC, maintains this basic layered structure, each 
region exhibits certain specificity, which must be taken into account when 
selecting areas for analysis (Khundakar et al. 2011b). The cytoarchitecture of 
the dlPFC is highly regimented, differentiated uniformly into the six layers of the 
granular isocortex. Conversely the OFC and ACC exhibit a more heterogeneous 
agranular limbic cortex, whilst still following the six-layered organization 
(Khundakar et al. 2011a; Khundakar et al. 2011c). 
Layer III and V, referred to as the external and internal pyramidal layers 
respectively, contain a very high proportion of pyramidal neurons in relation to 
other layers (Spruston 2008). Pyramidal neurons are responsible for long-range 
projections between cortices which are facilitated by their long axons. Pyramidal 
neurons are not all identical, varying between regions, but share several 
characteristics (Figure 1-2). Pyramidal neurons are relatively large, 
glutamatergic neurons, identifiable due to their distinctive pyramidal shape and 
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large apical dendrite extended towards the pial surface (Tekin and Cummings 
2002). The lone axon emanating from the base of the neurons has a high 
number of branches, making many excitatory, glutamatergic connections as it 
travels along its length (Spruston 2008). Projections originating from pyramidal 
neurons in layer III are thought to form intra-regional connections, whereas 
projections from layer V typically span further distances throughout the brain 
forming inter-cortical connection from the frontal cortices to other areas of the 
cortex as well as subcortical regions (Tekin and Cummings 2002; Khundakar et 
al. 2009). Some of these connections are thought to be bidirectional  allowing 
information and feedback to be shared between regions. Specifically, the ACC 
and the OFC have projections to the temporal lobe, with a series of intricate 
connections with the amygdala.  Ghashghaei et al reported modest connections 
between the amygdala and the lateral PFC suggesting minimum interaction 
between the two regions (Ghashghaei and Barbas 2002).  
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Figure 1-2 showing cortical neuronal connections within the PFC and subcortical 
areas of the brain. Neuronal connections of layer III largely project to areas within 
the PFC with few connections to subcortical brain regions in other areas of the 
circuit. Layer V contributes the majority of subcortical connections making up the 
circuit. Adapted from (Tekin and Cummings 2002)). 
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Figure 1-3 showing gross differences between layer III and layer V pyramidal neurons. Graphics 
adapted from Spruston et al (Spruston 2008). 
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 The prefrontal circuits 
 The dlPFC originates in Brodmann areas 9 and 46 (Figure 1-4) before 
projecting to the dorsolateral aspect of the caudate. It is involved mainly 
in executive function: the integration of processes such as working 
memory, problem solving and planning. Those suffering dysfunction of 
the dlPFC display impaired reasoning and lack mental flexibility. They 
lack the ability to maintain attention and appropriately focus on given 
tasks, being easily distracted, and requiring constant direction from 
examiners. They also demonstrated poor verbal fluency. The dlPFC 
appears to have modest connections with the limbic system  
(Ghashghaei and Barbas 2002). This executive dysfunction is a principle 
factor in dementias, in which subcortical circuits such as the dlPFC are 
thought to be affected. Additionally, those with lesions in the dlPFC 
struggle recalling long term memory based information for use in current 
tasks suggesting a dysfunctional link with the temporal lobe (Tekin and 
Cummings 2002).  
 The ACC, primarily located in Brodmann area 24, is notoriously 
heterogeneous with different aspects of the region commanding 
distinctively different roles (Gittins and Harrison 2011). The ACC 
concerns itself with the motivation of behaviour, with distinct lack of 
motivation being associated with dysfunction in this area. Indeed in some 
cases of bilateral lesioned individuals display akinetic mutism: a condition 
characterised by extreme apathy, indifference to pain, hunger or thirst. 
They may also struggle to understand new concepts or creative thought 
processes (Tekin and Cummings 2002). 
 The OFC possesses the strongest association with the limbic system 
sharing intricate bidirectional neuronal connections with the amygdala 
(Ghashghaei and Barbas 2002), as well as connection to the 
hypothalamus, and other hippocampal formations. This role introduces 
an emotional tone to outside stimuli, with the OFC connecting 
environmental cues to the subcortical limbic system (Lichter and 
Cummings 2001). Damage or degeneration to this circuit can lead to 
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personality changes i.e. emotional liability and behavioural disinhibition, 
lacking judgment and empathy (Tekin and Cummings 2002).  
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Figure 1-4 showing the location of the three PFC circuits and their relative functions. PFC = 
prefrontal cortex, dlPFC = dorsolateral prefrontal cortex, ACC = anterior cingulate cortex, and OFC 
= orbitofrontal cortex (O. Perry 1993). 
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 The prefrontal cortex circuit and vascular disease 
Executive dysfunction has been suggested as a predictor for VaD in post-stroke 
cases (Roman and Royall 1999; Pohjasvaara et al. 2002). The frontal lobe is 
particularly vulnerable to vascular-based pathology. Dermamecourt et al 
reported over 89.6% of demented cases had presence of SVD in the frontal 
lobe. Arteriolosclerosis was the most common pathological substrate present for 
87.3% of SVD sufferers with higher pathology located in the frontal lobes when 
compared the temporal lobes (Deramecourt et al. 2012).  
Clinical symptoms between different diseases can lend valuable insight to 
underlying pathological processes. Whereas AD sufferers may relinquish 
memory and language functions, indicative of temporal lobe atrophy, those with 
VaD express loss of executive functions; attention, and planning as vascular 
pathology initially localises in the frontal lobe, disrupting the ganglio-thalamo-
cortical circuits (Kalaria 2002; Roman and Royall 1999) .  
Frontal pathology can also cause non-cognitive symptoms which can overlap 
with cognitive features. Alexopoulos et al proposed that vasculature changes to 
the frontal lobe might result in depression in what they called the vascular 
depression hypothesis (Alexopoulos et al. 1997). Depression is linked to stroke, 
WMH, and hypertension (Teodorczuk et al. 2007) - similar risk factors 
associated with dementia. Indeed patients suffering from post-stroke depression 
have been found to suffer executive dysfunction (Leeds et al. 2001; 
Pohjasvaara et al. 2002).This link between vascular pathology and the frontal 
lobe functions cannot be ignored, indeed the cognitive dysfunction observed in 
vascular depressed cases paralleled the cognitive changes of those suffering 
VaD (Sultzer et al. 1993; Alexopoulos et al. 1997), suggesting vascular 
pathology disrupts vital cortio-cortio, cortico-subcortical circuits. Damage to the 
striato-pallido-thalamo-cortical pathways is common in CVD (Fujikawa et al. 
1993; Coffey et al. 1990; Krishnan et al. 1988), which may result from direct 
damage to the OFC, dlPFC, or ACC.   
Furthermore Burton et al reported significantly higher white matter lesions in the 
frontal lobe of post-stroke patients correlating with executive function and 
attention deficits and a result of lesion damage to the frontal circuits (E. Burton 
et al. 2003). Indeed, attention is most susceptible to disruption, and may be the 
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first cognitive function to decline (Pasquier and Leys 1997). WMH within the 
frontal lobe detected via MRI have long been associated with microvascular 
changes thought to affect executive functions in the ‘healthy’ population 
(DeCarli et al. 1995; O'Brien et al. 2002) with WMH severity linked to cognitive 
speeds and executive dysfunction in those suffering VaD suggesting WM 
damage affects the connectivity between these subcortical regions (Cohen et 
al. 2002).  
Age related changes to the integrity and structure in frontal WM have been 
linked to the disruption of the frontal subcortical circuits and is thought a result 
of vascular micropathology (Kalaria 2010). WM lesions are often seen in the 
elderly via MRI scans in anything between 5-90% of patients with some 
reporting higher incidence of WMH in women, with evidence that these WMH 
are a result of PVS and relate directly to cognitive dysfunction through 
disruption of the PFC circuits (de Leeuw et al. 2001). Indeed it has been shown 
that patients with increased vascular pathology at MRI have decreased glucose 
metabolism in the frontal cortex (Pascual et al. 2010). In addition, patients with 
lacuna infarcts displayed significantly reduced glucose metabolism in the 
dorsolateral prefrontal cortex which correlated with cognitive dysfunction (Reed 
et al. 2004). This trend has also been reported with those of suffering 
cardiovascular disease, as discussed, a known risk factor for VaD (Kuczynski et 
al. 2009).  
 Interneurons and the inhibition circuits 
The excitatory activity of the pyramidal neurons within the prefrontal cortex is 
mediated by a parallel counter system controlled by a sub-population of 
GABAnergic interneurons. Interneurons are arranged in the cortex in layers, 
similar to their excitatory counterparts.  
Though the vast majority of neurons within the neocortex are pyramidal 
neurons, accounting for 70-80% (DeFelipe and Farinas 1992), the remaining 
neurons are a collection of inhibitory interneurons, which utilise the y-amino-
butyric acid (GABA) as their transmitter, in lieu of the excitatory transmitter- 
glutamate (Markram et al. 2004). Interneurons have a range of varied synaptic 
and physiological characteristics. Though the overwhelming majority of 
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interneurons are inhibitory they receive both excitatory and inhibitory signals via 
their dendritic arbours.  
Biochemically interneurons can be characterised based on the heterogeneous 
expression of one or more of three specific calcium-binding proteins: 
Parvalbumin positive, calbindin positive, and calretinin positive (Table 1-2). 
Parvalbumin and calbindin positive cells are thought to act as endogenous 
buffers in certain neurons with calretinin acting as a template for preplate 
neurons (Markram et al. 2004).  
Interneurons can be distinguished from pyramidal neurons primarily due the 
lack of a large triangular soma, the presence of aspiny dendrites, the 
morphology of which are highly variable between interneurons and not useful in 
defining the specific sub-types of interneuronal species, and for the absence of 
the large apical dendrite which is so distinctive of pyramidal neurons (Spruston 
2008; Markram et al. 2004). Each cell type will have an axonal arbourisation 
specific to the cell domain, layer or cortical column being targeted. To this end, 
based on axonal morphology interneurons can be placed into three functional 
groups: axon-targeting (with the interneuron exhibiting an editing role in relation 
to the target cell’s excitability), soma and proximal dendritic targeting (allowing 
presynaptic neurons to control the gain/intensity of the action potential leaving 
the neuron), and distal dendritic and tuft-targeting (for control of local dendritic 
innervation) (DeFelipe 1997). Interneuron targeting of dendrites allow for control 
and influence of dendritic processing and the synaptic inputs (Markram et al. 
2004).  
Unlike pyramidal neurons, the inhibitory effect of interneurons is rarely felt 
outside the local cortical area, as interneurons do not project to distant brain 
regions. Interneuronal connections can however project to nearby layers and 
cortical columns effecting a local inhibitory response, sometimes called the 
‘local circuit neuron’ (Letinic et al. 2002) and can again be broken up into three 
sub-groups: intralaminar-intracolumnar, interlaminer-intracolumnar, and 
interlaminar-intercolumnar (Markram et al. 2004). 
 Type of Interneurons 
As well as those broad chemical-based distinctions, it is possible to further 
classify interneurons into 5 broad sub-types: 
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Basket cells (BC): BCs are a class of soma and proximal dendritic interneuron 
(Gilbert 1993; Y. Wang et al. 2002; Marin-Padilla 1969) accounting for around 
50% of all inhibitory neurons in the neocortex. In this role they can adjust the 
gain of the integrated synaptic responses. It is the converging nature of several 
of these cells around pyramidal neurons which give them the basket-shaped 
appearance from which their name derives. Basket cells can be histologically 
identified through their expression of one of two calcium binding proteins: 
parvalbumin, and calbindin. Basket cells can be further classified dependent on 
their axonal and dendritic morphologies: large basket cells, small basket cells, 
and nest basket cells.  
  
28 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-5 showing the soma and proximal dendrite-targeting interneurons of the prefrontal cortex 
(Markram et al. 2004)  Red lines = dendrites, blue line = axons, and blue dots = axonal boutons.  
Markram et al., 2004) 
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Chandelier cells (CC): These are axon targeting interneurons which influence 
the output of a pyramidal neuron, fine-tuning or nullifying inputs from other, 
dendritic or soma targeting interneurons (Buhl et al. 1994), and are found in 
cortical layer II through VI, expressing both PV and CB (Markram et al. 2004). 
 
 
Figure 1-6 showing the axon targeting interneuron. Red lines = dendrites, blue line = axons, and 
blue dots = axonal boutons. Adapted from (Markram et al. 2004). 
Martinotti cells (MC): These are unusual as they do not necessarily fall into the 
classic interneuronal sub-types as described. MCs may target several aspects 
of pyramidal neurons in layers and columns not immediately local to their area. 
MCs reside in layers II to IV but their axons project into layers I where they 
exact most their influence. Interestingly, MCs not only project away from their 
original layer but also across cortices influencing action potentials in 
neighbouring cortical columns. MCs target multiple domains of the target 
neuron such as both distal and proximal dendrites and peri-somatic dendrites 
and somata. MCs have been known to express both CB and CR. 
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Figure 1-7 showing dendrite and tuft-targeting interneurons. Red lines = dendrites, blue line = 
axons, and blue dots = axonal boutons. Adapted from (Markram et al. 2004) 
  
31 
 
 
Bipolar cells (BPC): BPC axons can project across all layers and have either 
excitatory or inhibitory properties. Due to their low bouton density they contact 
and therefore influence relatively few neurons when compared to their other 
interneuronal counterparts. They tend to target the basal dendrite of pyramidal 
neurons expressing mainly CR (Markram et al. 2004). 
Double bouquet cells (DBC):  DBCs are located in layers II through V (fig 9) 
and, like BP, target and inhibited basal dendrites of pyramidal neurons as a 
class of dendritic targeting cells. DBC express both CB and CR (Markram et al. 
2004). 
Bitufted cells (BtC): Though possessing a dendritic arbour less extensive than 
that of BPCS, and DBCs, BtC project mostly into other layers. A class of 
dendritic targeting cell, they can influence the input received by pyramidal 
neurons. BtC cells express CB and CR (Markram et al. 2004). 
 
Figure 1-8 showing the dendrite-targeting neurons in the prefrontal cortex. Red lines = dendrites, 
blue line = axons, and blue dots = axonal boutons. Adapted from (Markram et al. 2004).  
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The most common type of interneuron in both later II/III and V are large basket 
cells. In layer II/III this is followed by net basket cells, and Martinotti cells in 
layer V (Figure 1-9) (Markram et al. 2004).  
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Table 1-2 showing interneuronal subtypes and their respective immunohistochemical reactivity. 
Adapted from Markram et al (Markram et al. 2004). PV = parvalbumin, CB = calbindin, CR = 
calretinin.  
Interneuronal 
subtypes 
PV CB CR 
Large basket cell x x 
 
Nest basket cell x x 
 
Small basket cell x x 
 
Chandelier cell x x 
 
Martinotti cell 
 
x x 
Bipolar cell 
  
x 
Double bouquet 
cell  
x x 
Bitufted cell 
 
x x 
Figure 1-9 showing the distribution of interneuronal subtypes in layers II, III, and V of the 
prefrontal cortex. Adapted from Markram et al (Markram et al. 2004; Simpson et al. 2007; 
Chance et al. 2011). 
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 Glial cells 
Though pyramidal neurons form the vast majority of connections between 
regions of the brain, and interneurons are thought to keep check of these 
excitatory cells - glial form a major component of the central nervous system 
(CNS). Glial cells are an umbrella term representing a range of non-neuronal 
cells types from: astrocytes, oligodendrocytes and microglia (Nedergaard and 
Dirnagl 2005). There is not enough research focused on the role glial cells may 
play in the development of PSD, but as will be shown below, glial cells may play 
important roles in cognitive impairment and dementia.  
 Astrocytes, the neurovascular unit, and stroke 
Astrocytes form part of the neurovascular unit (NVU) (Nedergaard and Dirnagl 
2005; Hawkins and Davis 2005) controlling the supply of blood and nutrients to 
neurons dependent on their metabolic requirements, through the selective 
uptake of nutrients through their endfeet and control over vessel diameter 
(Simard et al. 2003; Nedergaard et al. 2003; Koehler et al. 2009). Following 
ischaemic injury astrocytes have a major role in controlling ion and water 
homeostasis (Leis et al. 2005; Dienel and Hertz 2005; Kimelberg 2005) in 
addition to supplying much needed trophic factors and scavenging reactive 
oxygen species (ROIs) (Trendelenburg and Dirnagl 2005). Astrocytes act as a 
sponge for excess glutamate and potassium ions which result from a stroke. 
Large numbers of glutamate transports are present in the glial cell’s membrane 
and act to protect the brain from excitotoxicity due to high concentration of 
antioxidants such as glutathione and ascorbic acid which protect against the 
ROS produced after an ischaemic event (Danbolt 2001). Lack of glutamate 
modulation due to astrocytic damage leading to increased excitotoxicity may be 
another pathway to neuronal dysfunction (C. M. Anderson and Swanson 2000). 
Astrocytes may be particularly vulnerable to the ageing process (Kalaria 2010) 
with changes to the astrocytic endfeet reported in ageing brains (Kalaria 1996), 
becoming more profound in those suffering neurodegenerative disease, 
exhibiting degenerated microvascular (Moody et al. 2004). The dysfunction of 
astrocytes may lead to a breakdown of the neurovascular unit, resulting in a 
failure in communication between neuronal activity and metabolism and blood 
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and nutrient flow. This would leave neurons in an undesirable state and may 
ultimately lead to neuronal dysfunction and death. Additionally, astrocytes are a 
major store for glycogen within the brain which is used to supply neurons with 
glucose in periods of high neuronal activity (A. M. Brown and Ransom 2007; 
Schousboe et al. 2010).  
Furthermore, in hypoxic environments and AD subjects, astrocytes have been 
shown to have increased reactivity, suggesting angiogenic signals are 
increased in these conditions in an attempt to counter the stroke/vascular 
damage and AD pathology (Kalaria et al. 1998; Burke et al. 2014). 
 Glial cells and white matter 
Oligodendrocytes are responsible for axonal myelination within the white matter 
of the CNS, and make up almost half of the total volume of the WM (Nave 
2010b, 2010a; Alberdi et al. 2005; Pfeiffer et al. 1993). Oligodendrocytes extend 
a composition layer of protein and lipid which is wrapped around the nearby 
axon (Sherman and Brophy 2005; Nave 2010b) (Figure 1-10). This sheath 
insulates the axon and enables salutatory conduction (or impulse propagation) 
along the length of the axon allowing action potentials to travel at speeds up to 
100x faster than in un-myelinated tracts (Nave 2010a). 
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Figure 1-10 demonstrating the mechanism with which oligodendrocytes myelinate axons (Sherman 
and Brophy 2005).   
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Damage to oligodendrocytes may result in reduced myelination in the WM, 
slowing action potentials and leading to the potential dysfunction of axonal 
connections between neurons, disrupting neuronal circuit communications and 
ultimately cognitive dysfunction. Additionally, damage to oligodendrocytes may 
lead to Wallerian degeneration, in which break down of the axonal white matter 
results in the retrograde damage to neurons in the grey matter (Nedergaard and 
Dirnagl 2005; Nedergaard et al. 2003; Cook and Wisniewski 1973; Mack et al. 
2001).  
Due to the expression of NMDA receptors and glutamate channels 
oligodendrocytes are the most vulnerable of the glia to hypoxic and excitotoxic 
insults resulting from ischaemic damage (Alberdi et al. 2005; Nedergaard and 
Dirnagl 2005) . This may play a significant role in stroke, CVD, and 
neurodegenerative disease, with loss of oligodendrocyte function as a result of 
oxidative stress and mitochondrial dysfunctions (Danbolt 2001; Sanchez-
Gomez et al. 2003).  
It has been proposed that axons regeneration following a pathological insult is 
impeded by the formation of a ‘glial scar’, made up of activated astrocytes and 
proteoglycans. The glial scar creates a barrier which prevents the potential 
reformation and reconnection of axons within the WM and are believed to be a 
major part in the failure of regeneration within the WM (Silver and Miller 2004).  
Oligodendrocyte dysfunction has also been associated with the development of 
cognitive dysfunction (Cook and Wisniewski 1973; Giaume et al. 2007; Ihara et 
al. 2010) 
 Microglia and immunoresponse in the brain 
The third most common type of glia are microglia which make up about 20% of 
the total glial cell population (Gehrmann and Kreutzberg 1994), inhabiting the 
brain parenchyma. Microglia form the major immune response system within 
the BBB as the CNS’ resident immunocompetent cell (Kreutzberg 1996). 
Microglia have a complex network of processes which are in contact with 
neurons, vessels and other glial cells to continuously monitor their local 
environment (Nimmerjahn et al. 2005; Fetler and Amigorena 2005). Insults to 
the brain increase the level activated microglia, stimulating the release of a 
38 
 
range of cytokines and chemokines (Nedergaard and Dirnagl 2005). The 
microglia create a tight network to seal off the damaged area establishing a 
barrier between healthy and injured tissue (Davalos et al. 2005; Giulian et al. 
1994).  
Brain inflammation, a pathological substrate of several diseases including 
stroke, can also result in glial cell proliferation, increasing the numbers of 
astrocytes and microglia and up-regulation of inflammatory markers, such as 
interleukin 1 beta, and TNFα in a phase known as reactive gliosis (Rouach et al. 
2002; Giulian et al. 1994) which may result in increased excitotoxicity which can 
lead to BBB dysfunction, increased neurotoxicity within the brain (Nedergaard 
and Dirnagl 2005) and in extreme circumstances may result in a glial scar (as 
described previously). Microglia have also been implicated in AD, aggregating 
around amyloid plaques, possibly in an attempt to clear Aβ, suggesting 
microglia may play a key role in AD and in potential therapeutic interventions in 
the future (Bolmont et al. 2008). 
It is unknown how these cells play a role in PSD. The intricate relationship 
between glial cells, neurons, axons, and vessels may be an important aspect of 
the neurovascular unit and cortical connections. Any disruption to this complex 
association may result in severe consequences for cognitive health.  
 The cognitive function after stroke (CogFAST) study and it’s key 
findings 
The cognitive function after stroke (CogFAST) study was a MRC funded 
prospective, unique, longitudinal study centred in Newcastle and designed to 
investigate the long-term pathological processes which may account for the 
development of dementia in stroke survivors (Allan et al. 2011). 
Over 50% of patients experienced improvements in cognition following a stroke 
(Ballard et al. 2003). Of the 355 subjects recruited into the study 176 had died 
within a mean follow-up time of 5.76 years, with a median survival time of 6.72 
years from the incident stroke. The three most significant univariate risk factors 
for death after stroke included the subject having suffered a previous disabling 
stroke, the number of cardiovascular risk factors, and a low CAMCOG executive 
function score (Table 1-3). When looking at multivariate risk factors as 
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predictors of death: older age, a history of smoking, and occurrence of previous 
strokes all increased risk of death (Allan et al. 2011) (Table 1-3).   
During a period of 1346 person-years 85 of the 355 participants had developed 
post-stroke dementia with an incidence of 6.32 cases in every 100 person 
years, with 39.5 percent of subjects having developed PSD after 7 years. Risk 
factors for developing PSD included low scoring in follow-up tests such as 
CAMCOG, the presence of more than one cardiovascular risk factors, and 
having suffered a previous stroke (Table 1-3). Mean survival time from baseline 
stroke did not significantly differ between those who developed PSD and those 
who remained cognitively stable. The majority of PSD cases fulfilled the 
currently used criteria for vascular dementia, with no typical destinction of 
vascular pathology seen between cases. Tau pathology was greater in those 
which developed PSD, whilst also exhibiting a higher proportion of microinfracts 
(Allan et al. 2011), with stroke survivors suffering from impairments to working 
memory and reduced executive function when compared to non-demented 
controls (Ballard et al. 2003).  
Genetic studies on the CogFAST cohort have revealed a single nucleotide 
polymorphism in the endothelial nitric acid synthase (NOS3) gene (codon 298) 
increased the risk of dementia in post-stroke subjects, possibly as a result of a 
reduction in nitric oxide production and cerebral perfusion (Morris et al. 2011). 
MRI imaging showed the left/right medial atrophy score was greater in subjects 
with PSD than those who were cognitively unimpaired. Cognitive scoring, as 
measured using baseline CAMCOG score, significantly correlated with atrophy 
scores. In turn CAMCOG scores significantly differed between PSD and PSND 
subjects. PSD subjects exhibited higher frequencies of Braak stage III or higher 
when compared to PSND (Allan et al. 2011).   
 Imaging studies 
MRI studies showed medial temporal atrophy predicted subsequent decline in 
CAMCOG memory scores, though no such relationship was found between 
cognition and baseline white matter hyperintensities and no significant 
difference was found between those who remained cognitively stable and those 
who would go on to develop PSD. However, global atrophy scores, assessed 2 
years post stroke, showed ventricular enlargement correlated with both medial 
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temporal atrophy (MTA) and total WMH (a marker for vascular/ischaemic 
pathology). Significant correlation between WMH and reduced cognition 
suggests a greater involvement in vascular pathology two years post-stroke 
(Firbank et al. 2012; Firbank et al. 2007). Firbank et al reported memory loss 
was related to both baseline memory and medial temporal atrophy but not WMH 
volume, suggesting a greater involvement of Alzheimer type pathology than 
vascular pathology in late-onset post-stroke dementia (Firbank et al. 2007). In 
addition, decreased pyramidal neuronal volume has been reported in both 
hippocampal subfields CA1 and CA2 of PSD subjects when compared to PSND 
and controls, with this apparent atrophy correlating with both global cognitive 
function scores and memory function, in post-mortem tissue (Gemmell et al. 
2012).  
Further studies found increased WMH in all key areas of the brain of stroke 
subjects. In particular correlations between total and frontal WMH and cognitive 
function such as attention and processing speeds (E. Burton et al. 2003). Other 
areas of the brain also appear significant in the development of post-stroke with 
Infarcts in the putamen correlating with memory impairment. Interestingly, 
arterial spin labeling MRI 3T imaging revealed cerebral blood flow in global grey 
and white matter was significantly reduced in post-stroke demented cases when 
compared to controls (Firbank et al. 2011). 
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Risk factors   Death PSD 
Age  yes yes 
CAMCOG <80  yes yes 
Number of CV risk factors:    
1 or 2  yes no 
>3  yes yes 
Previous Stroke  yes yes 
Smoking  yes yes 
Ischaemic heart disease  no yes 
Camcog total exec. Function  yes yes 
Geriatric depression score  yes yes 
Table 1-3 showing the relationship between risk factors and relative risk of death and dementia. 
Adapted from (Allan et al. 2011). CAMCOG = Cambridge Cognitive Examination, CV = 
Cardiovascular, exec = Executive function 
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 Neuropathological assessment and dementia diagnosis 
All cases in the brain bank undergo a standardised clinical assessment. 
Dementia is therefore established independently of the pathological findings. 
After death, stroke survivors and VaD, AD and mixed dementia subjects who 
came to autopsy underwent a macroscopic and microscopic pathology 
assessment with standardised protocols (Ihara et al. 2010; Kalaria et al. 2004). 
General neuropathological assessment of the brain structure, and assessment 
of infarcts was performed by experienced neuropathologists using haematoxylin 
and eosin with any infarcts <5mm classified as a microinfarct. CERAD rating of 
neuritic plaques and Braak staging for tau progression was performed using 
standard silver impregnation procedures and immunohistochemical techniques 
respectively. Distribution and burden of vascular amyloid was also noted in 
each case to assess the level of cerebral amyloid angiopathy. Subjects were 
diagnosed as AD if they presented with CERAD score of moderate-severe and 
a Braak score of V-VI with limited present of vascular pathology. VaD was 
diagnosed if subject’s brain showed evidence of vascular pathology such as: 
small vessel disease, cystic infarcts, lacuna infarcts, microinfracts, or 
leukoaraiosis which were deemed severe enough to contribute to result in 
dementia in the absence of neurodegenerative disease. In cases were vascular 
pathology deemed substantial enough to lead to a diagnosis of VaD in addition 
to moderate-severe Alzheimer’s pathology a diagnosis of mixed dementia was 
chosen.     
CogFAST cases underwent an additional global vascular assessment, which 4 
brain regions were examined for vascular lesion severity. A total vascular score 
out of 20 was given, made up of the interregional - subscores for each area: 
Frontal (/6), temporal (/6), hippocampal (/4), and the basal ganglia (/4). Each 
rating was based on the level of arteriolosclerosis, CAA, perivascular 
hemosiderin leakage, perivascular space dilation, myelin loss, and cortical 
infarct burden present in each respective region (Deramecourt et al. 2012)   
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This information, along with clinical data, was used to assign a final diagnosis of 
AD, VD, or mixed dementia.  
 
 Aims and objectives 
The study described in this thesis had two primary aims: 
i) to study and identify any morphological and immunohistochemical 
differences in the prefrontal grey and white matter between post-stroke 
demented and post-stroke non-demented subjects, and compare these to 
aged-matched controls and other ageing related-dementias in an attempt 
to elucidate any potential pathological differences which may explain why 
some individuals decline into dementia and others do not. 
ii) to identify any mechanistic changes in the prefrontal cortex which may be 
related to the clinical and pathological findings associated with PSD, or 
associated with a protective role in PSND. 
 
Each of the following experimental chapters will focus on a different aspect of 
pathology in an attempt to achieve the above aims. 
 Hypothesis I: Pyramidal neuronal volumes within the dlPFC, the ACC, and 
the OFC would show reduced neuronal volume in post-stroke demented 
and other age-related dementia subjects when compared to aged-controls 
and non-demented post-stroke survivors (Chapter 3). 
 Hypothesis II: The interaction between the excitatory system (primarily 
pyramidal neurons), the inhibitory system (interneurons), and glial cells 
will be related to the development of dementia (Chapter 4). 
 Hypothesis III: White matter pathology, concerning axons, myelin and 
oligodendrocytes within the prefrontal cortex will relate to pyramidal 
neuron volume change and cognitive impairment resulting from stroke 
(Chapter 5). 
 Hypothesis IV: Reduced metabolism in the grey matter within the 
prefrontal cortex will correlate with pyramidal neuron volume changes and 
pathology in the WM (Chapter 6). 
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Chapter 2. Methods and Materials 
 Introduction 
This chapter offers detailed descriptions of the materials and methods used 
throughout this study.  
 The Cognitive function after stroke (CogFAST) prospective study 
 The study design 
From October 1999 to July 2001 over 700 elderly stroke patients >75 years of 
age were screened from representative hospital-based stroke registers in 
Tyneside and Wearside. Subjects suffering from post-stroke dementia before 
the stroke, or within 3 months post-stroke were excluded from the study as well 
as those who suffered from any disability which may affect their ability to 
complete necessary assessments such as: aphasia or hemiparesis affecting the 
hand used for writing. 355 individuals were recruited into the study (Table 2-1 & 
Figure 2-1). 
Baseline characteristic n 
Number of subjects 355 
Age (SD) 80 (4.10) 
Gender - male (%) 184 (51.8) 
Total CAMCOG score (%) <80 50 (14.1) 
average MMSE (SD)  25.9 (2.8) 
Hypertension (%) 193 (54.4) 
APOE ε4, one copy (%) 64/273 (23.4) 
Previous stroke (%) 104 (29.3) 
Table 2-1 showing the baseline characteristics of post-stroke survivors in the CogFAST cohort. 
Adapted from Allan et al (Allan et al. 2011) 
The Diagnostic and Statistical Manual of Mental Disorders IV criteria (DSM-IV 
1994) was used to define dementia status. Annual neuropsychometric follow-up 
testing was used to assess cognitive deficit and dementia using the Mini Mental 
State Examination (MMSE), a 30-point questionnaire, with a score of <24 
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indicating dementia (Blake et al. 2002). The Cambridge Examination for Mental 
Disorders of the Elderly (CAMCOG), a standardized pen and pencil test, with a 
maximum score of 107 was used to assess global cognition (e.g. memory (/27), 
orientation (/10), attention (/7), perception (/11), and executive function (/28)). 
Subjects scoring <80 falling into the ‘demented’ category (Huppert et al. 1995). 
The Bristol Activities of Daily Living scale (Bucks and Haworth 2002) and the 
Sheffield Language-Screening test (Blake et al. 2002) were used to assess the 
subjects ability to perform day to day tasks and for assessing language skills, 
respectively.  
The incident dementia was recorded at follow up using the DSM-IV. These 
formed the two groups, which were compared in this study (Allan et al. 2011). 
Participants were invited to donate their brains to the NBTR. Those who 
donated their brain at death were given a clinical diagnosis of post-stroke non-
demented (PNSD), or demented (PSD). To date 88 subjects have donated their 
brains for research. 
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Figure 2-1 flow chart showing the CogFAST study design adapted from Allan et al (Allan et al. 
2011). CT = X-ray computed tomography scan, MMSE = Mini Mental State Exam, CAMCOG = 
Cambridge Cognitive Examination, AD = Alzheimer’s disease, C = degree celsius. 
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 Participants from the COGFAST study 
Three hundred and fifty five stroke patients ≥75 years of age were recruited into 
the CogFAST study. Stroke was defined according to the World Health 
Organization definition. Twenty participants were assessed at a maximum of 3 
months post stroke to test cognitive state. 
Participants were excluded if they declined participation, died or withdrew from 
the study before completing the baseline neuropsychological evaluation, had a 
disability precluding neuropsychological evaluation (e.g. visual impairment, 
aphasia, hemiparesis affecting the hand used for writing), had an MMSE 
score(Folstein et al. 1975) less than 24, or had a diagnosis of dementia 
according to DSM IV criteria. The assessment was repeated annually during a 
follow up period of 5-8 years.  
 The CogFAST cohort provided the post-stroke subjects for this study and is 
described in detail in the previous chapter. To assess the cognitive status of 
those taking part in the study, subjects were subjected to an initial battery of 
examinations. 
 
 Demographics of subjects analysed in the study 
Details of subject demographic are given in Table 3-1. The mean age at death 
and post-stroke survival times were not significantly different between groups 
thus dementia and executive dysfunction were the only features separating 
PSND and PSD (Table 3-1). Dementia was determined at the mean time of 7.6 
months before death. There were no significant differences in the location of 
stroke, or in the burden of vascular pathology between the PSND and PSD 
groups (Table 3-2). Both Alzheimer’s disease and mixed dementias showed 
significantly higher tau and amyloid pathology when compared to all other 
groups. 
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Table 2-2 showing the demographics of subjects investigated in this study. Controls = aged 
matched controls, PSND = post-stroke no dementia, PSD = post-stroke dementia, VaD = vascular 
dementia, mixed = mixed vascular and Alzheimer’s disease, AD = Alzheimer’s disease. FT = 
fixation time, PMD = post-mortem delay. Frontal vascular score (scored out of 6). Age (F = 1.146, p 
= 0.342, FT (F = 0.519, p = 0.759), PMD (F = 0.449, p = 0.844), CERAD (F = 9.134, p = 0.001), Braak (F 
= 24.75, p = 0.001), Frontal vascular score (F = 3.262, p = 0.016). 
All 
cases 
No of 
cases 
Age, 
years 
(range) 
Sex 
(female) 
FT, 
weeks 
(range) 
PMD, 
hours 
(range) 
CERAD 
(range) 
Braak 
(range) 
Frontal 
vascular 
score 
(range) 
Control 28 
81.5 
(71-98) 
15 
11.2 
(2-46) 
34.8 
(12-98) 
n/a 2 (1-4) n/a 
PSND 10 
83.3 
(78-88) 
3 
3.8   
(1-20) 
37.9 
(11-76) 
1.6     
(0-2) 
2.3   
(1-4) 
4.5 (1) 
PSD 11 
87.1 
(80-98) 
7 
2      
(1-3) 
40.3 
(17-99) 
1.3    
(0-3) 
2.6   
(1-4) 
4.3     
(3-6) 
VaD 15 
83.8 
(71-97) 
8 
5.1   
(2-12) 
46.3 
(13-74) 
1  
(0-2) 
2.2  
(1-4) 
5        
(4-6) 
Mixed 14 
83.9 
(72-94) 
5 
5.7  
(1-27) 
35.5 
(9-69) 
3  
(1-3) 
5.4  
(4-6) 
4  
(2-5) 
AD 17 
85.6 
(76-96) 
6 
7.6  
(1-26) 
38.6 
(6-94) 
3  
(3) 
5.4  
(4-6) 
1  
(1) 
FTD 4 
71.5 
(64-77) 
2 n/a n/a n/a n/a n/a 
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 Other participants 
Brains from non-CogFAST groups (aged-controls, VaD, mixed, and AD) were 
obtained on request from the Newcastle Brain Tissue Resource (NBTR). These 
were collected from other prospective clinical studies conducted within the 
institute. For the initial stereological study, serial cases were selected based on 
quality of the frontal lobe and availability of tissue due the requirement of a 
relatively large amount of tissue in this type of analysis. For 
immunohistochemical investigations cases were selected based on short 
fixation time and post-mortem delay. This was aided by additional cases which 
had become available from the NBTR.  
 Tissue acquisition 
Tissue was obtained from the NBTR, Institute of Neuroscience, Newcastle 
University. Ethical approval was granted by Newcastle upon Tyne Hospitals 
Trust ethics committees for use of post-mortem brain tissue in medical 
research. Neuropathological diagnosis and observations were transcribed from 
post-mortem reports. After post-mortem examination, brains from subjects in 
the CogFAST study were cut in 1cm thick coronal slices and sub-dissected into 
blocks; of which one hemisphere was fixed in 10% buffered formalin and the 
other was frozen at -80ºC. Standard protocols for fixation, sub-dissection and 
processing were used for all brains. After fixation, blocks were dehydrated in 
alcohol and cleared xylene and embedded in paraffin wax.   
Cases used in the project were prepared and cut with sufficient quantity and 
quality of frontal tissue available for the methodology to be used. During the 
course of the project, additional consecutive cases became available and these 
were added in later chapters. Cases were excluded if there were significant 
lesions in the prefrontal cortex, such as a large infarct, which precluded 
examination using the methods proposed. Control cases were excluded if there 
was a history of myocardial infarction or those who had died from another CVD 
cause.  
The total number of brains evaluated for the project was 99 (25x controls, 10x 
PSND, 11x PSD, 15 VaD, 14x mixed, 17x AD, and 4x FTD). Cases from this 
sample were selected for individual parts of the project based upon their 
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suitability for the methodology, for example, only cases with shorter fixation 
times were used for IHC studies. In each study, there were no differences 
between age (F = 1.146, p = 0.342), fixation time (F = 0.519, p = 0.759) or post 
mortem delay times (F = 0.499, p = 0.844) between any group regardless of the 
cases selected.  
 
 Sectioning and tissue preparation 
Sections were cut from paraffin embedded coronal blocks including areas 9, 11, 
and 24 containing the dlPFC, OFC, and ACC respectively, where possible 
between coronal levels 4-8 according to the Newcastle Brain Map (Figure 2-5). 
Cutting was performed using a Shandon FinesseE+ rotary microtome. 
To increase the adhesiveness of slides to tissue sections, clean slides were 
immersed in acetone for 5 minutes before being added to 2% APES (3 
aminopropyl triethoxysilane) solution in acetone for 5 minutes. Slides were then 
washed in distilled water, removing excess APES solution, before slides were 
dried in oven at 45ºC. 
The sections were adhered to the slide and then dewaxed through two rounds 
of xylene submersion lasting 10 minutes each before being rehydrated through 
decreasing concentration of alcohol baths sitting in 100%, 95%, 75%, and 50% 
alcohol/water mix for 1 minute each.  
Following each staining protocol, each section was then dehydrated by bringing 
the slides through 95% ethanol for 1 minute and two changes of 100% ethanol 
for 2 minutes each. Sections were then placed in two changes of xylene for a 
minimum of two minutes each. Cover slips were then applied using DPX and a 
mounting medium.  
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Figure 2-2 showing the Newcastle University brain map (O. Perry 1993).  
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 Histological staining 
 Haematoxylin and Eosin (H&E)  
H&E was used to visualise arterioles and blood vessels, as well as cell nuclei in 
blue, and eosinophilic structures in shades of red, orange and pink, in the 
dlPFC. Sections were dewaxed in xylene (Fisher Scientific, UK) and rehydrated 
in distilled water for 1 minute. Sections were then immersed in haematoxylin 
solution [5g haematoxylin (Sigma Aldrich, UK), 0.5g sodium iodate (BDH, USA), 
40ml glacial acetate (BDH, USA), 300ml glycerine (Fisher Scientific), and 700ml 
distilled water] for 3 minutes. Sections were the washed in tap water before 
being dipped in 1% acid alcohol for 40 seconds before a second wash in tap 
water. Sections were then immersed in eosin [10g eosin (Sigma Aldrich, UK), 
0.25g erytheosin B (Sigma Aldrich, UK), 1000ml 20% ethanol (Fisher Scientific, 
UK)] for 3 minutes. Excess eosin was washed off with tap water before section 
was differentiated in 95% ethanol. Slides were then checked under microscope 
and compared to previously stained sections for consistency.  
 Cresyl Fast Violet (CFV) 
CFV staining was used to visualise the soma, nuclei and the nucleolus of 
pyramidal and non-pyramidal neurons and glial cells. Thirty μm sections were 
cut for use in 3D stereological analysis, and dewaxed in 2 changes of xylene for 
5 and 10 minutes respectively. Sections were placed in 100% ethanol for 1 
minute before being rehydrated in 95% ethanol for 1 minute. Sections were 
then placed in 1% acid alcohol for 5 minutes before being rinsed in three 
changes of deionised water. Sections were incubated in CFV solution for 10 
minutes at 60ºC in the oven, before being removed from the oven and let cool 
for a further 10 minutes. Sections were then differentiated in 95% alcohol until 
the background was a pale purple, before sections were dehydrated in one 
change of 95% and two changes of 100% ethanol and mounted with cover slips 
in DPX (Merk, UK). Staining consistency was checked under the microscope 
and compared to a previously stained section. CFV solution was made up using 
between 25-50mls (0.2% w/v CFV in deionised water) in 500mls deionised 
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water and 500mls acetate buffer, pH 4.5 (13.5mls acetate, 23.5g sodium 
acetate, and 2000mls deionised water).  
 Luxol Fast Blue (LFB) 
LFB was used to visualise the myelinated axons in the WM of the dlPFC. As a 
copper phthalocyanine dye LFB is attracted to the lipoproteins making up the 
myelin sheath, staining them blue. Tissue sections were dewaxed in xylene and 
rehydrated in 95% ethanol before being incubated for 2 hours in LFB stain (1g 
of luxol fast blue and 5mls of 10% acetic acid in 1000mls of 95% alcohol) at 
60ºC. Sections were then cooled for 10 minutes before being washed in 70% 
alcohol for 1 minute. Sections were then differentiated in 4 cycles of; 1 minute 
distilled water, 10 seconds in LiCoO3, and 1 minute in 70% ethanol. If grey 
matter remained blue after 4 complete cycles, additional cycles were performed 
until the cortex appeared colourless. Sections were then immersed in distilled 
water before being counterstained with CFV solution (0.1% CFV in 1% acetic 
acid) for 2 minutes at room temperature. Sections were then washed in distilled 
water and differentiated in 95% ethanol before being compared under 
microscope to previously stained sections for consistency.  
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Figure 2-3 showing two frontal sections stained with luxol fast blue. Image ‘a’ 
demosntrates a section with intact WM. Image ‘b’ shows some signs of WM 
degeneration.  
a) 
b) 
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 Immunohistochemistry (IHC) 
  IHC methods 
Paraffin wax embedded sections were dewaxed in two changes of xylene (5 
and 10 minutes, respectively) before being rehydrated in 3 changes of alcohol 
(100%, 95%, and 75%) before being placed in deionised water. 600mls of 10% 
tri sodium citrate solution (BDH, USA) (60mls TSC to 540mls water) were then 
brought to boil in the microwave at high power. Once brought to boil, any 
evaporated water was replaced and sections were added. Sections and TSC 
solution were again brought to boil. Once boiling the power was switched from 
high to medium-high power for 11 minutes. Sections and TSC were then left to 
cool for 20 minutes. Sections were then quenched in 500mls of tris-buffered 
saline with triton (TBS-T) [12g Tris (Fisher Scientific, UK), 81g NaCl (Fisher 
Scientific), 7mls Concentrated hydrochloric acid, and 20mls triton (Sigma 
Aldrich, UK)], and 15mls hydrogen peroxide (H2O2) (Fisher Scientific, UK) for 15 
minutes. After quenching, the sections were washed in TBS-T buffer with 3 
changes of 3 minutes each to remove any H2O2. Sections were then placed on 
IHC rack and blocked (15µl of serum for every 1mls of buffer). The amount of 
buffer used was based on the amount needed to suitably cover the section. 
Non-specific binding was blocked with horse serum (anti-mouse primary), goat 
serum (anti-rabbit primary), or rabbit serum (anti-goat primary). Block was left to 
incubate with section for 30 minutes at room temperature. Excess block was 
then removed from the section, but not washed, and the primary antibody was 
added. The amount of primary antibody used was dependent on individual 
protocol. Bovine serum albumin (BSA) was added to the primary antibody at a 
ratio of 1:300. Sections were then left to incubate at 4ºC overnight. The 
following day, sections were washed in TBS-T with three washes. Sections 
were then incubated for 30 minutes with secondary antibody (5µl of secondary 
– targeted at the host animal the primary antibody originated, and 15ul of block, 
for every 1mls of buffer), followed by a wash of three three-minute changes of 
TBS-T. Sections were then incubated with tertiary antisera ABC solution (1 drop 
of A and 1 drop of B for every 2.5mls of buffer for 30 minutes, followed by three 
three-minute washes in TBS-T. Immunocomplexes were visualised using 
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diaminobenzidine (DAB) (Sigma Aldrich, UK) (100mls DAB and 267ul H2O2 in 
400mls of buffer).  
Sections were then washed, dehydrated through 75%-100% ethanol, placed in 
two changes of xylene for 5 minutes, and mounted using DPX (Merk, UK). 
 Fluorescent labelling (double immunofluorescence) 
Ten μm sections were dewaxed as previously described. In addition to the 
antigen retrieval steps previously described, sections were placed in formic acid 
for 4 hours at room temperature. As section were to be dual stained with two 
different primary antibodies they were blocked with both goat and horse 
antibody, as previously described, and washed. Sections were then incubated 
with both sets of primary antibody overnight. Following another wash phase, 
sections were then incubated with Dylight fluorescent secondary antibodies 
(Rabbit- red 550 and mouse- green 488) (Vectalabs, UK) for 45 minutes (all 
fluorescent staining was performed in the dark, with sections covered with 
aluminium foil to prevent bleaching of the antibody), followed by another wash 
phase. Sections were then mounted with Vectashield (Vecta Labs, UK) 
mounting solution with DAPI staining. All staining was performed in PBS buffer 
at a pH of 7.5. Sudan black was used to reduced the auto-fluorescence of 
lipofuscin, with care not to remove too much Dylight fluorescence.  
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Antibody Target Manufacturer Species Concentration 
4G8 Amyloid β, APP Signet Mouse 
(MAb) 
1:1000 
AT8 Hyperphosphorylated 
tau 
Invitrogen Rabbit 
(MAb) 
1:2000 
Calbindin Calcium-binding proteins Sigma Mouse 
(MAb) 
1:2000 
Calretinin Calcium-binding proteins Sigma Rabbit 
(PAb) 
1:1000 
COX4 Cytochrome oxidase IV Abcam Mouse 
(MAb) 
1:200 
Parvalbumin Calcium-binding proteins Sigma Mouse 
(MAb) 
1:1000 
GRP78 Glucose-regulated 
protein 
Abcam Rabbit 
(PAb) 
1:2000 
SMI31 Phosphorylated 
neurofilaments 
Alpha center Mouse 
(MAb) 
1:50,000 
SMI32 Phosphorylated 
neurofiliaments 
Convance Mouse 
(MAb) 
1:1000 
 
2-3 table showing list of antibodies and methods used in this study. All normal horse serum 
blocked at 5%. MAb = monoclonal antibody, PAb = polyclonal antibody. Secondary antibody 
concentration 0.5%. 
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 Imaging and image analyses techniques 
 Brightfield microscopy 
Images from stained sections were captured on either a Zeiss Axioplan 2 or an 
AX10 microscope, with an infinity 2 camera at a magnification determined by 
the type of stain used and type of analysis to be performed. The number of 
images subsequently taken was sufficient to provide a suitable illustration of the 
sample area (between 10 and 15 images).  
 Densitometric image analysis 
Image Pro (Mediacybernetics, USA) was used to assess staining levels in 
images captured from section. Using the software, measurements of the total 
area of immunoreactivity as a per area percentage (p/a) could be ascertained. 
Staining intensity, as measured by integrated optical density (IOD), could also 
be measured, which assesses the level of staining per pixel.  
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Figure 2-4 demonstrating quantitative image analysis using the 
densitometric technique using Mediacybernetics Image Pro 
software. This screen capture demonstrates how the histogram-
based analysis highlights areas immunestained in red and 
translates this information into a percentage of the total area 
analysed.  
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 Three dimensional stereology 
Sections of thirty μm thickness Nissl stained were analysed using 3D stereology 
as described previously (Foster et al. 2014). Stereology allows for the random, 
unbiased, and systematic analysis of tissue (Gundersen et al. 1988; Gundersen 
1988; Moller et al. 1990; West et al. 1991; Mayhew and Gundersen 1996). It is 
considered more reliable than traditional 2D analysis for its allowance of 
analysis using a 3D sampling area, making use of the x, y, and z axis for 
sampling. A 4µm guard volume was removed from the top and bottom of 
section to remove potential mechanical damage artefact which may result from 
cutting. This still left a 22µm thick section which has been shown as sufficient 
for this form of analysis (Harding et al. 1994). Using a wand tool, areas of 
interest were mapped out at 2.5x objective using Visiopharm Integrated 
Software (VIS). The programme then selects 25-40 frames at random from 
within the area of interest.  Neuronal volume estimates and cell counts were 
performed at 100x objective from each of these randomly selected frames. Cell 
densities were measured using an optical disector where counts are performed 
on neurons within a specific disector box, and overall densities calculated using 
the following equation (Sterio 1984). 
 
 
 
Where: Nv = Numerical density  
 p-  = Disector samples  
 Q-  = Number of objects counted  
 P   = Total number of disectors 
 V  = Disector box volume           
 
VP
Q
Nv
p





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Individual pyramidal neuron volume estimated using the nucleator method 
(Gundersen et al. 1988; Gundersen 1988), in which a probe is placed in the 
centre (or nucleolus) of a cell, from which 6 randomly orientated lines are fired. 
An operator then marks on screen where these probes intersect the cell 
boundaries. From this information the software programme can then make an 
estimate on neuronal volume (Figure 2-5). 
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Figure 2-5 a) illustrating frontal lobe regions (O. Perry 1993)  and b) image of the nucleator principle for 
assessing neuronal volumes. 
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Figure 2-6 cartoon demonstrating the multi-planed, 3D nature of the stereology technique.  
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 2D analysis of pyramidal neurons 
Images were taken from a selection of the Nissl stained sections used in the 
previous 3D stereological study which contained both the dlPFC and the OFC. 
From these images pyramidal neurons were randomly selected from layers III 
and V of the dlPFC and the OFC. On screen measurements were then used to 
assess the individual neurons maximum length and width. The ratio between 
length and width was then calculated using the following formula: ratio = 
length/width.  
To assess neuronal volumes, these images from the dlPFC and OFC from 
control cases were used to calculate neuronal size. Using the wand tool to draw 
around these individual cells it was possible to use densitometric analysis to 
determine the total number of pixels within the area of the delineated cell. 
Neurons containing more pixels were deemed to have a larger volume than 
those containing fewer pixels. All images were also analysed using Image Pro 
analysis (Mediacybernetics, USA). 
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 Sclerotic index measurements. 
The diameters of the lumen and vessel were measured using the software, 
VasCal. VasCal was developed by a former member of the Neurovascular 
Research Group (NRG), Y. Yamamoto (Yamamoto et al. 2009). By 
superimposing lines onto an image of a cross sectioned vessel it is possible to 
calculate the lumen size, vessel diameter, and the ratio of the two, giving the 
sclerotic index. The line measurements are related to the actual size of the 
vessel as the software is previously calibrated by measuring a graticule (Figure 
2-7).  
  
Figure 2-7 showing a cartoon of a vessel’s lumen being assessed the VasCal 
software.  
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 Atrophy analysis estimates 
We measured the degree of atrophy in dlPFC of PSND brains versus those of 
PSD. Adapted from methods proposed by Lon White et al (Gelber et al. 2012) 
and correspondence with the author we investigated three markers for atrophy: 
the ratio of brain weight to intracranial volume, the ratio of cortical thickness to 
head diameter, and neuronal loss. 
Brain weight was established from post mortem examination of the CogFAST 
cases. Intracranial volume was measured from MRI during the CogFAST study, 
where available.   
Cortical thickness was taken from the sulcus of area 9 of the dlPFC at 2.5x 
objective. Three measurements were taken from each side of the sulcus and a 
mean calculated to remove any artefact which may result from cutting the 
section anything other than perfectly coronal which may course the cortex to 
appear thicker than it actually is. 
Head diameter was taken from a population mean as established by R. P. 
Ching et al (Ching 2007). Neuronal loss was scored on a 1-8 scale (1 = no loss, 
8 = severe) in the region of the dlPFC. 
All raw data was converted into a Z score allowing for each individual marker to 
be compared to one another.  
                                                                 Z = (x-u)/σ 
Where: X = raw score U = mean, and σ = standard deviation 
 
Each marker was assigned a percentage weight indicating how much its Z 
score would influence the final result (Gelber et al. 2012). Specific parameters 
were selected and given a percentage based on their perceived impact on 
cortical atrophy. The three parameters used to assess cortical atrophy were: 
1. Brain weight vs. intracranial volume (50%) 
2. Cortical thickness vs. head diameter (40%) 
3. Neuron density (10%) 
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The final score for each subject group was the total Z score based on the above 
percentages. 
 Myelin index 
Ten μm sections were stained using LFB and analysed using image pro as 
previously described by Ihara et al (Ihara et al. 2010). 
An image was taken of each slide using a digital camera before being 
converted to grey scale images in Photoshop. Myelin loss was then determined 
in a large series of LFB stained serial coronal section from cases and controls. 
White matter was drawn around using the want tool map out the area of interest 
(ROI).  
The detected range of grey level within the WM in each image, depicting level of 
staining intensity 0-115 (0, black; 115, white) was divided into quartiles for 
example 0-29, 30-59, 60-89, 90-119 and the median of each quartile calculated; 
14.4, 43.1, 71.9, 100.6. 
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Figure 2-8 demonstrating the quartile analysis method for determining myelin 
index (Ihara et al. 2010). 
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 Golgi-Cox technique 
 Rapid single-section Golgi technique 
Each 200µm free floating section was placed in 4% paraformaldehyde, 0.2% 
picric acid in 0.1M phosphate buffer solution (pH7.4) solution, before being 
placed on an orbital shaker to be gently agitated for 24 hours in the dark. 
Sections were rinsed in 0.1M phosphate buffer before being immersed in 0.02% 
osmium tetroxide solution for 20 minutes. Again sections were placed in the 
dark on an orbital shaker. Following this sections were then rinsed in 0.1M 
phosphate buffer for two minutes before being immersed in 3% potassium 
dichromate and again placed on orbital shaker in the dark for a further 24 hours. 
Excess chromation was removed with a distilled water rinse, and sections were 
then placed between two glass coverslips, with epoxy/cyanoacrylate used as an 
adhesive. Sections were then immersed in 1.5% silver nitrate for 24 hours in 
dark, at room temperature. Coverslips were then removed and the section was 
rinsed in distilled water to remove excess crystals which have formed overnight. 
Sections were then mounted on gelatin-coated slides before drying at room 
temperature for one hour. Sections were then dehydrated in 95% - 100% 
ethanol (as previously described). Sections were then placed in two sets of 
xylene (5 minutes at each) before mounting section with cover slips using DPX 
as an adhesive. Images were then taken using brightfield microscopy. Adapted 
from Dall’Oglio (Dall'Oglio et al. 2010) and Gabbot (Gabbott and Somogyi 
1984). 
   
 Golgi-Kopsch technique 
Tissue sections ~1.5cm2 and 0.3cm thick were cut using vibratome before being 
rinsed in deionised water. The section was then placed on wadded sterile 
cotton gauze in chromation solution of 2% potassium dichromate, 3.5% 
paraformaldehyde (pH). pH was checked at intervals with a pH of 4.7 indicating 
the need for a solution change. A total of eight solution changes were 
performed in 96 hours. Tissue sections were then placed in increasing 
concentrations of silver nitrate solutions (filtered before use): 0.2, 0.5, 0.75% for 
five minutes. Sections were then allowed to sit in 1% nitrate for one week in the 
dark. Following this incubation, tissue sections were then washed in three 
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changes of deionized water over 2 hours, before dehydrated in ascending 
alcohol concentrations. Sections were then embedded in paraffin wax from 
which serial sections ranging from 25um – 100um were cut using a 
Microtome®, before being mounted onto slides with DPX. This method was 
adapted from Rosoklija, G., et al (Rosoklija et al. 2003). 
 
 Statistical analyses 
All statistical analysis was performed on IBM SPSS statistics 22 (IBM, USA). 
Distribution analysis was performed using the Shapiro-Wilk analysis, test for 
normality. Differences between groups were performed using either using the 
ANOVA or Kruskal-Wallis tests for normal and non-normally distributed data, 
respectively. If these tests picked up significance between groups then pairwise 
differences between groups were performed using Mann-Whitney U test (for 
normally distributed data) or Tukey (parametric testing). Significance was set at 
p < 0.05. Spearman’s rank coefficient (rho) was used to test correlations 
between ages, fixation times, post mortem delay, and other variables. Scatter 
diagrams were then used to access the relationship between variables with 
significant correlations.
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Chapter 3. Pyramidal neurons of the prefrontal 
cortex 
 Introduction 
The frontal lobe is classically associated with executive functions. These 
cortico-subcortical networks, which may span relatively vast distances 
throughout the brain are formed via the projections of large cortical nerve cells 
known as pyramidal neurons. Changes or damage to these neurons may result 
in selective disconnection of cortico-cortical pathways in those with vascular 
pathology and AD, and linked to cognitive decline and executive dysfunction 
(Tekin and Cummings 2002; N. Ishii et al. 1986; Wolfe et al. 1990; Stout et al. 
2003; Hof and Morrison 2004, 1991; Hof et al. 1990; Hof et al. 1989; Hyman et 
al. 1986; Lewis et al. 1987). Frontal lobe damage is common in several disease 
states associated with dementia and executive function including VaD and 
FTLD (Deramecourt et al. 2012; Ratnavalli et al. 2002; N. Ishii et al. 1986; E. J. 
Burton et al. 2004), and AD (Binetti et al. 1996). Neuronal loss in the prefrontal 
cortex is common in AD, associated with memory loss due to temporal lobe 
atrophy (Khachaturian 1985; Chan et al. 2001), with symptoms beyond memory 
loss, such as executive function, (Morrison and Hof 1997; Hof et al. 1990; 
Binetti et al. 1996). It has been reported that larger pyramidal neurons, those 
responsible for cortio-cortical connections between the prefrontal and temporal 
regions have been shown to be more vulnerable than smaller neurons to 
pathology (Hof and Morrison 1991; Hof et al. 1990) such as 
hyperphosphorylated tau, which is found in high proportion in these cell types 
(Braak and Braak 1986). Additionally, Buee et al reported that specifically, the 
most vascularised areas, layers III and V, exhibited the highest burden of 
microvascular pathology (Buee et al. 1994). Hoff and colleagues reported 
reduced SMI-32 immunoreactivity (a marker for healthy neurons) in large 
pyramidal neurons within layers III and V of Alzheimer subjects (Hof et al. 
1990). This suggests that these layers are particularly vulnerable to pathology, 
as indicated by the presence of fewer healthy neurons. This decline in healthy 
neurons may relate directly to disruption of the cortical circuits through neuronal 
dysfunction. In addition, those suffering depression, a disease thought to be 
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related to vascular pathology within the frontal lobe (Alexopoulos et al. 1997), 
were found to have reduced pyramidal neuronal volumes within the dlPFC 
when compared to aged matched controls, though no change in glial or non-
pyramidal neuron number (Khundakar et al. 2009). This evidence suggests a 
significant relationship between vascular abnormalities and excitatory pyramidal 
neuron dysfunction within frontal lobe circuitry.  
The dorsolateral prefrontal cortex appears to be vulnerable to vascular 
pathology (Deramecourt et al. 2012; N. Ishii et al. 1986), which is known to 
negatively impact executive functions. In those suffering depression the dlPFC 
has been shown to be affected by vascular pathology (Alexopoulos et al. 1997; 
Alexopoulos et al. 1999; Alexopoulos 2003). The OFC and ACC appear to be 
spared suggesting a significant role for dlPFC in the development for such 
disease states (Khundakar et al. 2009; Khundakar et al. 2011c, 2011b; 
Rajkowska et al. 1999). MRI studies have shown WMH in the frontal lobe white 
matter (E. Burton et al. 2003). This area contains the cortico-cortical 
connections emanating from pyramidal neurons of the dlPFC, ACC, and OFC, 
any breakdown of which may result in executive dysfunction (Tekin and 
Cummings 2002). 
 
 Stereological analysis of the pre-frontal cortex 
Several previous studies have relied on two-dimensional (2D) analysis to 
assess neuronal volumes and densities. The potential problem with this single-
plane analysis is that it can result in over counting in favour of larger neurons 
whose profiles may appear across several serial sections leading to inaccurate 
and unreliable counts (Gundersen et al. 1988; Mayhew and Gundersen 1996). 
Historically, neuronal volume was often assessed by appearance and shape, 
relying heavily on the subjections of the operator (West and Slomanka 2001).  
Three dimensional (3D) stereology allows for a 3D interpretation of extra thick 
sections for accurate, quantitative analysis. Utilising random, unbiased, 
systematic sampling techniques, and analysing thicker tissue section (> 30um) 
(Harding et al. 1994), it is possible to gain reliable counts and volume estimates, 
as neurons can be viewed in their entirety within the tissue unlike with 2D 
analysis where neurological bodies are viewed at the discretion of their 
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topological orientation (West and Slomanka 2001; Baddeley 2001; West 1999; 
Schmitz and Hof 2007). Neurons are then only counted if they fulfil three 
criteria: size, shape, and the presence of a nucleolus. Neuronal volumes are 
assessed using the nucleator tool (Three dimensional stereology) (Gundersen 
et al. 1988), using the nucleolus as the centre-reference point for each cell.  
Using 3D stereology, Bussiere et al (Bussiere, Giannakopoulos, et al. 2003) 
assessed SMI32 stained, pyramidal neuronal volumes in layers III and V of the 
dlPFC in those with AD, finding significantly lower volumes in those with 
dementia when compared to controls (Bussiere, Gold, et al. 2003). Khundakar 
et al used 3D stereology to access neuronal volumes in the three pre-frontal 
circuits which control executive function in depression. Interestingly they found 
decreases in pyramidal neuronal volumes in the dlPFC of those suffering 
depression, but did not find similar changes in the OFC or the ACC, suggesting 
a localised and specific response in this area of the brain (Khundakar et al. 
2011b, 2011c). It is plausible that vascular changes in depressive illness 
(Alexopoulos et al. 1997), may reflect the decreases in volumes resulting from 
reduced trophic factors, combined with a chronic hypoxic state affecting the 
functioning of these cells. This may have implications for other vascular 
pathology based diseases such as PSD or VaD. This correlation between 
cellular volumes and disease states suggest reduced neuronal size may be a 
reliable marker for decreased function. The dlPFC appears vulnerable to other 
disease processes, too. Neuronal atrophy in the dlPFC was also reported in  
sufferers of select autism (Courchesne et al. 2011), and schizophrenia (Pierri et 
al. 2001).  
Though the vascular pathology may impact the frontal lobe, reduced cerebral 
blood flow can have a global impact, affecting other areas of the brain. Reduced 
neuronal volume changes are also apparent within the temporal lobe, with 
reduced pyramidal neuronal volume apparent in the hippocampus of AD, VaD, 
and post-stroke suffers (Gemmell et al. 2012). Though the hippocampus is not 
traditionally associated with executive function, the complex interplay between 
the hippocampus and the frontal lobe means that damage to one brain region 
may impact on another (Tekin and Cummings 2002). However, though profound 
changes in pyramidal neurons have been reported in the hippocampus in post-
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stroke survivors (Gemmell et al. 2012), little is known of the effect of stroke 
within the prefrontal cortex, or how this may impact delayed PSD. 
The purpose of this study was to assess the pyramidal neuronal population 
within the three pre-frontal cortices; the dlPFC, OFC, and ACC, in post-stroke 
survivors. These would then be compared with subjects with AD, VaD, and 
Mixed AD/VaD and aged-matched elderly controls. Pyramidal neuron cell 
volume and population density were quantified and related to clinical findings 
gathered from the COGFAST study in an attempt to delineate the pathological 
substrates which determine dementia after stroke between post-stroke 
demented and post-stroke non-demented subjects. All brain samples from the 
subjects were assessed for hallmark vascular pathology and AD type pathology 
in an attempt to assess their respective effects. 
 
 Methods 
 
 Subject demographics 
Details of the subjects are given in Table 3-1. Mean age at death and post-
stroke survival times were not significantly different between groups thus 
dementia and executive dysfunction were the only features separating PSND 
and PSD (Table 3-1). Classification between PSND and PSD groups was made 
at a mean of 7.6 months before time of death. The location of the stroke did not 
appear to influence cognitive outcome, nor did the level of vascular pathology 
between PSND and PSD (Table 3-2). Both Alzheimer’s disease and mixed 
dementias showed significantly higher tau and amyloid pathology when 
compared to all other groups. 
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Group 
(+ SEM) 
No of 
cases 
Age, 
years 
PMD, 
hours 
FT, 
weeks 
Frontal 
vascular 
score 
Braak  CERAD 
Control 24 81.5 (2) 35.7 (5) 11.3 (3) N/A 2 (1) N/A 
PSND 10 83 (1) 
37.9 
(6) 
3.8 (2) 
4.5 (1) 2.3 (1) 1.6 
(0.2) 
PSD 11 87 (1) 
40.3 
(8) 
1.9 (1) 
4.3 (1) 2.6 (1) 1.3 
(0.3) 
VaD 14 83.8 (2) 
46.9 
(6) 
4.9 (1) 
5 (0.6) 2.2 
(0.3) 
0.8 
(0.3) 
Mixed 12 83.9 (2) 
36.8 
(6) 
4.6 (2) 
4 (1) 5.4 
(0.2) 
2.7 
(0.2) 
AD 12 85.6 (2) 
43.4 
(9) 
7 (2) 
1 (1) 5.4 
(0.2) 
3 (1) 
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Table 3-2 Stroke subject demographics. OSCP = Oxford community stroke project LACS = lacunar stroke, PACS = partial 
anterior stroke, POCS = posterior circulation stroke, TACS = total anterior circulation stroke. Unknown = no CT report 
available. 
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 Three dimensional stereological analysis of neuronal volumes and 
densities 
The neuronal volumes and densities of the pre-frontal cortex in three cresyl fast 
violet stained 30µm serial sections were measured using three-dimensional 
stereology. The optical dissector and nucleator techniques were used to 
estimate neuronal density and neuronal volume, respectively (see Three 
dimensional stereology). In addition to analysing PSND and PSD subjects 
aged- controls, VaD, mixed, and AD subjects were also analysed.  
 Two dimensional analysis 
Neuronal volume and dimensions of pyramidal neurons were measured in 
control cases in both the OFC and dlPFC using 2D dimensional densitometric 
analysis and onscreen measurements. The purpose of this analysis was to 
establish whether or not the differences between neuronal volumes detected 
using 3D stereology between the two regions could be detected using a less 
sensitive technique such as 2D analysis.  All analysis was performed on CFV 
stained sections at a magnification of 25x (See 2D analysis of pyramidal 
neurons).  
 Sclerotic index 
SI measurements were performed using the VasCal programme as described 
earlier (see methods). A minimum of 10 vessels were imaged in grey matter of 
the dlPFC and the white matter of the prefrontal cortex. All analysis was 
performed on 10 µm haematoxylin and eosin stained sections. 
 Immunohistochemistry 
Ten μm sections were stained using immunohistological techniques as 
described previously. SMI31 (Alpha center, USA) (1:50,000) was utilised to 
stain neurofilament proteins present in damaged or struggling neurons, 
whereas SMI32 (Convance, USA) (1:1000) was used to highlight physically 
healthy, functioning neurons. AT8 antibodies (Innogetics, UK) were used to 
detect hyperphosphorylated tau in the dlPFC in all groups.   
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 Fluorescent immunohistochemistry 
10µm sections from the frontal lobe of each disease group containing the dlPFC 
were stained with AT8 and 4G8 (Signet, USA) antibodies for 
hyperphosphorylated tau and β-amyloid, respectively and visualised with dylight 
kit (Vector Laboratories, UK), mounted with vector shield mounting media, with 
DAPI (Vector Laboratories, UK) and imaged as described previously in 
methods. 
 Cortical thickness measurements and atrophy estimates 
Cortical ribbon thickness in all cases was assessed at 2.5x magnification in 
30µm Nissl stained sections. Measurements were taken from the pial surface to 
the edge of the WM from both sides the sulcus of area 9 containing the dlPFC. 
Three measurements were taken from each side of the sulcus, from the pial 
surface to the WM and averaged to avoid any artefact which may arise from 
uneven cutting of the section (see Atrophy analysis estimates).  
Cortical atrophy scores of the dlPFC were estimated using an adapted formula 
first proposed by White et al (Gelber et al. 2012) as well as personal 
correspondence. Z scores were calculated from the values determined from 
three markers of cortical atrophy: the ratio between brain weight to intracranial 
volumes, cortical thickness to head diameter, and local neuronal loss (see 
method).  Cortical thickness means were compared between layers III and V 
with correlations investigated using spearman’s rank coefficient. 
 Stroke location analysis 
Review of the pathologist’s report of post-stroke subjects recruited into the 
CogFAST study revealed the location of the initial stoke. This data was used to 
investigate the relationship between stroke location and cognitive outcome. 
 Statistical analysis 
All statistical analysis was performed using IBM SPSS Statistics 21 software 
package. Neuronal volumes and densities were found to be non-normally 
distributed. Group means were compared using Kruskal-Wallis test and 
differences in neuronal volumes and densities and SI measurements between 
groups were analysed using Mann-Whitney U test. Correlations between 
volumes and densities and other variables were established using spearman’s 
rank coefficient. Z scores were established using the formula: z = (x-u)/σ. 
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 Results 
 Pyramidal neuronal densities 
There were no significant differences between any group within layers III or V of 
the dlPFC (total 36 132 and 39 739 mm2), nor the ACC (43 497 and 39745 in 
layers III and V, respectively). When disease cases were removed from analysis 
in layer III of ageing controls neuronal density was calculated to be (per mm2): 
35 110, 49 372, and 33 321 in the dlPFC, the ACC, and the OFC, respectively. 
Whilst pyramidal neuronal densities in layer V were calculated at (per mm2): 39 
436, 41 057, and 30 960 in the dlPFC, ACC, and OFC, respectively. 
There were no significant differences in the density of pyramidal neurons 
between controls and disease groups, or in the neuronal densities between 
post-stroke survivors in any area in either layers III or V in the dlPFC or the 
ACC (p > 0.05). In the OFC pyramidal neuronal densities in layer III and V in 
mixed (p = 0.001, and p = 0.015 respectively), and layers III of VaD were 
significantly lower than non-demented controls (p = 0.023). In addition, when 
compared to PSD layers III and V of mixed dementia showed significantly lower 
densities in the OFC (p = 0.049, and p = 0.028 respectively). AD was found to 
have significantly lower density than non-demented subjects in layer V (p = 
0.007) (Figure 3-1).  
Correlation studies between neuronal densities and post-mortem reports 
showed no clear evidence to indicate that neuronal densities or volumes were 
affected by the length of fixation period (σ = -0.130, p = 0.232), post-mortem 
delay (σ = 0.017, p = 0.883), age (σ = 0.141, p = 0.213), Braak (σ = 0.108, p = 
0.352), or CEARD (σ = 0.016, p = 0.905). 
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Figure 3-1 neuronal densities in the dlPFC, ACC, and OFC. Controls = aged matched 
controls, PSND = post-stroke no dementia, PSD = post-stroke dementia, VaD = 
vascular dementia, mixed = mixed vascular and Alzheimer’s disease, AD = 
Alzheimer’s disease. * = significance different to ageing controls (p < 0.05). Controls 
vs mixed layer III and V (p = 0.001, and p = 0.015 respectively), PSD vs mixed layer III 
and V (p = 0.049, p = 0.028 respectively), Controls vs VaD in layer III (p = 0.023), PSND 
vs AD in layer III (p = 0.007).  
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 Pyramidal neuronal volumes 
Pyramidal neuronal volume varied largely between brain regions (Figure 3-2), 
with average neuronal volumes in layer III of aged controls found to be (in μm3) 
1129, 1087, and 732 in the dlPFC, the ACC, and the OFC respectively. 
Neuronal volumes in the ACC were significantly larger than those in both the 
dlPFC (p = 0.001, p = 0.004 in layers III and V, respectively) and the OFC (p = 
0.001, p = 0.001 in layers III and V, respectively), across all groups. Neuronal 
volumes of the OFC, in both layers III and V, was significantly lower when 
compared all groups of the ACC, and in controls (p = 0.042, p = 0041 in layers 
III and V, respectively) and PSND (p = 0.001, and p = 0.002 in layers III and V, 
respectively) of the dlPFC, with neuronal volumes decreasing in the following 
order: ACC > dlPFC > OFC. Average neuronal volumes in both layers III and V 
of the OFC were found to be ~50% lower than all groups in the ACC, and non-
demented groups of the dlPFC (p = 0.001).  
In contrast to neuronal densities, neuronal volumes were markedly affected in 
demented subjects. In the dlPFC, all demented groups exhibited reduced 
pyramidal neuronal volumes in layer III when compared to both controls and 
PSND. PSD (p = 0.027, p = 0.01), VaD (p = 0.012, p = 0.001), mixed (p = 0.03, 
p = 0.004), and AD (p = 0.035, p = 0.005) displaying significantly smaller 
neurons when compared to controls and PSND, respectively. Pyramidal neuron 
volumes in layer V showed a similar pattern: PSD (p = 0.007), VaD (p = 0.002), 
mixed (p = 0.008), and AD (p = 0.015) were reduced when compared to 
controls. Pyramidal neuron volumes in VaD the group were also significantly 
lower when compared to post-stroke non-demented survivors (p = 0.034). In 
both layers III and V controls exhibited similar neuronal volumes to post-stroke 
non-demented survivors (p = 0.084 and p = 0.291 in III and V respectively). 
There was no significant difference in neuronal volumes between control cases 
and PSND (p > 0.05). 
Correlation studies were implemented to assess and compare the relative rate 
of neuronal volume change in layers III and V of the dlPFC, seeing as this 
region appeared most vulnerable to the apparent neuronal changes. Layer III 
and V neuronal volume correlated in ageing controls and AD (σ = 0.696, p= 
0.012 and σ= 0.695, p = 0.026 respectively), however in all vascular based 
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groups; post-stroke survivors, VaD, and mixed AD/VaD pathology layer III did 
not correlate with layer V (Table 3-3). 
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Thickness 
(mm) 
Controls PSND PSD VaD Mixed AD 
Mean 
(SEM) 
2.96 + 0.13 2.75 +0.11 2.89 +0.17 2.78 +0.10 2.98 +0.12 2.86 +0.13 
Volume       
Layers III 
and V R (p 
value) 
0.696 
(0.012) 
0.468 
(0.172) 
0.181 
(0.594) 
0.610 
(0.061) 
0.378 
(0.282) 
0.695 
(0.026) 
Table 3-3 showing correlations between layer III and layer V pyramidal neuronal volumes in the 
dlPFC. Ageing controls = aged matched controls, PSND = post-stroke no dementia, PSD = post-
stroke dementia, VaD = vascular dementia, mixed = mixed vascular and Alzheimer’s disease, AD = 
Alzheimer’s disease. 
84 
 
 
 
 
 
 
 
Figure 3-2 pyramidal neuron volumes in the dlPFC, ACC, and OFC. Controls = aged matched 
controls, PSND = post-stroke no dementia, PSD = post-stroke dementia, VaD = vascular dementia, 
mixed = mixed vascular and Alzheimer’s disease, AD = Alzheimer’s disease. * = significant to 
controls, ** = significant to controls and PSND (p < 0.05). Controls vs PSD (P = 0.027), VaD (p = 
0.012), mixed (p = 0.03), and AD (p = 0.035). PSND vs PSD (p = 0.01), VaD (p = 0.01), mixed (p = 
0.004), and AD (p = 0.005) in layer III. In layer V controls vs PSD (p = 0.007), VaD (p = 0.002), mixed 
(p = 0.008), and AD (p = 0.015). PSND vs VaD (p = 0.034).   
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 Two dimensional analysis 
Two dimensional analysis of pyramidal morphology was undertaken in order to 
a) confirm the volumetric differences between neurons in the dlPFC and the 
OFC, and b) assess the relative shape and dimensions of the respective 
pyramidal neuronal populations (if the neuronal difference detected using 3D 
stereology was as profound as thought, a less sensitive technique such as 2D 
analysis should be able to pick it up). Neuronal volumes as assessed using 2D 
densitometry analysis showed pyramidal volumes in the dlPFC were on 
average 34% and 27% larger than those of the OFC in layers III and V 
respectively (Figure 3-3). Analysis showed length/width ratio was significantly 
higher (p = 0.012, p = 0.002 layer III and V, respectively) in the OFC than 
pyramidal neurons in the dlPFC, suggesting those in the OFC are longer and 
slimmer than those in the dlPFC. 
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Figure 3-3 showing pyramidal neuron volumes in layers III and V in control cases of 
the dlPFC and OFC. P/A = per area (a count of average pixel content of each neuron). 
* = significant compared to other brain region (p < 0.05). dlPFC vs OFC layer III (F = 
21.457, p = 0.010), layer V (F = 11.096, p = 0.027). 
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Figure 3-4 showing significant correlations between pyramidal neuronal volumes in the dlPFC and 
clinical variables. a) σ = 0.707, p = 0.0001), b) σ = 0.500, p = 0.021, c) σ = 0.583, p = 0.006, and d) σ = 
0.444, p = 0.044. 
 
 Correlations with neuropathological findings 
To relate neuronal changes to cognitive function we examined the relationship 
between neuronal densities and volumes within the dlPFC and 
neuropsychometric measures which were taken as part of the CogFAST study. 
Neuronal volume in layer III correlated with a) total CAMCOG scores (σ = 
0.707, p = 0.0001), b) MMSE (σ = 0.500, p = 0.021), and c) the CAMCOG sub 
score for the executive function, orientation (σ = 0.583, p = 0.006). Neuronal 
volumes in layer V correlated with clinical dementia rating (σ = -0.760, p = 
0.003), and d) memory scores (σ = 0.444, p = 0.044) (Figure 3-4).  
  
a) b) 
c) d) 
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 Clinical features in post-stroke dementia and VaD subjects 
Information on the stroke type and location was collected and placed in to a 
table (Table 3-2). From the available clinical information of the cohort analysed 
in this study; nine post-stroke survivors suffered from lacunar strokes, five from 
partial anterior circulation stroke, two from posterior circulation strokes, and five 
from a total anterior circulation stroke with no relationship found between stroke 
type or location and the ultimate fate of the post-stroke survivor (p > 0.05).  
 
 SMI31/32 positive cells in the dlPFC of post-stroke cases and other 
dementias 
To further differentiate between the post-stroke cohort and the other disease 
groups, sections were stained for neurofilament markers SMI31 and SMI32. 
Neuronal counts of pyramidal neurons positively stained with SMI32 did not 
appear significantly different between either post-stroke groups, or between 
post-stroke survivors and aged-control groups in either layer III or V. Counts in 
VaD and AD revealed no significant differences between any groups in layers III 
or V. However, pyramidal neuronal counts were significantly lower in layer V of 
the mixed AD/VaD subjects compared with those with PSND (p = 0.004) and 
PSD (p = 0.037). There was no significant difference between mixed dementia 
subjects and controls (P > 0.05). In addition, no significant difference was found 
in SMI32 counts between any groups in layer III (p < 0.05) (Figure 3-5, Figure 
3-7). 
SMI31 counts showed significantly increased numbers of pyramidal neurons 
displaying positive staining in both PSD (p = 0.004) and VaD (p = 0.031) in 
layer III, but not in layer V (p > 0.05) when compared to PSND. Additionally 
increased SMI31 immunoreactivity was correlated with decreased neuronal 
volumes in both PSD and VaD (σ = 0.573, p= 0.016) (Figure 3-6, Figure 3-8).  
Further analysis showed correlation between SMI31 positive neuron counts in 
layer III and layer V (σ = 0.529, p = 0.001). Additionally, SMI32 positive neuron 
counts correlated significantly with layer III pyramidal neuronal volumes (σ = 
0.733, p = 0.016), with SMI31 positive neuronal counts in layer III correlating 
significantly with SMI31 counts in layer V in those suffering post-stroke 
dementia (Figure 3-9).  
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Figure 3-5 showing SMI32 positive pyramidal neurons in layer III of the dlPFC. a) aged-controls, b) 
PSND c) PSD, d) VaD, e) Mixed, and f) AD. Size bar = 20μm. 
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Figure 3-6 Showing SMI31 positive neurons in layer III of the dlPFC. a) aged-controls, b) PSND, c) 
PSD, d) VaD, e) Mixed, and f) AD. Arrows indicates SMI31 positively stained pyramidal neurons. 
Size bar = 20μm. 
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Figure 3-7 showing counts for SMI31 positive pyramidal neurons in layer III and V. Controls = aged 
matched controls, PSND = post-stroke no dementia, PSD = post-stroke dementia, VaD = vascular 
dementia, mixed = mixed vascular and Alzheimer’s disease, AD = Alzheimer’s disease. * = significant 
to PSND. PSND vs PSD (p = 0.004), VaD (P = 0.031). 
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Figure 3-8 showing counts for SMI32 positive pyramidal neurons in layer III and V. Controls = aged 
matched controls, PSND = post-stroke no dementia, PSD = post-stroke dementia, VaD = vascular 
dementia, mixed = mixed vascular and Alzheimer’s disease, AD = Alzheimer’s disease. * = significant to 
PSND and PSD. PSND vs mixed (p = 0.004), PSD vs mixed (p = 0.037). 
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Figure 3-9 showing correlations (a) relationship between SMI31 staining in layer III vs layer V, (b) SMI32 staining in layer 
V vs SMI31 staining in layer V, (c) SMI32 staining vs layer III volume in post-stroke non-demented subjects, and (d) SMI31 
staining in layer III vs layer V in post-stroke demented subjects. ‘a’ (σ = 0.529, p = 0.001), ‘b’ (σ = ), ‘c’ (σ = 0.733, p = 
0.016), ‘d’ (σ = 0.259, p = 0.020) 
 
 
  
(a) (b) 
(d) (c) 
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 Cortical thickness and dlPFC atrophy 
To explain if neuronal atrophy in the dlPFC of post-stroke subjects was also 
reflected in reduced cortical thickness we compared cortical depths in PSD, 
PSND and controls subjects. Global atrophy or diffuse neocortical ribbon 
reductions were investigated using the technique and formula already described 
above (see Cortical thickness measurements and atrophy estimates). Firstly, 
investigations into to potential changes in the cortical ribbon thickness within the 
dlPFC revealed no significant difference in the degree of cortical thinning 
between demented and non-demented groups which would explain the 
volumetric changes ( 
Table 3-4). There were no significant differences found between the cortical 
thicknesses between any group (p > 0.05) (Figure 3-10, Table 3-5, Table 3-6). 
Secondly, the clinical and post-mortem data of the CogFAST study allowed for 
a more detailed and in-depth cortical atrophy analysis between the two stroke 
survivor cohorts. Using the technique and formula adapted from White et al 
(correspondence) for establishing whole brain atrophy, we calculated potential 
atrophy of the dlPFC, as described earlier (see Cortical thickness 
measurements and atrophy estimates). Parametric ANOVA revealed no 
significant differences in dlPFC cortical atrophy between post-stroke survivors 
or controls (p = 0.193). However student T-test (this test was used in place of 
ANOVA as we were following the protocol set out originally by Lon White et al) 
revealed post-stroke demented subjects did trend towards a significantly larger 
degree of cortical atrophy (lower Z scores) (p = 0.070). T-test  analysis of 
separate components of the formula found that brain weights of those suffering 
from post-stroke dementia were significantly lower than those of PSND (p = 
0.022). No significance was found between tissue fixation times which may 
have affected cortical thickness. 
(SEM) Controls PSND PSD VaD Mixed AD 
Cortical 
thickness 
2.97 
(0.13) 
2.75 
(0.11) 
2.89 
(0.17) 
2.78 
(0.12) 
2.98 
(0.12) 
2.86 
(0.13) 
Significance 
to controls 
(p = ) 
 0.911 0.999 0.959 1.00 0.988 
 
Table 3-4 displaying the mean cortical thickness of the dlPFC in each disease group and their 
respective significance to controls. Control = aged controls, PSND = post-stroke non-demented, 
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PSD = post-stroke demented, VaD = vascular dementia, mixed = mixed AD/VaD pathology, AD = 
Alzheimer’s disease.  
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Table 3-5 showing weight/volume, cortical thickness/head diameter, and neuronal 
density ratios (z scores) within the dlPFC) 
Table 3-6 comparing the cortical atrophy index (z) score between non-demented 
controls and post-stroke dementia. Control = aged controls, PSND = post-stroke non-
demented, PSD = post-stroke demented. 
Figure 3-10 Cortical atrophy Z scores in the dlPFC. Controls = aged matched 
controls, PSND = post-stroke no dementia, PSD = post-stroke dementia. 
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 Comparison of Alzheimer’s type pathology between cases.  
Immunostaining for hyperphosphorylated tau (AT8), and fluorescent co-
localised staining for amyloid β and hyperphosphorylated tau (4G8 and AT8 
respectively) was conducted on the dlPFC to ensure that pathology in this area 
of the brain did not account for the volumetric changes reported. Dual staining 
made it possible to ensure that any one specific brain region was free of either 
pathology, through one assay. No substantial difference was found in the level 
of tau pathology between post-stroke survivors, nor between controls, or VaD. 
Mixed and AD groups, as one might expect, had significantly higher levels of 
hyperphosphorylated tau pathology than any other group. A qualitative analysis 
of hyperphosphorylated tau and amyloid burden demonstrated and reinforced 
this finding (Figure 3-11).   
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Figure 3-11 shows fluorescent stained images from the 
dlPFC layer III of control subjects (A), post-stroke no 
dementia (B), post-stroke dementia (C), vascular 
dementia (D), mixed dementia (E), and Alzheimer’s 
disease (F).  Background auto-fluorescence from 
lipofuscin and red blood cells is evident in all images. 
Hollow arrows = amyloid plaques (green), solid arrows = 
hyperphosphorylated tau (red). Scale bar 50μm. 
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 Discussion 
 3D stereological analysis 
3D stereological analysis revealed changes in pyramidal neuron volumes in 
both layers III and V of the dlPFC which may be associated with changes in 
cognitive function in post-stroke survivors and other ageing related dementias. 
Interestingly, neuronal density appears unaffected in the dlPFC, regardless of 
cognitive status, suggesting neurons are not necessarily lost in these disease 
states.  
 Neuronal densities 
There were no significant changes detected in neuronal densities between any 
group of the dlPFC or the ACC. It has previously been suggested that cognitive 
dysfunction was a direct result of neuronal loss (Fiskum et al. 1999) and would 
have been expected in the regions believed to be pivotal in functions affected in 
dementia. Neuronal death within the dlPFC would be reflected in a reduction in 
the neuronal numbers, marked by a lower neuronal density. The lack of change 
in density would suggest that, although the majority of the neurons appear to be 
still present in diseased cases, with comparable numbers to those of the non-
demented controls, these neurons are in fact not operating as they should. As 
discussed, the individual neuron is part of a much larger, sophisticated unit 
(Nedergaard et al. 2003), both in terms of operating in conjunction with other 
cells such a glia and other neurons and in its own far-reaching role as a 
connective entity (Tekin and Cummings 2002). This complexity increases the 
plethora of potential dysfunction which may befoul a neuron, but not result in its 
death. In contrast, analysis of the OFC revealed specific reductions in neuronal 
density in layer III of mixed dementia when compared to non-demented 
subjects, and VaD, mixed, and AD when in layer V. This loss may be indicative 
of cell death as a result of vascular or neurodegenerative pathology. This 
apparently specific effect in the OFC suggests particular vulnerability of these 
pyramidal neurons. However, no such changes were reported in the post-stroke 
cohort. Additionally pyramidal neurons where found to be significantly smaller in 
the OFC when compared to the other two regions in all groups, including non-
demented controls, suggesting that although this may not be a pathological 
trait, the smaller size makes the neurons more susceptible to damage, and thus 
neuronal loss which may explain the density change. Interestingly, this effect 
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only appears to affect the vascular-based dementias, and is more apparent in 
layer V than layer III. This would suggest that the OFC is particularly vulnerable 
to ischemic damage. The increased susceptibility of layer V may be explained 
by the greater distance these projection neurons must travel in contrast to those 
of layer III (Khundakar et al. 2009). This is reinforced by the lack of significant 
difference in neuronal density between non-demented controls in the three 
separate regions suggesting that though reduced densities were found in the 
OFC of some disease states, all areas begin with a similar density of neurons. 
The loss of neuronal density in layer III may be a result of the synergistic effect 
of damage from both vascular and Alzheimer- type pathology. 
These findings did not correlate with Braak or CERAD scoring, or with fixation 
or post-mortem delay, reinforcing the suggestion that this apparent neuronal 
loss is a result of vascular pathology (Figure 3-1).  
 Neuronal volumes 
In contrast to neuronal densities, analyses of pyramidal neuron volumes 
revealed specific changes within the PFC (Figure 3-2). Within the dlPFC, 
pyramidal neuron volume was found to be significantly lower in all demented 
cases when compared to controls in both layers III and V and when compared 
to PSND in layer III. In layer V neuronal volumes in VaD were significantly lower 
than in PSND. These findings suggest an extreme vulnerability of the dlPFC to 
pathological insult, regardless of aetiology. There also appears to be a strong 
and distinct relationship between neuronal volume and cognitive function. 
Whether pathological insult affecting the dlPFC results in neuronal damage and 
dysfunction which leads to cell shrinkage, or whether naturally reduced 
neuronal volume (as a result of age) increases vulnerability to other risk factors 
which otherwise may not result in dementia in isolation, is unclear. Studies have 
shown a distinct relationship between WMH as seen in imaging studies and 
ischaemic brain pathology detected at post-mortem in subjects suffering small 
vessel disease (Duering et al. 2013; Yamamoto et al. 2009), suggesting 
vascular pathology alone is enough to impact pyramidal neuronal volume, 
without additional pathology. Pyramidal neuron shrinkage in the dlPFC has 
been reported in a number of disease states (Khundakar et al. 2009; 
Courchesne et al. 2011; Pierri et al. 2001) and may therefore suggest distinct 
vulnerability of these cell types, potentially as a result of their increased 
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metabolic requirements. Pyramidal neuronal shrinkage appears to occur in all 
disease groups, regardless of aetiology. Due to the wide-ranging nature of the 
pathology examined it is unlikely that morphological changes observed are 
triggered by the same mechanism each time. Vascular damage as that which 
characterises PSD, VaD and Mixed may result in reduced blood flow to the 
dlPFC; pyramidal neurons in this area then undergo hypoxic stress which 
results in their breakdown and shrinkage. Alternatively, increased WM 
pathology as that found in vascular pathology (Ihara et al. 2010) may disrupt 
neuronal axons connecting the different brain regions. This disconnection may 
lead to a feedback mechanism ultimately resulting in neuronal shrinkage. Those 
suffering from neurodegenerative disease may increasingly struggle as internal 
proteins such as tau (in AD) begin to build up (Goedert 1996; Mandelkow and 
Mandelkow 1998), placing metabolic strain on the neuron. As the tau burden 
increases the neuron eventually begins to dysfunction and reduce in volume. 
This disease related neuronal atrophy was not mirrored in the ACC nor the OFC 
suggesting this is an area specific affect, with the dlPFC either specifically 
vulnerable to such damage, or the OFC and ACC more resistant.  
In aged matched controls neuronal volumes were found to be larger in the ACC, 
followed by the dlPFC, and smallest in the OFC, indicating significant variations 
across different cortices of the brain, perhaps dependent on each regions 
individual role in cognition, or the varying vascular patterns which may present 
in each brain region.  
Neuronal volumes in the OFC were found to be up to 50% smaller than the 
dlPFC or the ACC, with neuronal volumes in the OFC consistent between 
groups, including aged matched controls, suggesting that this smaller volume 
was in fact a regional trait, and not a pathological response to underlying 
pathology. This finding was confirmed using 2D analysis, a less sensitive 
technique, with a similar margin of change (Figure 3-3). 
 Neuronal volumes and cognitive impairment 
The clinical significance of this neuronal shrinkage in the dlPFC is demonstrated 
by correlations between neuronal volume and clinical findings. Neuronal 
atrophy in layer III correlated with both total CAMCOG scores, and MMSE 
scores (Figure 3-4) suggesting a direct relationship between neuronal volume 
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and cognitive dysfunction. However it is not clear whether these changes are a 
direct result of neuronal volume shrinkage in the dlPFC, or as a result of 
neuronal damage elsewhere (Firbank et al. 2007; Gemmell et al. 2012), or 
further along the frontal circuit (Tekin and Cummings 2002). Perhaps more 
significantly neuronal volume also correlated with orientation - a component of 
executive function controlled by the dlPFC, creating a direct link between these 
neuronal changes and executive dysfunction. Neuronal volumes in layer V 
correlated with clinical dementia ratings and memory scores. This is in keeping 
with our understanding of the role of these long-range projection neurons. As 
these projections breakdown, the pre-frontal cortex losses connection with 
areas of the brain such as the hippocampus which is responsible for memory.   
 Stroke location 
The was no apparent correlation between stroke location and clinical outcome 
for post-stroke survivors or neuronal volume changes, suggesting single insult 
sites bare little impact for prognosis (Table 3-2). When taking PSD, VaD and 
Mixed cases into account, long term vascular pathology appears to have a 
severe impact on cognitive outcomes. Damage occurring after a stroke can be 
mediated and limited, quelling potential long term cognitive decline. Factors 
such as the susceptibility of the astrocytes making up the neurovascular unit are 
thought to play an important role in any recovery, especially those suffering a 
stroke (Nedergaard and Dirnagl 2005). With this in mind, stroke sufferers with 
concurrent CVD are perhaps less likely to recover than those without. However, 
no significant differences were found between vascular pathology between 
PSND and PSD which suggest that another, unknown mechanisms may be at 
play. 
 
 Interlaminar correlation 
Though this reduction in pyramidal neuronal volume appeared to affect layer III 
and V in equal measure, it was necessary to explore any potential relationship 
between these two sets of changes. Spearman’s rank coefficient revealed 
significant correlations between layer III and V neuronal volume in both controls 
and AD subjects. There was no correlation detected between layer III and V in 
PSND, PSD, VaD, or mixed cases. This finding would perhaps be expected in 
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control cases where no change of neuronal size is apparent. The lack of 
correlation may suggest that layers III and V are affected differently to vascular 
pathology, or neurons in each layer respond varying degrees. Layer V 
pyramidal neurons extend their axons across greater expanses of WM, perhaps 
making them more vulnerable to the ischaemic damage, pathology which may 
be present in the WM of these cases. Conversely, layer III neurons may be less 
affected as their axons do not tend to project in the deep WM, remaining 
isolated and protected. The significant correlation between layers III and V in 
AD cases suggest different mechanisms may be at work than those in vascular 
pathology groups. The toxic impact of interneuronal tau may affect pyramidal 
neurons in both layers III and V to comparable degrees resulting in a similar 
rate of volumetric decline (Table 3-3).  
 Comparison of neurofilament markers in post-stroke survivors and 
other groups   
Pyramidal neurons positively stained for SMI31 (a marker for cellular damage) 
were found in larger numbers in PSD, VaD, and mixed when compared to 
PSND, however this significance was not shown against aged-controls. This 
finding further differentiated the two post-stroke survivor groups PSND and 
PSD, with a higher proportion of neurons showing damage in the demented 
cases, following a similar pattern to neuronal volume loss, though no correlation 
was found between SMI31 counts and neuronal volume (p > 0.05). 
Interestingly, increased SMI31 staining was seen in both VaD and mixed 
dementia groups (see results), suggesting a vascular component contributing to 
neuronal damage. The lack of significant difference when compared to controls 
was unexpected. One reason may be due to the eclectic nature of the aged-
control subjects. The post-stroke subjects were selected from a well 
characterised cohort, with well-documented clinical histories of disease 
progression which ensured a certain homogeneity between the characteristic 
shared between cases. The control groups, in contrast had very little, if any 
patient history, making it difficult to identify markers which may preclude 
underlying characteristics or pathology potentially affecting each case. In 
addition this made the control group much more heterogeneous when 
compared to post-stroke survivors. Whilst this made them an ideal group to 
demonstrate a wide and varied population, it also gave rise to the possibility of 
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very varied data, with evidence showing that even in the cognitively healthy, 
age can have a detrimental effect on neurons and neuronal connections (West 
et al. 1994; Morrison and Hof 1997). Conversely, mixed dementia showed a 
markedly decreased count for SMI32 positive ‘healthy’ pyramidal neurons within 
layer V when compared to post-stroke survivors, this combined with increased 
SMI31 counts suggests neuronal volume loss, in this group at least is a result of 
neuronal damage. The lack of similar SMI32 findings in other group may again 
pay testament to the synergistic pathology of both AD type pathology and CVD 
(Kalaria et al. 2012; Kalaria 2003). 
Perhaps unsurprisingly, SMI31pyramidal neuronal counts in layer III correlated 
positively with neuronal counts in layer V, suggesting that damage occurs 
simultaneously in both layers. Though when analysed individually, only in PSD 
did SMI31 staining in layer III correlate strongly with counts in layer V (Figure 
3-9). However, this finding was not mirrored in SMI32 stained sections, 
suggesting a limited relationship between SMI31 and SMI32 staining. With this 
in mind, it is necessary to stain with both SMI31 and SMI32 to gauge an 
accurate count of healthy and non-healthy pyramidal neurons.  
 Neuronal volume loss, cortical thinning and atrophy 
Cortical thinning can occur in normal ageing, through atrophy, fixation, 
dehydration, and in disease through neuronal loss (Harding et al. 1994; Kril et 
al. 1997; Opris and Casanova 2014) and this atrophy is thought to result in the 
thinning of the microcolumns which make up the dlPFC (Opris and Casanova 
2014) with early changes in cortical thickness noted in cognitive impairment 
(Cruz et al. 2004) and related to cognitive changes in MCI and AD(Chance et al. 
2011). It was therefore necessary to investigate any potential affect cortical 
change may have on the reported neuronal atrophy. All results were checked 
against fixation times and post-mortem delay for correlation where possible. 
Pyramidal neuronal volumes changes did not correlate with either. No 
correlations were found between dlPFC cortical atrophy index of PSND or PSD, 
or between cortical thicknesses between any groups. This suggests neuronal 
volume changes occur independently of cortical alterations, reinforcing the 
association between neuronal volume change and cognitive dysfunction. In 
addition, any effect of tissue shrinkage, or global atrophy affecting neuronal 
volumes or density changes would be expected to impact all tissue types and 
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regions in the same way. Brain weights were found to be significantly lower in 
PSD cases than PSND. This weight reduction is indicative of tissue loss. 
Though no cortical loss was detected in the dlPFC it does appear there is 
selective, but global loss in the brains of those suffering post-stroke dementia. 
 Alzheimer’s type and vascular type pathology in post-stroke 
dementia and other dementias. 
Neuronal volume changes demonstrate a stark and striking difference between 
the two post-stroke survivor cohorts. As discussed, this change was also found 
in other vascular demented cases, as well as those with high AD pathology. 
Qualitative AT8 analysis revealed no significant difference between the two 
post-stroke survivor cohorts, nor between post-stroke survivors, VaD or control 
groups. However, as expected both mixed and AD groups displayed 
significantly higher levels of hyperphosphorylated tau as detected with AT8 
staining than non-neurodegenerative disease groups. Fluorescent dual staining 
for AT8 and 4G8 confirmed this finding. This data suggests that the clinical, 
cognitive, and pathophysiological differences between PSND and PSD are not 
the result of Alzheimer type pathology. Additionally, investigation of the vascular 
pathology in the frontal lobe revealed no significant difference between PSND 
and PSD subjects, or between any other group. These findings suggest that 
vascular pathology may not be the deciding factor as to why a post-stroke 
sufferer would decline into dementia. However, the lack of significant 
differences detected between any other group, including between mixed, VaD 
and controls would suggest that SI may not be a good predictor of vascular 
pathology, at least not in the frontal lobe grey matter. Furthermore, SI data did 
reveal greater pathology in the WM when compared to the GM in all groups, 
suggesting that the GM may be less susceptible to such damage, and a more 
sensitive technique is required to detect any potential differences between 
disease groups. No significant difference to PVS was reported between any 
groups which was also surprising. PVS have previously been associated with 
WMH (Yamamoto et al. 2009), which are reportedly higher in frequency in those 
suffering specific types of dementia, such as VaD. However, it can be 
suggested that MRI, due to its 2mm limited resolution, may make separating 
large WMH from what are in fact several vessels, all with minor PVS. Though, 
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the sheer number of PVS may be significant in the development of dementia, it 
may suggest why, in this study, no changes to PVS size was identified.  
 Conclusion 
These findings provide original and novel evidence to suggest that reduction to 
pyramidal neuronal volume, specific to the dlPFC, is a significant pathological 
substrate in the development of post-stroke dementia and other dementias. 
Surprisingly, neuronal loss was not evident in the PSD or other dementia 
groups in the dlPFC, suggesting an underlying mechanism which may result in 
this neuronal and cognitive dysfunction. These findings also suggest that these 
volume reductions in the dlPFC are independent of AD pathology and may be 
more in line with vascular based pathologies, with reduced blood flow resulting 
in neuronal atrophy. These findings are associated with increased neuronal 
damage in vascular cases as shown by increased SM31 staining in PSD and 
VaD subjects. This suggests specific damage to the cytoskeleton of pyramidal 
neurons in the dlPFC as a result of vascular pathology.   
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Chapter 4. Non-pyramidal neurons and glial cells 
within the dorsolateral prefrontal cortex 
in post-stroke dementia 
 
 Introduction 
 Non-pyramidal neurons and disease  
Previous studies into the density of non-pyramidal neurons have been revealing 
to the nature of these cells. Hof et al reported that interneurons which stain 
positive for calretinin are resistant to degeneration in AD (Hof et al. 1993). Hoff 
et al also reported differential staining sensitivity of interneurons in the cortex of  
AD subjects, with a subset of interneurons located in layers II, III, and V 
displaying particularly heavy staining of calbindin (Hof and Morrison 1991; Hof 
et al. 1991). This suggested that interneuronal subtypes exhibit differential 
vulnerability in AD. Satoh et al reported parvalbumin positive interneurons in 
those suffering AD were significantly smaller and fewer in number when 
compared to controls (Satoh et al. 1991). Studies in mice have suggested that 
decreased parvalbumin positive neurons contribute to dysfunction in cellular 
networks, with possible connotation in AD subjects (Verret et al. 2012) 
suggesting a role for these cells in cognitive dysfunction.  
Khundakar et al reported no significant changes in non-pyramidal densities in 
the dlPFC, despite reporting significantly smaller pyramidal neurons in elderly 
depressed subjects when compared to controls (Khundakar et al. 2009). This 
lack of change was also reported in the OFC and ACC. Rajkowska et el 
reported no changes in interneuronal numbers in depressed subjects, despite 
finding a 30% decrease in pyramidal neuron volumes in the OFC (Rajkowska et 
al. 2005). Bernstein et al reported partial loss of parvalbumin positive 
interneurons in dementia with Lewy bodies (Bernstein et al. 2011), suggesting 
this loss may be the result of a chronic excitatory state from increased calcium 
concentrations, eventually resulting in mitochondrial dysfunction and cell death 
in parvalbumin-expressing interneurons in the hippocampus (Bernstein et al. 
2011). There are no clinicopathological studies of frontal interneurons in cases 
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with cerebrovascular disease.  In rat models Wang et al reported that short-term 
cerebral ischaemia results in the dysfunction in the excitability of inhibitory 
interneurons, and the subsequent over excitation of pyramidal neurons (J. H. 
Wang 2003). This suggests a potential mechanistic link between interneuron 
dysfunction and pyramidal neuronal pathology in stroke subjects.    
 Glial cells 
There is strong evidence to suggest a more glial-centric aetiology to 
neurological disease (Lobsiger and Cleveland 2007), with astrocytes (Shin et al. 
2005; Custer et al. 2006), microglia (Boillee et al. 2006), and oligodendrocytes 
(Tomimoto et al. 1994) all being involved. The overall roles and characteristics 
of glial cells have been previously described in the introduction (See Glial cells). 
Astrocytes form part of a network which support their neighbouring neurons, 
aiding the formation and maintenance of synapses, and regulating cerebral 
blood flow (Lobsiger and Cleveland 2007). In addition they supply various 
nutrients to the neuronal cell. Mutations in the genes coding for glial cells have 
been shown to have impaired ability to uptake excess glutamate in mice with 
Huntington’s disease (Shin et al. 2005) and in other mouse models (Custer et 
al. 2006). These studies highlight the importance of glial cells role in 
maintaining glutamate homeostasis in protecting neurons, which can play a 
critical role in ischaemic damage.  
As previously mentioned, microglial cells have been shown to accumulate 
around amyloid plaques but also around sites of ischaemic damage (Bolmont et 
al. 2008; Lees 1993) with mouse models showing  glial cell activation and 
increased gliosis in the substantia nigra in association with dopaminergic 
neurodegeneration (Liberatore et al. 1999). Additionally, transgenic mouse 
models overexpressing α-synuclein in oligodendrocytes resulted in a similar 
syndrome to multiple system atrophy (associated with neurodegeneration of 
specific areas of the brain) (Yazawa et al. 2005).   
 Glial cells and SVD 
Increased numbers of activated astrocytes (astrogliosis) have been found at 
lesion sites (both ischaemic and neurodegenerative), and are thought to play a 
role in neuronal remodelling through the release of cytokines such as tumour 
necrosis alpha (TNF-α), which may influence the growth of synapses by 
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inducing the insertion of AMPA receptors at post-synaptic membranes 
(Sofroniew 2009; Sofroniew and Vinters 2010; Nagele et al. 2004). It is 
therefore apposite to inference that glia play a crucial role in both post-stroke 
and vascular dementia. Primeape studies have found increased activation of 
microglia and astrocytes associated with cognitive impairment (Kemper et al. 
2001) and in hypertensive rats, with enlarged astrocytes present at the site of 
lesions, forming around leaky sites in the vasculature (Fredriksson et al. 1988). 
Astrocytes form a continuous lining (glial limitans) to seal off the lesions (Giulian 
et al. 1994). Microglial cell numbers in Binswanger’s disease, a form of vascular 
dementia, were found to be unchanged when compared to controls. However 
increased numbers of activated microglia were up to three fold higher in those 
suffering vascular pathology (Tomimoto et al. 1994; Akiguchi et al. 1997).  
The previous chapter revealed pyramidal neuron volumes were related to 
dementia with CVD and AD pathology within layers III and V specific to the 
dlPFC, as well as being associated with cognition and executive functions. 
These findings are both specific and distinctive. To further understand the 
pathological processes which may be at work it is necessary to investigate other 
components which make up the dlPFC.  
The aim of this study was to assess non-pyramidal neuron and glial cell density 
in post-stroke demented subjects and compare to aged-controls and other 
disease groups. 3D stereology was used to isolate specific pathologies within 
the dlPFC. Interneuronal sub-types were also assessed using 
immunohistochemistry and 2D analysis. Changes to glial cell and interneurons 
were related to pyramidal neuron changes reported in the previous chapter. 
Additionally the relationship between glial cell density and interneuronal density 
was also investigated to establish whether any changes occurred in unison or 
separately.  
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 Methods 
 Subject demographics 
   
Table 4-1 Subject details. Controls = aged matched controls, PSND = post-stroke no 
dementia, PSD = post-stroke dementia, VaD = vascular dementia, mixed = mixed 
vascular and Alzheimer’s disease, AD = Alzheimer’s disease. FT = fixation time, PMD 
= post-mortem delay. Vascular score (/6). Age (F = 1.005, p = 0.423). FT (F = 2.207, p = 
0.066), PMD (F = 1.029, p = 0.412).  
 
(SEM) 
No of 
cases 
Age, 
years 
PMD, 
hours 
FT, 
weeks 
Vascular 
score 
Braak  
(I – VI) 
CERAD 
Control 
 
11 
     81  
(3) 
26.6 
(5) 
12.6 
(5) 
n/a 2 (0.41) n/a 
PSND 
 
10 
83.3 
(1) 
42.3 
(7) 
      3.8  
(2) 
4.5 
(0.26) 
2.3 
(0.47) 
1.6 
(0.26) 
PSD 
 
11 
87.2 
(1) 
35.7 
(7) 
      1.9  
(1) 
4.4 
(0.32) 
2.8 
(0.34) 
1.3 
(0.30) 
VaD 
 
10 
83.6 
(2) 
47 (9) 
      5.3  
(2) 
5.5 
(0.50) 
2.4 
(0.34) 
1.2 
(0.40) 
Mixed 
 
10 
84.4 
(2) 
33.6 
(7) 
      4.6  
(3) 
4.0 
(1.00) 
5.1 
(0.31) 
2.6 
(0.29) 
AD 10 
85.8 
(2) 
44.1 
(10) 
       5.5  
(2) 
1.20 
(1.00) 
5.5 
(0.21) 
2.9 
(0.11) 
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 Three dimensional analysis of non-pyramidal neuron and 
glial cell densities in layers III and V of the dlPFC. 
Non-pyramidal neuron and glial cell density was analysed using 3D stereology 
as described previously (See Three dimensional stereology). Glial cells were 
identified by their consistently round shape and size, as well as a distinctive 
punctate-style nucleus (Figure 2-5). Non-pyramidal neurons were identified by 
size (typically smaller than pyramidal neurons) and lack of large pyramidal cell 
soma.  
 Immunohistochemical analysis of interneuronal cell 
populations in layers III and V the dlPFC 
Neuronal counts were performed on 10µm frontal sections containing the 
Brodmann 9 of the dlPFC as described previously. Three serial sections were 
stained with; calbindin (Sigma ,UK), parvalbumin (Sigma, UK), and calretinin 
(Sigma, UK) respectively. Each of these antibodies stained a specific sub-type, 
or range of specific sub-types, of interneurons. Individual neuronal counts were 
then performed. Upon analysis of IHC stained sections a sub-population of 
markedly darker interneurons were identified in some of the sections (see 
figure). These cells appeared throughout each of the three different stains and 
seemed to retain a higher level of pigment than the surrounding cells of the 
same interneuronal sub-population. 
 Darkly stained interneurons 
Additional counts were performed on a sub-set of cell which appeared very 
darkly stained (Figure 4-5). The initial hypothesis was that these darkly stained 
neurons were either a) expressing extraordinarily high levels of stain or, b) had 
shrunk in volume, thus increasing the concentration of stain within each cell, 
causing the neuron to appear much denser than its more ‘healthy’ counterparts. 
Hypothesis ‘a’ revolved around the nature of apoptosis. It is understandable to 
assume that in situations of extreme stress, such as hypoxia brought about by 
cerebral ischaemia or some other pathology, that vulnerable neurons may 
undergo cell death, a result of a heavy influx of calcium ions. This influx may 
show up as increased staining, this being a calcium-binding albumin. Theory ‘b’ 
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revolved around the idea that neurons undergoing physical stress may shrink, 
increasing the relative concentration of stain. To assess the true number of 
darker stained interneurons against the total counts, the value for total darkly 
stained neurons were divided against total interneuronal cell counts to give a 
percentage value of the total population of darkly stained neurons.  
 Statistical analysis 
Statistics were performed as described previously. ANOVA with post-hoc LSD 
was used for normally distributed data, or the Kruskall Wallis and the Mann-
Whitney U test was used for non-normally distributed data. The Mann Whitney-
U test was used to test for significant differences between groups and 
Spearman’s rank coefficient was used to assess relationships between 
variables in non-normally distributed cases. ANOVA with post-hoc; lowest 
significant difference (LSD) was used for normally distributed cases.   
 
 Comparing interneuronal and glial cell densities 
To highlight any potential relationship between glial cell and interneuronal 
densities with each other, or with clinical variables from the CogFAST study, 
spearman’s rank coefficient was used. 
 Results 
 Distribution of non- pyramidal neurons 
Normality testing revealed 3D stereologically assessed non-pyramidal density 
and IHC based cell counts for parvalbumin, calretinin, and calbindin to be non-
normally distributed in all layers except layer II.  
 
 Three dimensional stereological analysis of interneuronal densities 
in pyramidal layers III and V of the dlPFC. 
Nissl stained interneuronal densities were analysed in both layer III and V in the 
dlPFC. Mean densities in layer III were; (per mm3) 59298, 71348, 66474, 
83412, 101393, 92563 (in aged-controls, PSND, PSD, VaD, mixed, and AD 
respectively), and in layer V; (per mm3) 205642, 213196, 220423, 270594, 
226849, 210491(in aged-controls, PSND, PSD, VaD, mixed, and AD, 
respectively). There were no significant differences between PSD and PSND in 
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either layers III or V in the dlPFC. However, in layer II only the PSND, and PSD 
groups against controls were analysed. PSND and PSD showed significantly 
higher neuronal density when compared to control cases (p = 0.023 and p = 
0.006, respectively).  
Interneuronal density in VaD, mixed, and AD groups was significantly increased 
when compared to controls in layer III (p = 0.017, p = 0.003, p = 0.017, 
respectively). In addition, mixed dementia showed significantly higher 
interneuronal densities when compared to both post-stroke survivors groups (p 
= 0.016, p = 0.009, respectively).  Conversely, no changes were found in layer 
V between control and disease groups. With all groups exhibiting comparable 
interneuronal densities. Layer II revealed no changes in interneuron density 
between PSND and PSD in the dlPFC (p > 0.05) (Figure 4-4). Layer II revealed 
non-pyramidal neuron densities in PSND and PSD were significantly higher 
when compared to controls (p = 0.023 and p = 0.006, respectively). 
 Correlations between non-pyramidal neurons and other variables 
Non-pyramidal neuron density in layer III correlated with both CERAD and 
Braak scoring (σ = 0.133, p = 0.021 and σ = 0.231, p = 0.001 respectively), and 
MMSE score (σ = -0.205, p = 0.009). Non-pyramidal neuronal density 
correlated with frontal vascular pathology (σ = 0.818, p = 0.05). Non-pyramidal 
neuron density significantly correlated with glial cell density in layer III in both 
AD and control subject groups (σ = 0.758, p = 0.011, and σ = 0.755, p = 0.007, 
respectively). 
  
114 
 
Figure 4-1 showing Nissl stained non-pyramidal neuron densities in control and disease groups in 
layers III and V of the dlPFC. Blue  = Layer III. Green = layer V. Control = aged control, PSND = post-
stroke no dementia, PSD = post-stroke dementia, VaD = vascular dementia, Mixed = mixed 
dementia, AD = Alzheimer’s disease. Controls vs VaD (p = 0.017), Mixed (p = 0.003), AD (p = 0.017). 
Mixed vs PSND (p = 0.016), PSD (p = 0.009).  
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Figure 4-2 scatter graphs showing significant correlations between non-pyramidal neuronal densities in 
layers III and V and clinical and morpholoigical variables. a) σ = 0.133, p = 0.021, b) σ = -0.125, p = 0.021, 
c ) σ =0.231, p = 0.001, d)  0.818, p = 0.05. 
  a) b) 
c) d) 
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Figure 4-3 scatter graphs showing significant relationships between non-pyramidal neurons 
and glial cell density in layer III of the dlPFC in a) control (σ = 0.755, p = 0.007) and b) AD (σ 
= 0.758, p = 0.011) subjects. 
a) 
b) 
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Figure 4-4 bar chart showing non-pyramidal neuron density in control, PSND, 
and PSD subjects in layer II of the dlPFC. Control = aged control, PSND = post-
stroke no dementia, PSD = post-stroke dementia. * = significance to controls. 
Controls vs PSND (p = 0.023), PSD (p = 0.006). 
  
118 
 
 
 Immunohistochemical analysis of non-pyramidal neurons 
 Immunohistochemistry 
All antibodies showed specific staining to small cells with very little background. 
Parvalbumin stained section revealed the pale but very specific staining for 
interneurons, with few, if any, pyramidal neurons stained. In addition 
parvalbumin appeared to stain short lengths of dendritic process. Calbindin 
stained a higher proportion of neurons compared to the other two stains and 
was less selective, picking up pyramidal neurons as well as interneurons. 
Calretinin was selective for interneurons, similar to parvalbumin, calretinin 
appeared to stain few, if any pyramidal neurons (Figure 4-5).  
 
 Layer III 
In addition to the 3D stereological analysis of Nissl stained sections, 2D 
analysis was also performed to identify if there were specific changes in 
parvalbumin, calbindin, and calretinin positive neurons. On screen counts 
revealed mean total interneuronal counts in controls were; (per 10 images) 246 
(parvalbumin), 276 (calbindin), 121 (calretinin).  
There were no significant differences in interneuronal counts between the 
PSND and PSD in any stain (p > 0.05). Total counts of parvalbumin stained 
interneurons showed reduced parvalbumin positive interneurons in neuronal 
layer III of mixed subjects when compared to control cases (p = 0.034). There 
were no differences in calbindin positive cells, or calretinin positive cells 
between any of the groups (p > 0.05) (Table 4-2). 
 Analysis of darkly stained neurons in layer III 
When darkly stained neurons were counted there were no differences between 
total darker stained neurons between PSND and PSD subjects (p > 0.05). Total 
darkly stained neuronal counts in control groups were; 98 (parvalbumin), 53 
(calretinin), and 102 (calbindin). There were no differences found between any 
other group in parvalbumin, calbindin, or calretinin positive cells (p >0.05).  
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When total darkly stained non-pyramidal neurons were expressed as a 
percentage of the total neuronal population counted there was no difference 
between PSND and PSD subjects. However, both PSND and VaD showed 
significantly lower levels of calbindin positive staining than control subjects (p = 
0.014, and p = 0.022 respectively) (Table 4-2, Figure 4-2).  
 Layer III Correlations 
Total parvalbumin staining in layer III correlated with pyramidal neuronal volume 
changes in layer V (σ = 0.430, p = 0.003). In addition, frontal myelin staining 
loss, as measured by myelin index revealed significant correlation when 
compared to percentage of darkly stained PV neurons to non-stained neurons 
(σ = 0.376, p = 0.011). Analysis of calretinin positive section revealed a number 
of significant correlations.  
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Figure 4-5 showing parvalbumin (PV), calbindin (CB), and calretinin (CR) 
positive neurons in layer V of the dlPFC. Solid black arrows = darkly stained 
neurons, hollow arrows = pale stained neurons. Left column taken at x10 
magnification, right side column taken at x40 magnification. Left scale bar = 
100μm. Right scale bar = 20μm 
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 Interneuron 
counts 
(mean) layer 
III 
Control 
(SEM) 
PSND PSD VaD Mixed AD 
Parv total 
246 
(19) 
250 
(31)  
189 
(22) 
214 
(27) 
186 
(22) 
216 
(30) 
Parv total 
dark 
98 103 
(21) 
71 91 89   
(17) 
88  
(17) (9) (12) (10) 
Parv % dark 
40 39 36 44 47 39 
(3) (3) (3) (3) (5) (3) 
CalB total 
276 
(46) 
298 
(59) 
326 
(56) 
306 
(55) 
283 
(31) 
250 
(70) 
CalB total 
dark 
103 
(15) 
84  
(16) 
96  
(15) 
93  
(20) 
 87    
(9) 
88  
(21) 
CalB % dark 
40 30 32 30 32 39 
(5) (2) (4) (2) (3) (4) 
CalR total 
122 
(22) 
136 
(17) 
96   
(14) 
127 
(15) 
101 
(12) 
127 
(18) 
CalR total 
dark 
53   
(14) 
56 37 54 45 51 
(11) (8) (8) (9) (13) 
CalR % dark 
40 41 35 42 43 40 
(5) (6) (3) (3) (5) (2) 
Table 4-2 showing mean total counts for immunohistochemical stained 
interneurons. Parv = parvalbumin, CalB = calbindin, CalR = calretinin. Control = 
aged-control, PSND = post-stroke no dementia, PSD = post-stroke dementia, 
VaD = vascular dementia, Mixed = mixed dementia, AD = Alzheimer’s disease. 
Parv total: Controls vs mixed (p = 0.034). CalB % dark: controls vs PSND (p = 
0.0144, and mixed (p = 0.022).  
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 Layer V 
Total mean counts of positively stained interneurons in controls were; (per area 
analysed) 225 (parvalbumin), 156 (calbindin), and 162 (calretinin).  
Total counts of calretinin positive cells in layer V of the dlPFC revealed a 
significantly higher number of interneurons in PSND when compared to PSD (p 
= 0.049). There were no significant differences between PSND and PSD 
subjects in either parvalbumin or calbindin positively stained interneurons 
(Figure 4-5)   
Parvalbumin positive neurons in mixed dementia showed significantly lower 
mean counts than non-demented controls (p = 0.023) and PSND subjects (p = 
0.023). In addition mixed dementia also showed significantly lower means when 
compared to subjects with AD (p = 0.049). VaD sufferers also expressed higher 
total counts of calretinin positive cells when compared to PSD (p = 0.021). 
Subjects with AD showed significantly lower total counts of calretinin positive 
neurons than both VaD and PSND groups (p = 0.049) (Table 4-3). 
 Analysis of darkly stained neurons in layer V 
There were no significant differences between PSND or PSD when assessing 
total darkly stained neurons in any stain. PSND, VaD, and mixed dementia 
showed significantly higher total darker stained calretinin positive neuron counts 
when compared to aged matched controls (p = 0.049, p = 0.006, p = 0.049 
respectfully). Subjects suffering VaD exhibited significantly higher darkly 
stained, calretinin positive neurons when compared to PSD subjects (p = 
0.037). The total counts for calbindin positive neurons revealed significantly 
lower total darkly stained neurons in VaD when compared to controls (p = 
0.034) and AD (p = 0.026) (Table 4-3). 
When expressed as a percentage of total cells counted, darkly stained calretinin 
positive non-pyramidal neurons were significantly higher in all demented groups 
when compared to controls (p = 0.023, p = 0.019, p = 0.002, p = 0.013, and p = 
0.010 for PSND, PSD, VaD, Mixed, and AD respectively) (Table 4-3).  
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There were no significant differences  in parvalbumin positive sections of either 
total darkly stained cell counts, or percentage darkly stained (p > 0.05) (Table 
4-3).  
 Layer V Correlations 
Spearman’s rank coefficient revealed total non-pyramidal neuronal counts for 
calbindin positive cells in layer V correlated with neuronal volume in  layer V of 
PSND, PSD, and VaD (σ = 0.456, p = 0.018,). The percentage of darkly stained 
neurons also correlated with neuronal volumes in subjects suffering mixed VaD 
and AD pathology (σ = 0.738, p = 0.037). When testing for disease groups total 
parvalbumin cell counts correlated with MMSE scores (σ = 0.406, p = 0.017), 
and calretinin correlated with MMSE scores in VaD subjects (σ = -0.900, p = 
0.037) (Figure 4-6). 
The percentage of darkly stained interneurons in post-stroke cases correlated 
with total neuronal counts in parvalbumin positive section, and PSND in 
calbindin stained sections.   
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 Interneuron 
counts 
(mean) layer 
V 
Control 
(SEM) 
PSND PSD VaD Mixed AD 
Parv total 
225 
(19) 
259 
(38) 
205 
(23) 
189 
(30) 
146 
(23) 
212 
(26) 
Parv total 
dark 
54 71 52 54 38 45 
(8) (18) (9) (11) (10) (7) 
Parv % dark 
23 25 21 27 23 22 
(3) (3) (3) (3) (4) (3) 
CalB total 
156 
(17) 
117 
(20) 
129 
(11) 
126 
(15) 
127 
(16) 
162 
(22) 
CalB total 
dark 
37 25 25 25 27 34 
(5) (5) (3) (6) (3) (4) 
CalB % dark 
23 19 18 18 22 21 
(2) (3) (1) (2) (1) (2) 
CalR total 
162 
(13) 
170 140 
(14) 
197 
(15) 
149 
(13) 
140 
(17) (7) 
CalR total 
dark 
25 46 42 67 45 41 
(7) (6) (8) (11) (8) (7) 
CalR % dark 
16 27 29 33 30 28 
(3) (3) (4) (4) (4) (3) 
Table 4-3 showing mean total counts for immunohistochemical stained 
interneurons in layer V of the dlPFC. Parv = parvalbumin, CalB = calbindin, 
CalR = calretinin. Control = aged control, PSND = post-stroke no dementia, 
PSD = post-stroke dementia, VaD = vascular dementia, Mixed = mixed 
dementia, AD = Alzheimer’s disease. Bold + red = signifcant to controls. Bold + 
blue = significant to mixed. Bold + green = significant to PSND. CalR total: 
PSND vs PSD (p = 0.049). Parv total: mixed vs control (p = 0.023), PSND (p = 
0.023), AD (p = 0.049). CalR total: PSD vs VaD (p = 0.021), AD vs VaD (p = 
0.010), PSND (p = 0.049). CalR dark: controls vs PSND (p = 0.049), VaD (0.006), 
mixed (p = 0.049). PSD vs VaD (p = 0.037). CalB dark: VaD vs controls (p = 
0.034), AD (p = 0.026). 
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Figure 4-6 scatter graphs showing significant correlations between non-pyramidal 
neuronal density in layer V and clinical variables. PV = parvalbumin, CB = calbindin, CR = 
calretinin. a) σ = 0.456, p = 0.018, b) σ = 0.738, p = 0.037, c) σ = 0.406, p = 0.017, d) σ = 
0.900, p = 0.037. 
 
a) b) 
c) d) 
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 Three dimensional stereological analysis of glial cell density.  
 Layer III 
Three dimensional stereological analysis revealed no significant differences 
between PSND subjects and PSD subjects when assessing glial cell densities. 
When analysing post-stroke demented groups alone, glial cell density 
correlated with pyramidal neuronal volume in layer V (σ = 0.609, p = 0.047). 
Further analysis revealed significantly lower glial cell densities in VaD when 
compared to controls (p = 0.002), PSND (p = 0.003), PSD (p = 0.001), and 
mixed (p = 0.05). VaD subjects revealed a correlation between glial cell density 
and non-pyramidal density (σ = 0.594, p = 0.011), and glial cell density and 
MMSE score (σ = 0.960, p = 0.015) (Figure 4-7). 
 Layer V  
Similar to layer III, no significant difference was found between PSND and PSD 
subjects. There was no significant difference revealed in glial cell density 
between any group in layer V (p >0.05). However, glial cell density did correlate 
with pyramidal neuronal volumes in PSD in layer V (σ = 0.764, p = 0.006) 
(Figure 4-8). Additionally, glial cell density in layer V correlated with glial density 
in layer III. (σ = 0.535, p = 0.001) (Figure 4-7).  
 Layer II 
There was no significant difference between PSND or PSD in layer II of the 
dlPFC, or between PS subjects and aged matched controls (p > 0.05) (Figure 
4-9).  
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Figure 4-7 showing non-pyramidal neuron densities in control and disease groups in layers III (blue) and V 
(green) of the dlPFC. Control = aged control, PSND = post-stroke no dementia, PSD = post-stroke dementia, 
VaD = vascular dementia, Mixed = mixed dementia, AD = Alzheimer’s disease. VaD vs controls (p = 0.002), 
PSND (p = 0.003), PSD (p = 0.001), (mixed p = 0.05) in layer III. 
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Figure 4-9 showing non-pyramidal neuron densities in control and disease groups in layer II of 
the dlPFC. Control = aged control, PSND = post-stroke no dementia, PSD = post-stroke 
dementia. No significant differences between groups (p <0.05). 
Figure 4-8 showing the correlation between pyramidal neuron volumes and 
glial cell densities in layer V (σ = 609, p = 0.047). 
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 Discussion 
 3D stereological analysis of non-pyramidal neuron density in 
the dlPFC 
Non-pyramidal neuronal density in the dlPFC was assessed to establish if 
general atrophy of the neocortex explained the differences between PSD and 
PSND subjects or whether previous findings in dlPFC were specific to pyramidal 
neurons. Non-pyramidal neuron density were found to be higher in layer III in 
these subjects when compared to controls in a depression study (over 50,000 
per mm3 compared to under 20,000 per mm3), however findings in layer V 
were more comparable (Around 20,000 mm3) (Khundakar et al. 2009).There 
were no significant differences apparent in non-pyramidal density between PSD 
and PSND in either layers III or V. This finding suggests interneuronal number 
changes are not a key factor in the development of PSD, or explain the primary 
morphological differences between PSND and PSD. Additional analysis was 
performed in layer II of the dlPFC to assess the behavior of interneurons in a 
layer where pyramidal neuronal atrophy may not have such an impact. There 
were no significant differences between the two PS groups. However, both PS 
groups showed significantly increased neuronal density when compared to 
controls. This was unexpected as little or no cortical atrophy was found in the 
dlPFC. However, it does suggest that layer II of the dlPFC may be affected in 
stroke patients, though it does not appear to have an impact on cognitive 
outcome in these subjects.  
When assessing other disease groups, 3D stereological analysis revealed 
significantly increased non-pyramidal neuron density in VaD, mixed, and AD 
subjects when compared to post-stroke survivors and age-matched controls in 
layer III (p < 0.05) (Figure 4-1). This increased density of neurons is unlikely to 
be the result of an increased neuronal population. One possibility being that this 
density increase was the result of post-mortem fixation shrinking the tissue, and 
thus compacting the neurons tighter together, increasing neuronal density. This 
theory however, was dismissed as post-mortem processing artifact would have 
most likely affected all groups equally, not just those diagnosed with vascular 
and neurodegenerative dementias. An alternative theory, based around cortical 
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atrophy was proposed. Loss of tissue and thinning of the cortical ribbon would 
potentially result in an artificial increase in neuronal density. As the cortical 
ribbon decreases in thickness, the spacing between neurons becomes less 
abundant. This would result in a higher number of neurons being counted in a 
particular sampling area and thus artificially giving the impression of a higher 
neuronal number. This would explain why no density changes were recorded in 
PSND and PSD as it was previously shown that these cases do not suffer 
cortical atrophy in the dlPFC (Cortical thickness and dlPFC atrophy), and whilst 
VaD, mixed, and AD did not show signs of cortical thinning, it was impossible to 
assess the cortical atrophy in these subjects leaving atrophy as a potential 
cause for neuronal density change. 
 3D stereological analysis of Glial cell densities 
There were no significant differences in glial cell density between PSND and 
PSD subjects. There was a large difference in glial cell densities between layer 
III and V (means of ~ 100,000 mm3 and ~ 50,000 mm3 respectively) in controls. 
Counts in layer III were comparably high when compared to measurements of 
controls taken from a depression study (mean of ~ 65,000 mm3), with layer V 
measurement more in agreement (mean ~ 65,000 mm3) (Khundakar et al. 
2009). The lack of difference between groups in this study was surprising as it 
has previously been shown that following a stroke these cells proliferate and 
may become hypertrophic in response to the insult (van Rossum and Hanisch 
2004). However, bivariate analysis did reveal that glial cell densities significantly 
correlated with pyramidal neuron volumes in layer V, which suggests a 
relationship between glial cells and neurons, perhaps reinforcing the importance 
of the neurovascular unit in maintaining cognition (Hawkins and Davis 2005).  
VaD showed significantly reduced glial cell density when compared to controls, 
PSND, and PSD in layer III but not in layer V, with no difference identified when 
compared to mixed dementia or AD groups. Glial cell decreases in VaD were 
not unexpected, as glial cells are damaged as a result of compromised oxygen 
metabolism once the vasculature is damaged (Roman et al. 2002). However, 
this reasoning would follow that both PSD and mixed demented subjects would 
follow the same pattern, which did not occur. 
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Glial cell densities correlated with non-pyramidal neuron densities in both 
control groups and AD subjects (changes in the AD subjects also correlated 
with both CERAD and Braak staging, suggesting a link with AD pathology), but 
not in VaD, or mixed subjects. The differential absence of this correlation in the 
vascular groups suggests differential pathological effects on different cell 
populations in different disease states. Indeed, this relationship between glial 
cell densities and interneuronal densities was expected in aged-control 
subjects, where no apparent changes in glial or neuronal densities were 
present. In AD subjects this significant correlation between glial cell and 
neuronal densities suggests a similar rate of density change between the two, 
which may be the result of cortical atrophy. 
The lack of correlation between glial and neuronal densities in mixed and VaD 
suggest perhaps a different pathological cause than atrophy, in which damage 
to the vasculature may result in decreases in neuronal density in one layer at a 
higher rate than the other. However, in all three groups; VaD, mixed, and AD, 
no changes were found in pyramidal neuronal density, which would be 
expected if there was a global tissue alteration affecting interneurons (Harding 
et al. 1994).  
Pyramidal neuron soma volume has been linked to the extent of a cells 
dendritic arbour, with larger cells commanding more processes and smaller 
neurons with decidedly less (Hayes and Lewis 1993; Glantz and Lewis 2000). A 
theory has therefore been put forward that this potential dendritic loss created 
additional space – gaps within the tissue with which other non-pyramidal 
neurons could move into, thus becoming more compact and increasing 
neuronal density as assessed using 3D stereology. Further investigation into 
neuronal dendritic arbour is needed to confirm or disprove this theory. 
Interestingly, this relationship between interneuron densities between the 
disease groups was not repeated in layer V of the dlPFC, were no significant 
differences in neuronal density were reported between any group (p > 0.05). If 
the changes observed in layer III were a result of cortical tissue change or a 
result of reduced neuronal arbour, then neuronal density changes would have 
been expected in both layers. These findings suggest that whatever 
pathological substrates may be at play, they appear to be either specific to layer 
III, or may affect each area differently. Interestingly, when excluding AD and 
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mixed cases from analysis, changes in layer III significantly correlated with 
frontal vascular scores. Perhaps vascular pathology has a greater effect on the 
dendritic arbour of cells in layer III than layer V. The additional analysis of non-
pyramidal layer II revealed some interesting findings with both PSND and PSD 
cases showing significantly higher neuronal densities when compared to 
controls, but no differences between each other. This finding is not consistent 
with either layer III or V and suggests perhaps another mechanism is at play in 
layer II.  
 Immunohistological analysis of interneurons in the dlPFC. 
 Total interneuron counts 
One restriction of 3D stereological analysis of Nissl stained section is the 
inability to distinguish between different sub-populations of interneuronal types 
from each other. As previously discussed (See Interneurons and the inhibition 
circuits) there are several distinct sub-populations of interneurons, each with its 
own role within the inhibitory system of the dlPFC. Using 2D analysis to assess 
IHC stains for three different calcium binding proteins (calretinin, calbindin, 
parvalbumin), it was possible to analyses a wider range of interneuronal sub-
groups. 
 Total interneurons and post-stroke dementia 
Analysis of layer III revealed no significant difference in parvalbumin, calretinin, 
or calbindin-positive cell counts between either PSND or PSD. This finding 
suggests there is little or no impact of any sub-type of interneurons in the 
development of PSD. The lack of correlation between interneuronal total counts 
and pyramidal volume also suggests a minimum pathological relationship 
between the two cell types. However, the total calretinin-positive cell count was 
lower in PSD subjects when compared to PSND in layer V. Calretinin positive 
cell loss has been reported in the hippocampus of those suffering AD 
(Takahashi et al. 2010) and is thought to impact the progression of the disease. 
It is possible that decreased numbers of interneurons in layer V of the dlPFC 
may contribute to the progression of PSD.  
 Interneurons and other disease groups 
Two dimensional analysis of parvalbumin positive interneurons revealed 
significantly fewer interneurons in mixed dementia subjects when compared to 
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age matched controls in both layer III and V, and PSND in layer V. Any 
reduction in numbers may result in a distinct over excitation of local pyramidal 
neurons and thus dysfunction to the local circuit (Conde et al. 1994; Daviss and 
Lewis 1995). This change was only observed in subjects suffering from mixed 
VaD/AD pathology. The lack of apparent change in other disease subjects 
suggest that it is the additive effect of both AD type pathology and CVD which 
results in reduction on parvalbumin interneurons. In parvalbumin positive 
interneurons in layer V of mixed dementia, there were significantly fewer 
parvalbumin positive cells than in AD. These data suggest the mixed pathology 
with both AD pathology and vascular disease affecting the interneuronal 
population. Total cell counts of parvalbumin positive interneurons in layer V 
correlated with layer V pyramidal neuronal volumes, suggesting a link between 
the number of parvalbumin positive interneurons and potential pyramidal 
neuron dysfunction in the dlPFC.  
Those with AD showed significantly fewer positively stained interneurons than 
either VaD or PSND suggesting calretinin positive interneurons are more 
sensitive to neurodegenerative pathology than CVD.  
 
 Analysis of darker stained neurons in layers III and V of the dlPFC. 
Total counts of parvalbumin, calretinin, and calbindin positive interneurons 
revealed a specific subpopulation of very darkly stained interneurons. These 
cells appeared with varying frequency throughout the analysis, dependent of 
the case studied. It was theorised that these neurons may be a pathological 
substrate which may distinguish between PSND and PSD disease groups (See 
Darkly stained interneurons).  
Neither total number of darkly stained interneurons nor the percentage total of 
darkly stained neurons vs. total interneurons numbers showed any significant 
differences between PSND and PSD subjects. These findings do not appear to 
support the theory that the darkly stained neurons are associated with declining 
cognitive ability in PSD cases.  
Analysis of layer III revealed significantly lower percentage of calbindin positive 
cells were darkly stained in both VaD and PSND subjects when compared to 
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controls cases. This lower percentage of potentially diseased interneurons in 
VaD was interesting, as it appears that subjects with higher vascular pathology 
do not appear to exhibit interneuronal damage.  
 Conclusions 
Three dimensional stereological data suggested decreased interneuronal 
densities in layers III and V of the dlPFC do not distinguish between the PSND 
and PSD subjects. However, changes in non-pyramidal density appear 
associated with VaD, mixed, and AD dementia. Interneuronal density does not 
appear to a predictor for the development of dementia in subjects who have 
suffered a stroke. The immunohistochemical results support the suggestion that 
interneuron and glial cell numbers have little impact on the progression of 
cognitive dysfunction after stroke. However, the relationship between glial cell 
density and pyramidal neuronal volumes suggests a potential mechanistic 
relationship between neuronal dysfunction and glial cell numbers.  Additionally, 
darkly stained interneurons appear to have no influence on the cognitive 
outcome in PS subjects suggesting that this is not a specific marker of neuronal 
damage. 
135 
 
 
Chapter 5. White matter changes in the frontal lobe 
in post-stroke dementia. 
 Introduction 
The decreased pyramidal neuron volumes in post-stroke demented and other 
demented subjects appeared to associate neuronal atrophy with specific 
features of executive function in PSD and other dementia subjects. These data 
demonstrate some involvement of the specific regions of the cortical grey matter 
in the development of PSD. However, it is not clear if these findings are linked 
to any potential pathology in the frontal underlying WM in these subjects. WM 
changes detected as white matter hyperintensities (WMH) on T2 weighted MRI 
are a common finding in CVD (DeCarli et al. 1995; O'Brien et al. 2002). Burton 
et al (E. J. Burton et al. 2004) reported significantly greater volumes of WMH in 
subjects after stroke, correlating with attention deficits. WMH have also been 
associated with decreased cognitive processing speed (E. J. Burton et al. 
2004). Processing speed pertains to the ability to perform tasks quickly and 
under pressure. It may be a basic component of information processing, in 
those with CVD, suggesting a direct link between apparent WM damage and 
cognition (E. J. Burton et al. 2004). This is perhaps not surprising as WMH are 
thought to indicate damage, or at least disruption of the myelin or axonal tracts 
which connect the prefrontal circuits. However, WMH in the frontal lobe may be 
more significant in the current study, with executive dysfunction correlating with 
WMH in those suffering VaD (Cohen et al. 2002). This highlights the importance 
of the prefrontal circuits in executive function, and their relative vulnerability to 
ischaemic damage.  
 
 Myelin and axons in post-stroke and other dementias.  
Mechanistically, loss of myelination leads to the slowing of action potentials 
between neurons (See Glial cells and white matter), ultimately affecting 
cognitive function. Though this is a logical inference, it is unclear how myelin 
loss relates, interacts, and influences axonal damage, and indeed how much 
axonal damage impacts dementia (Ferguson et al. 1997). By comparing 
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markers for both myelin and axonal damage it may be possible for elucidate the 
relationship between the two pathologies (Ferguson et al. 1997). Axon damage 
has been implicated in other disease processes such as multiple sclerosis (MS) 
following myelin damage and loss (Ferguson et al. 1997). The role of axonal 
damage in the development of dementia is not certain though mouse studies 
have found impaired axonal transport in frontotemporal dementia (Ittner et al. 
2008). Axonal dysfunction has also been implicated in AD, with the build-up of 
hyperphosphorylated tau impairing axonal transport as demonstrated in mouse 
models expressing mutant forms of APP, Presenilin-1 and in tau proteins, 
resulting in axonal dysfunction (Gallagher et al. 2012).Potential markers for 
axonal damage such as APP and SMI32 can shed light on the underlying state 
of axons (Werner et al. 2001). APP is transported via axons, with the 
accumulation of the protein indicating a dysfunction in the axon’s ability to 
transport constituents which may build in the tracts. SMI32 is a marker for non-
phosphorylated neurofilaments, indicating axonal damage (Budde et al. 2008). 
Ferguson et al reported increases in APP as a marker of axonal damage in 
acute inflammation of patients suffering multiple sclerosis (Ferguson et al. 
1997). Previously, conventional stains such as luxol fast blue (LFB), used to 
assess myelinated axons, have been used to indicate myelin loss, as a marker 
of WM damage in post-mortem analysis (Smallwood et al. 2012; Deramecourt 
et al. 2012; Ihara et al. 2010). Loss of or weaker LFB staining in these cases is 
interpreted as myelin loss and thus WM damage. Ihara et al also found an 
inverse correlation between degraded basic myelin protein (dBMP) and myelin 
index, reinforcing the link between LFB loss and myelin damage (Ihara et al. 
2010). 
 
 Retrograde vs. anterograde neurodegeneration. 
Though WM degeneration appears to play a major role in dementia and other 
cognitive disorders (Medana and Esiri 2003), it remains unclear how influential it 
may be in the development of post-stroke dementia. It is unknown which event 
precedes the other: neuronal dysfunction, or white matter loss, and to the 
degree with which one may influence the other. Strong evidence suggests 
pyramidal neuronal volumes are reduced across several disease states 
(Khundakar et al. 2009; Gemmell et al. 2012), and indeed, WMH have been 
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reported in PSD subjects (E. Burton et al. 2003). However, pyramidal neuronal 
volume changes in PSD and other disease cases are the result of anterograde 
or retrograde degeneration. From MRI or post-mortem studies, it is not possible 
to distinguish between cause and effect, but the degree to which neuronal 
damage may affect WM pathology (and vice versa), still remains a very 
important question. 
 Wallerian, or anterograde, degeneration occurs when damage originating in 
neurons residing in the grey matter results in degeneration of the WM. As a 
neuron loses function as a result of either neurodegeneration or ischaemic 
injury. This loss of functional is eventually passed down the axonal tract, 
resulting in further dysfunction. This effect may be delayed, but results in 
disconnection of the distal end of the axon and will appear pathologically as 
lesions in the WM (Mack et al. 2001; Cook and Wisniewski 1973). 
 
    Retrograde degeneration, conversely, refers to the dying back of the cells 
from the axon, either due to demyelinating diseases or ischemic damage 
affecting the axon directly. This deafferentation results in a disruption in 
communication between the neuron and its target resulting in a loss of tropic 
support. In retrograde degeneration damage to the WM in disease’s such as 
VaD may result in delayed transmission to connecting neurons (Cook and 
Wisniewski 1973; V. H. Perry et al. 1991; Mack et al. 2001). 
 Vascular pathology and frontal white matter. 
Previous studies have reported high WM vascular pathology associated with 
cognitive dysfunction (Fernando et al. 2006; Yamamoto et al. 2009; Esiri et al. 
1997). Damage to the vasculature may lead to a chronic hypoxic state. Craggs 
et al reported increased sclerotic index in the WM of SVD subjects, indicating 
increased atheroloscheriosis, when compared to controls  (Craggs et al. 2013). 
This increased vulnerability of the WM in those suffering CVD suggests a 
potential mechanism by which the observed pyramidal neuronal volume 
changes are, in CVD cases as least, a result of WM damage and thus due to 
retrograde degeneration. Additionally, several neuroimaging studies have linked 
WMH with cognitive dysfunction (E. Burton et al. 2003; E. J. Burton et al. 2004; 
Firbank et al. 2012; K. R. Burton et al. 2014). Oligodendrocytes have been 
shown to be recruited in areas of WM pathology (Franklin et al. 1997) with 
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increased immunoreactivity in response to WM lesions (Simpson et al. 2007) 
most likely as response to demyelination, suggesting that this process is key in 
WM pathology.  
The potential effect of damage to the prefrontal cortex, and its impact on the 
cognitive and executive function has already been outlined in previous chapters 
(The prefrontal cortex). This study focused on the WM underlying the PFC 
including myelinated axons which make up and form the major connections 
between the different regions of the brain. Though several studies have looked 
into WM pathology in PS subjects through imaging techniques, few pathological 
studies have attempted to access the impact of WM pathology on neurons in 
PS sufferers. 
It was hypothesised that differential changes in the WM may explain the 
neuronal volume loss in PSD compared to PSND subjects with implications for 
neurodegenerative disorders such as in AD and mixed dementia. The relative 
lack of vascular pathology in AD cases would suggest that any potential WM 
and/or axonal pathology would not be the result of direct CVD factors, but 
potentially anterograde damage originating in axons. Immunohistochemistry 
(IHC) and tinctorial staining methods were used to evaluate WM changes. LFB 
stained sections were analysed to assess the integrity of myelin in the dlPFC of 
post-stroke survivors and other ageing-related dementias. In addition, serial 
sections were stained for markers of axonal damage. 
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 Methods 
 Details of subjects used in this study 
 
  
Table 5-1 Subject details. Controls = aged matched controls, PSND = post-stroke no 
dementia, PSD = post-stroke dementia, VaD = vascular dementia, mixed = mixed 
vascular and Alzheimer’s disease, AD = Alzheimer’s disease. FT = fixation time, PMD 
= post-mortem delay. 
 
 
No of 
cases 
(SEM) 
Age PMD FT 
Frontal 
vascular 
score  
Braak CERAD 
Control 10 
86.5 
(11) 
32.3 
(19) 
2.9  
(1) 
n/a 2 (0) n/a 
PSND 10 83 (3) 
42.3 
(19) 
3.8  
(6) 
4.5 
(0.3) 
2.3 
(0.4) 
1.6 
(0.3) 
PSD 10 
87.8 
(6) 
36.5 
(23) 
2  
(1) 
4.4 
(0.3) 
2.8 
(0.4) 
1.3 
(0.3) 
VaD 10 
85.5 
(8) 
52.1 
(22) 
2.7  
(1) 
5.5 
(0.5) 
2.4 
(0.4) 
1  
(0.5) 
Mixed 10 84 (8) 
33.4 
(19) 
5.3 
(9) 
4  
(1) 
5.3 
(0.3) 
2.7 
(0.3) 
AD 10 
83.5 
(5) 
36.8 
(24) 
1.5  
(1) 
1  
(1) 
5.5 
(0.3) 
3 (0) 
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 IHC and image analysis  
Immunohistochemistry was performed for SMI31, SMI32 (Convance, USA), and 
GRP78 (Abcam, UK) on 10μm frontal sections as described previously 
(Immunohistochemistry (IHC)). GRP78 was selected as an appropriate marker 
to stain oligodendrocytes within the WM. 2D Image analysis was performed 
using Image Pro as described previously, to assess both per area of staining 
(p/a), and the mean optical density (intensity of staining, IOD). Images were 
taken at 10x magnification with numerical aperture 0.3. Ten evenly distributed 
images were taken throughout the WM with care to avoid including any U-fibres 
which are unaffected in these disease states.  
 Myelin index assessment 
Ten μm thick frontal sections from Newcastle Brain Map layers 4-8, containing 
the dlPFC (Brodmann area 9) were stained with LFB as described previously 
(See Myelin index). Myelin index was then calculated as described previously 
(methods section, (Yamamoto et al. 2009)) from low power stained images of 
the entire frontal section, with WM delineated from GM for analysis. 
 Undamaged myelin assessment 
Due to some degree of pathology in all groups it was deemed necessary to take 
specifically selected areas of undamaged myelin to use as an additional control 
group to assess the relative levels of pathology in each group. This is consistent 
with evaluating normal appearing WM from the same cases which also exhibit 
damaged WM (Simpson et al. 2007).  
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 Results 
 Myelin Index 
There was no significant difference in the myelin index in the frontal lobe WM 
between PSND and PSD subjects (p=0.514), or combined post-stroke cases vs. 
controls (p = 0.103). (Figure 5-1). Analysis showed VaD to have significantly 
higher myelin loss (i.e. an increased myelin index) when compared controls (p = 
0.034). VaD showed higher myelin loss when compared to PSND (p = 0.072) 
though this did not reach significance. All demented cases showed comparable 
level of myelin loss with no significant differences found between PSD, VaD, 
mixed, or AD subjects. 
 Undamaged myelin 
Some control subjects exhibited a surprisingly high degree of WM abnormality, 
possibly attributed to older age, which may explain why only VaD exhibited 
significantly different pathology. In order to compare myelin loss in demented 
groups to undamaged age matched normal control with minimal WM pathology, 
analysis was performed on specific undamaged areas of myelin to ascertain a 
suitable baseline with which to compare myelin loss to other disease groups. 
There was no significant difference between post-stroke survivors, or between 
post-stroke survivors and age matched controls, or between aged matched 
controls and undamaged myelin (p > 0.05). However PSD did show significantly 
higher WM pathology than undamaged myelin cases (p = 0.025) (Figure 5-1). 
Undamaged myelin regions were not significantly different from the myelin 
scores of controls (p=0.291) or non-demented post stroke cases (p = 0.155). 
However, other demented groups showed increased myelin index scores 
(increased WM pathology) when compared to undamaged myelin: VaD (p = 
0.001), mixed (p = 0.003), and AD (p = 0.002).  
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Figure 5-1 showing the myelin index in the frontal WM of controls and disease 
subjects.  Controls = aged controls, PSND = post-stroke non-demented, PSD = 
post-stroke dementia, VaD = vascular dementia, Mix = mixed dementia, AD = 
Alzheimer’s disease. * = significant to controls. Ɨ = significant to undamaged 
myelin. Mean MI: Undamaged myelin = 25, control = 28, PSND = 30, PSD = 34, 
VaD = 43, mixed = 36, AD = 40. Controls vs VaD (p = 0.034). Undamaged myelin 
vs VaD (p = 0.001), mixed (p = 0.003), AD (p = 0.002). 
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 Correlations between myelin index and other variables 
To investigate the relationship between myelin index and other potential 
disease factors, correlations studies were undertaken. Bivariate analysis 
revealed myelin index (increased severity) significantly negatively correlated 
with MMSE and CAMCOG scores (σ = - 0.451, p = 0.001 and σ = - 0.320, p = 
0.02), decreased learning memory (σ = 0.516, p = 0.001), attention (σ = - 0.388, 
p = 0.016), calculation (σ = - 0.344, p = 0.034) in PS cases. Myelin index score 
also correlated with SMI31 positive neurons in layer III (σ = 0.277, p = 0.028) 
(Figure 5-2) when looking at all groups. There was no significant between 
myelin index and pyramidal neuron atrophy (p > 0.05) 
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Figure 5-2 showing significant correlations between clinical variables and myelin loss index. a) 
σ = -0.320, p = 0.02, b) σ = -0.451, p = 0.001, c) σ = -0.344, p = 0.034, d) σ = -0.516, p = 0.001, e) σ 
= -0.388, p = 0.016, f) σ = 0.277, p = 0.028. 
a) b) 
c) d) 
e) f) 
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 SMI32 analysis of axonal damage 
SMI32 staining shows a variety of staining patterns between subjects, with 
some of the more affected subjects displaying punctate-like staining, with areas 
showing a build-up of SMI32 in specific areas of the frontal WM. SMI32 
immunoreactivity was quantified by 2D analysis for percentage area stained 
(p/a) PSND, VaD, and mixed dementia had significantly higher P/A staining 
when compared to age matched controls (p = 0.018, p = 0.041, p = 0.001, 
respectively) and with PSD showing a trend towards significance (p = 0.072). 
Mixed dementia also showed significantly higher p/a SMI32 staining when 
compared PSD and to AD cases (p = 0.041 and 0.005). There was no 
significant difference between post-stroke survivors (Figure 5-4). IOD staining 
shared a similar pattern. 
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Figure 5-3 showing SMI32 positively stained axons in the frontal WM. a) aged-controls, b)  PSND  c) 
PSD, d) VaD, e) Mixed, and f) AD. Size bar = 20μm. 
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.  
 Correcting for myelin loss 
To assess the relative axonal damage across the groups SMI32 values were 
corrected for myelin loss, as the myelin index. This was to avoid bias towards 
those disease states with a disposition towards myelin loss which may result in 
axonal damage. The aim was not only to assess the effect of myelin loss on the 
axons, but the effect of axonal damage on cognition as a factor independent of 
myelin pathology.  
 Adjusted SMI32 staining values 
To correct for any apparent WM change, SMI32 immunoreactivity scores were 
normalised to myelin index scores. Additionally, one PSND case was removed, 
as it was deemed inadequate for reliable analysis as a large proportion of the 
slide had been damaged during the assay. Great care was taken to perform the 
assay on all slides on the same day in an attempt to minimise potential 
variations, which may affect staining. With this in mind it was deemed 
unnecessary and inappropriate to restain the missing section as any variation 
may further affect results (Figure 5-4). When accounting for this correction; 
PSND, PSD, VaD, Mixed, and AD all show significantly increased SMI32 
staining (p = 0.014, p = 0.029, p = 0.006, p = 0.001, p = 0.029 respectively) 
when compared to controls. Mixed dementia showed increased SMI32 staining 
compared with PSND, PSD, and AD (p = 0.049, p = 0.034, p = 0.029, 
respectively). 
 Correlations between SMI32 and other clinical variables 
Including all groups, corrected SMI32 p/a staining correlated with both MMSE 
and CAMCOG scores for both p/a (σ = - 0.319, p = 0.020 and σ = 0.296, p = 
0.037). SMI32 staining also correlated with recent memory (σ = -0.421, p = 
0.007) and language comprehension (σ = -0.339, p = 0.033) (Figure 5-5). There 
was no correlation between myelin index and SMI32 p/a staining or between 
SMI32 changes and pyramidal neuronal volumes (p > 0.05). 
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Figure 5-4 showing SMI32 staining (blue) and corrected SMI32 
staining (green) in controls and disease groups. Controls = 
aged controls, PSND = post-stroke non-demented, PSD = post-
stroke dementia, VaD = vascular dementia, Mix = mixed 
dementia, AD = Alzheimer’s disease. * = significant to controls. Ɨ 
= significant to mixed dementia. Uncorrected: Controls vs PSND 
(p = 0.018), VaD (p = 0.041), mixed (p = 0.001). Mixed vs PSD (p = 
0.041), and AD (p = 0.005). Corrected: Controls vs PSND (p = 
0.014), PSD (p = 0.029), VaD (p = 0.006), mixed (p = 0.001), and 
AD (p = 0.029). Mixed vs PSND (p = 0.049), PSD (p = 0.034), and 
AD (p = 0.029). 
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Figure 5-5 showing significant correlations between clinical variables and SMI32 frontal WM staining. a) σ = -
0.319, p = 0.020, b) σ = -0.339, p = 0.033, c) σ = 0.296, 0.037. 
c) 
a) 
b) 
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 Analysis of SMI31 staining in the white matter.  
Per area (p/a) staining in VaD was significantly higher than controls (p = 0.016). 
Mixed dementia had a very similar mean to that of VaD, however the large 
variation (SEM) indicated no significant differences against controls. There were 
no significant differences found between any other groups (p > 0.05) (Figure 
5-7). 
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Figure 5-6 SMI31 positively stained axons in the frontal WM. a) aged-controls, b)  PSND  
c) PSD, d) VaD, e) Mixed, and f) AD. Size bar = 20μm. 
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 SMI31 clinical variables correlations 
SMI31 p/a staining significantly correlated with CAMCOG scores (σ = -0.301, p 
= 0.034). SMI31 p/a also correlated with remote memory (σ = -0.335, p =0.035, 
respectively), praxis (σ= - 0.350, p = 0.027), calculation (σ = -0.336, p = 0.034), 
and frontal vascular pathology (σ = 0.684, p = 0.001) (Figure 5-8). Analysis was 
performed on IOD staining producing no remarkable results. 
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Figure 5-7 showing mean SMI31 staining in the frontal WM of controls and diseased 
subjects. Controls = aged controls, PSND = post-stroke non-demented, PSD = post-
stroke dementia, VaD = vascular dementia, Mix = mixed dementia, AD = Alzheimer’s 
disease. * = significant to controls. Controls vs VaD (p = 0.016). 
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Figure 5-8 showing significant correlations between SMI31 frontal WM staining and clinical variables. a) σ = -
0.336, p = 0.034, b) σ = -0.301, p = 0.034, c) σ = 0.684, p = 0.001, d) σ = -0.350, p = 0.027. 
a) b) 
d) c) 
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 Analysis of vascular pathology in the white matter 
There were no apparent differences in the SI scores of microvascular measures 
in the pre-frontal WM, though VaD did appear to trend towards significance 
when compared to AD cases (p = 0.07). In addition, no significant changes 
were observed in PVS between any of the groups (p > 0.05) (Figure 5-9).  
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Figure 5-9 showing frontal vascular pathology in the WM of controls and disease subjects. Controls = 
aged controls, PSND = post-stroke non-demented, PSD = post-stroke dementia, VaD = vascular 
dementia, Mixed = mixed dementia, AD = Alzheimer’s disease. SI = sclerotic index, PVS = perivascular 
space. No significance between groups: WMSI (p = 0.053), PVSWM (p = 0.863). 
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 GRP78 staining of oligodendrocytes 
As GRP78 also stained oligodendrocytes in the frontal WM rather specifically 
these cells were quantified. Visually there was a notable difference between 
individual subjects, however the total mean of each group remained similar 
(Figure 5-10). 2D densitometric analysis of GRP78 revealed no differences 
between any of the disease groups, or between post-stroke diseased cases and 
non-demented controls (p > 0.05). GRP78 staining did not differentiate the 
demented and stable post-stroke survivor subjects (Figure 5-11).  
  
Figure 5-10 showing GRP78 staining of the WM in a) AD and b) VaD. Bar = 20μm. 
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Figure 5-11 showing GRP78 staining in the frontal WM of controls and disease 
subjects. Controls = aged controls, PSND = post-stroke non-demented, PSD = 
post-stroke dementia, VaD = vascular dementia, Mix = mixed dementia, AD = 
Alzheimer’s disease. No significance between groups (p = 0.868). 
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 Discussion 
 White matter loss 
There was no significant difference in myelin index scores between PSND 
cases and PSD which would explain the cognitive deficits in PSD, and suggests 
myelin loss is comparable between the two groups, in turn suggesting myelin 
loss is not the primary cause of cognitive dysfunction in post-stroke subjects. 
This was surprising as previously WM damage has been shown in those with 
PSD (E. Burton et al. 2003). When assessing axonal damage SMI32 staining 
revealed no significant differences between either post stroke groups, again 
suggesting the cognitive dysfunction in this groups are not the result of WM 
damage, but possibly due to direct damage to neuronal bodies, as described 
previously (See Retrograde vs. anterograde neurodegeneration. ). Furthermore 
SMI32 staining revealed no significant difference between PSND and PSD, 
again suggesting little variation between the levels of non-damaged axons in 
each case. When compared to undamaged WM, all demented cases showed 
significantly higher MI though interestingly not when compared to age matched 
controls and non-demented post-stroke survivors.   
These findings suggest two important potential consequences; (i) Underlying 
pathology is present in all cases, including controls.  This technique may not be 
sensitive enough to distinguish the threshold with which WM pathology begins 
to affect cognition, and (ii) that there is indeed an underlying demyelinating 
aspect to these demented groups, regardless of aetiology, with both vascular 
based pathology, and AD type dementia appearing to have more severe WM 
damage than controls. In addition to these points, it is of interest, that no 
significant difference was reported between PSND and PSD (p >0.05), only 
PSD subjects were significantly difference when compared to undamaged 
myelin, suggesting that in fact PSD subjects have a higher degree of myelin 
index when compared to PSND. 
When investigating the other groups, myelin index analysis revealed an 
increased myelin index in VaD when compared to controls, suggesting a higher 
level of myelin loss, and thus, white matter damage. The hypoxic state, caused 
by the breakdown of the vasculature in the frontal part of the brain, results in 
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death by excitotoxicity of the residing oligodendrocytes (Nedergaard et al. 2003) 
and may explain the decline in cognitive function. Indeed it has previously been 
shown that myelin loss may occur in conjunction with shrunken 
oligodendrocytes in subjects suffering from VaD (Ihara et al. 2010). These cells 
are very vulnerable to this type of hypoxic insult, with their death resulting in 
decreased myelination of the surrounding axon. The resultant dysfunction of the 
WM in these cases would explain the clinical cognitive affects seen in those 
suffering VaD. Interestingly, mixed dementia did not show significance when 
compared to controls (p >0.05), which was unexpected. Mixed cases, in this 
cohort, had a comparable vascular pathology when compared to VaD, and this 
lack of conformity between VaD and mixed is surprising. VaD also showed a 
trend in greater MI when compared to AD subjects. This difference helps 
highlight the separate aetiologies of these two diseases; despite both displaying 
reduced neuronal volume in the dlPFC, they do not share comparable vascular 
pathology. Perhaps most telling, AD subjects revealed a trend towards higher 
myelin loss (p = 0.068) when compared to controls. AD pathology is well 
documented in the grey matter, but it also appears to play potential role in the 
disruption of cortical circuits via damage to the WM. This may occur as a result 
of CAA accumulation around the vasculature (Rose et al. 2000), resulting in 
oligodendrocyte death by affecting blood supply to the cells.  
No significant difference was found in WM myelin index scores between the two 
post stroke groups. Frontal myelin index score correlated strongly with the 
executive function; attention. This is not surprising- cortical disruption caused by 
loss of myelin in the prefrontal cortex may lead to a breakdown of the one or 
more of the pre-frontal cortices, suggesting a direct causal link between myelin 
loss and cognitive dysfunction, this is reinforced by the significant correlation 
between myelin index and learning memory. This suggest further break down of 
the cortico-subcortical circuit, disrupting the link between the frontal cortex and 
the limbic system, inhibiting the subject’s ability to form or access long-term 
memory.  
 Corrected SMI32 as a marker for WM damage.  
Two dimensional analysis revealed striking differences between PSND, VaD, 
and mixed pathology cases when compared to controls (p = < 0.05), with PSD 
trending towards significance (p = 0.077). Interestingly AD subjects did not 
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show similar results. This reinforces the relationship between axonal function 
and cognition. This increased immunoreactivity may indicate higher levels of 
concentrated SMI32 staining as a result of axonal transport disruption, which 
can occur following a stroke (Andres et al. 2011). Increased damage to the 
axonal tracts may interrupt action potentials between neurons which culminate 
in cognitive inhibition (Ferguson et al. 1997). Evidence of this relationship is 
further supported by the correlation between SMI32 WM staining and CAMCOG 
and MMSE scores, with axonal damage in the frontal lobes directly relating to 
global cognitive scores in PS cases. Indeed axonal damage has been shown to 
be reliable predictor in several other disease states (Medana and Esiri 2003). 
Specific functions such as recent memory and language comprehension were 
also significantly affected in post-stroke patients. Such damage also appears to 
effect the connections between areas of the brain responsible for language 
processing such as Broca’s or Wernicke’s area. However, no significantly 
differences were reported in location or severity of stroke between the PSND 
and PSD subjects, though language comprehension was found to be 
significantly lower in post-stroke demented patients. 
 
 SMI31 analysis of frontal WM integrity. 
SMI31 staining was anticipated to be higher in controls and post-stroke non-
demented cases when compared to demented groups. However, SMI31 
staining p/a values were greater in VaD compared to age-matched controls in 
p/a suggesting a higher level of healthy axonal tracts in these subjects than 
controls which contradicted the results on SMI32 analysis. There were no 
significant differences observed between any other group. This was perhaps 
surprising, as it was postulated that SMI31 antibody would target healthy, intact 
axons. This result does not support this notion as it was expected for VaD to 
have significantly less healthy axonal tracts (Gorelick 2004). In addition, it is 
worth noting that mean SMI31 staining between PSD, VaD, and Mixed groups 
was very similar, and noticeably higher than controls, PSND, and AD. This 
pattern did not reach significance however, though this may be a result of rather 
large SEMs. Though SMI31 appeared to effectively stain axons within the WM, 
it appears 2D densitometric analysis is too insensitive a technique for detecting 
the suitable differences which may exist between post-stroke subjects.  
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 Myelin loss as an effective measure of axonal damage and of 
cognitive function.  
CAMCOG and MMSE scores correlated with both myelin loss index, and axonal 
damage markers. This provides a strong mechanistic pathway in which to 
explain the cognitive decline in post-stroke patients, suggesting that myelin loss 
in the frontal white matter, as measured by LFB staining intensity appears to 
relate with cognitive decline, and can thus be used as an effective measure for 
cortico-cortical circuit damage. In addition axonal damage marker SMI32 also 
correlated with MMSE and CAMCOG scores suggesting a direct link between 
axonal dysfunction and cognitive impairment. However, no correlation was 
observed between myelin loss and axonal damage. This lack of relationship 
between the two markers suggests that the two pathologies occur 
independently of one another and that myelin loss does not necessarily result in 
subsequent axonal damage as previously suggested (Ihara et al. 2010).  
Interestingly, neither axonal markers nor myelin index correlated with pyramidal 
neuron volume changes in dlPFC (p > 0.05). This was surprising, as it was 
hypothesised that the changes reported in neuronal volume of the dlPFC were 
potentially related to damage within the WM of the frontal lobe.  
This finding, whilst unexpected, may also shed some light onto the question of 
anterograde vs. retrograde degeneration. Due to the apparent lack of 
relationship between WM changes and neuronal volume decreases, it can be 
argued that each pathology occurs independently of the other. Thus, if it is 
assumed that neuronal volume change is a pathological response, and in turn 
results in cognitive decline, then the lack of correlation between WM pathology 
would suggest that this volume change is a result of anterograde degeneration, 
where direct damage to the grey matter results in this decreased neuronal size, 
though this is hard to prove due to the widespread underlying WM pathology 
detected in dementia. However, pyramidal neuron damage as detected by 
increased SMI31 positive neuron counts does suggest a mechanistic link 
between damage to the frontal WM and cognitive dysfunction. 
 Vascular pathology in frontal WM 
Similar to findings in the grey matter, SI analysis of WM pathology revealed no 
significant differences between any disease group when compared to each 
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other, or non-demented controls. This was unexpected as previous studies 
(Deramecourt et al. 2012; Craggs et al. 2013) have reported significantly 
increased vascular pathology in the WM in some diseases i.e. CADASIL 
(Cerebral Autosomal-Dominant Arteriopathy with Subcortical Infarcts and 
Leukoencephalopathy). Indeed, a prerequisite for a VaD diagnosis is a high 
burden of vascular pathology. However, the extreme age of this cohort may 
result in a higher level of vascular pathology in controls and non-vascular based 
dementias. Indeed, SI detects arteriolosclerosis, a vascular change thought to 
occur in in the early stages of disease (Deramecourt et al. 2012) and thus may 
be present in all disease groups at this late stage. Perhaps a more sensitive 
technique would reveal any potential subtle changes in this particular type of 
pathology between disease groups in older subjects. 
 GRP78 staining as a marker for oligodendrocyte pathology 
GRP78 is induced when cellular endoplasmic reticulum are stressed, acting as 
an apoptotic regulator by protecting the host cell against ER stressed induced 
cellular death (Rao et al. 2002; Hayashi et al. 2003). However, as GRP78 stains 
all cells which contain ER it is a reliable maker for staining oligodendrocytes. 
There were no differences in GRP78 immunostaining in the WM between any of 
the groups. This lack of difference in GRP78 immunostaining was surprising as 
it has been shown previously that oligodendrocytes are lost following stroke 
(Aboul-Enein et al. 2003) due to their particular vulnerability to hypoxic insult 
(Alberdi et al. 2005). 
 
 Conclusion 
This study revealed there was considerable variation in the myelin index of 
aged-controls and post-stroke non-demented subjects. In general all cases 
showed some degree of WM pathology when compared to undamaged myelin. 
Increased myelin index, indicating increased WM loss correlated with cognition 
and executive scores, suggesting myelin index is a reliable correlate of 
cognitive function, and that reduced cognition is likely to reflect WM damage. 
The SMI32 staining related strongly with disease groups, showing increased 
axonal damage in those suffering dementia, correlating strongly with cognitive 
status and features executive dysfunction. This suggests an association 
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between axonal damage and dysfunction of the fronto-cortical circuits. This 
trend was not supported by SMI31 axonal staining, which did not appear to 
stain for undamaged axons as postulated, not consistent with the SMI32 
results. However, SMI31 staining was intense, and very strong due to the high 
numbers of axons present in the WM, so any changes between groups being 
undetectable using 2D analysis. 
GRP78 immunoreactivity in the WM was an effective marker for glial cells in the 
WM, localising with oligodendrocytes. Its expression p/a did not differ between 
PSND and PSD, and did not relate to cognitive function. From these findings it 
is clear that WM pathology plays a strong role in the development of cognitive 
impairments though it is not apparent whether glial cells play a role in the 
development of PSD.  
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Chapter 6. Markers of metabolism in the dlPFC 
 
 Introduction 
 Neuronal metabolism 
The overall health of the brain is dependent on the fulfilment of the metabolic 
needs of individual neurons. The vast majority of cells in the cortex are 
metabolically expensive excitatory (Waldvogel et al. 2000), with excitatory, 
glutamatergic based, action potentials using up to 47% of the energy of the cell 
(Attwell and Laughlin 2001).  The high metabolic requirements of these cells 
make them vulnerable to pathology which impacts oxygen and trophic factor 
supplies (Spruston 2008). Changes which alter the metabolic activities of these 
cells may have a detrimental effect on cognition, breaking down neuronal 
circuits (Tekin and Cummings 2002).   
Cerebral metabolism of glucose and oxygen uptake have been found to be 
reduced in ischaemic stroke subjects, with, 1.5T MRI revealing decreased 
metabolism in the infarction area four days following a stroke (Kuhl et al. 1980). 
Increased lactate levels in these subjects suggest neurons continue to function 
sometime after the initial event, though, due to poor blood circulation, struggle 
to obtain sufficient oxygen for metabolism which may result in gradual neuronal 
dysfunction (Bruhn et al. 1989). Decreased cerebral metabolism has also been 
reported in AD subjects. The build-up of hyperphosphorylated tau is thought to 
result in the gradual dysfunction of these neurons (K. Ishii et al. 1998; Blass 
2001; Mosconi 2005) by disruption to cellular processes within the cell. GRP78, 
a glucose regulated protein which is ubiquitously expressed in all cells 
(Quinones et al. 2008) has been shown to increase when a cell is stressed 
(Rao et al. 2002), and is linked to diseases such as Parkinson’s and AD 
(Paschen 2001). GRP78 is also thought to bind to the amyloid precursor protein 
and decrease β amyloid secretion in what is perceived as a protective 
mechanism (Yang et al. 1998). GRP78 has been linked to have a protective 
effect against glutamate excitotoxicity (Lee et al. 1999; Paschen 2001), which 
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may play an important role in ischaemic diseases, following stroke glutamate 
neurotoxicity. As mentioned previously, glial and neuron uptake systems 
remove glutamate released by synapses (Choi and Rothman 1990). When 
these systems break down, the build-up of glutamate can be lethal to the 
neuron as it may trigger an influx of extracellular calcium (Choi and Rothman 
1990; Nedergaard and Dirnagl 2005). In more chronic hypoperfusive states, 
occurring in areas remote to the stroke, neurons may be subjected to a cascade 
of biochemical fallout. The decreased glucose and oxygen transport sets off a 
chain of events resulting in increased glial activation and oxidative stress. Cells 
switch to secondary pathways which utilise lowered oxidation of glucose and 
reduced cytochrome oxidation, ultimately resulting in reduced ATP production 
and cellular dysfunction (de la Torre 1999). These changes may be pivotal 
events in the development of cognitive impairment following stroke. 
 Mitochondrial function 
Mitochondria are the powerhouses of the neuron, producing adenosine 
triphosphate (ATP) through the phosphorylation of adenosine diphosphate 
(ADP) via a process known as the electron transport chain (ETC). The ETC is 
the primary, aerobic, mechanism through which ATP is produced. Electrons are 
transferred through a series of electron donors and receptors, through REDOX 
reactions. This electron transfer is coupled with the transport of proton (H+ ions) 
through a series of protein pumps housed in the membrane of the mitochondria 
(Cadenas and Davies 2000). By far the highest metabolic pressure of a neuron 
is the active ion transport which is initiated following an action potential, and 
resets the neurons, ready for more signal transduction (Attwell and Laughlin 
2001).  Enzymes such as cytochrome oxidase C serve as reliable indicator of 
neuronal oxidative capacities and energy metabolism. The tight coupling 
between energy metabolism and neuronal activity enable this scrutiny of 
cytochrome oxidase C as a sensitive neuronal marker (F. N. Wong-Riley, 
Robert F. Hevner, Suyan liu 1998). Cytochrome oxidase is the terminal enzyme 
in complex 4 of the ETC – catalysing the oxidation of cytochrome C and 
reduction of molecular oxygen. COX4 expression has been shown to be 
reduced in diseases such as AD (Parker et al. 1990) in both the frontal and 
temporal lobes (Kish et al. 1992). Conversely Chagnon et al reported no 
significant differences in COX4 expression in those suffering CVD (they did find 
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lower levels in AD)(Chagnon et al. 1995). However, very little is known about 
COX4 expression in PSD. 
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Figure 6-1 demonstrating the electron transfer chain in mitochondria (Moncada and Erusalimsky 
2002). 
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 Dendritic arbour  
Excitatory synapses have been shown to be more metabolically demanding 
than their inhibitory counterparts. With this in mind, any changes to pyramidal 
neuron metabolisms would have drastic effects of dendritic output (Waldvogel et 
al. 2000). This mismatch in respective energy consumption stems from the 
synapses of different cell types possess. Dendritic outputs from pyramidal 
neurons are more numerous, but less efficiently located than inhibitory 
synapses (Waldvogel et al. 2000). Additionally, excitatory synapses form the 
majority of the grey matter (Abeles 1991; Geortzel 1997) with the distribution of 
mitochondria suggesting that these are the major consumers of metabolic 
energy (M. T. Wong-Riley 1989; M. Wong-Riley et al. 1998). As previously 
mentioned, dendritic arbour has been linked to the soma size of the neuron 
(Harrison and Eastwood 2001), suggesting that any reduction in neuronal 
volume would indicate a reduction in the surrounding dendritic arbour. Any 
breakdown or reduction in dendritic arbour could theoretically impact directly on 
neuronal-neuronal connectively, disrupt brain circuitry, and potentially resulting 
in neurological dysfunction. Post-mortem studies have found that stroke or brief 
ischaemia can induce changes in dendritic arbours and branch complexity and 
spine density (Gonzalez and Kolb 2003; C. E. Brown et al. 2007). However it is 
unclear how dendritic arbour remodelling differs between those suffering PSND 
and those who decline into dementia. 
Pyramidal neurons play an important role in the development of dementia. The 
previous 3 chapters have gone into great detail investigating the morphological, 
histological, and biochemical changes which may relate to specific pathological 
substrates which may separate post-stroke non-demented individuals from 
post-stroke demented subjects. This chapter will investigate the potential 
mechanisms, which may result in the dysfunction of these cells. 
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 Methods 
 Details of subjects used in this study  
Table 6-1 details of subject used in this chapter. PMD = post-mortem delay. 
Controls = aged matched controls, PSND = post-stroke no dementia, PSD = post-
stroke dementia, VaD = vascular dementia, mixed = mixed vascular and 
Alzheimer’s disease, AD = Alzheimer’s disease. FT = fixation time, PMD = post-
mortem delay. 
   
No of 
cases 
(SEM) 
Age PMD FT 
Frontal 
vascular 
score 
Braak CERAD 
 
Control 
 
10 
85.3 
(16) 
30.6 
(17) 
3 
(1) 
n/a 2 (1.2) n/a 
PSND 
 
10 
83.3 
(3) 
42.3 
(19) 
3.8 
(6) 
4.5 
(0.8) 
2.3 (1) 1.6 
(0.7) 
PSD 10 
87.8 
(6) 
35.7 
(22) 
2  
(1) 
4.3 
(0.9) 
2.6 (1) 1.3  
(1) 
VaD 10 
84.3 
(9) 
52.1 
(22) 
2.8  
(1) 
5  
(1) 
2.2 (1) 0.9  
(08) 
Mixed 10 
83.2 
(8) 
33.4 
(19) 
5.3  
(9) 
4  
(1.7) 
5.4 
(0.7) 
2.7 
(0.7) 
AD 10 
84.3 
(5) 
36.8 
(24) 
1.5  
(1) 
1  
(0) 
5.5 
(0.8) 
3  
(0) 
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 Immunohistochemical analysis 
Ten μm Sections containing the dlPFC from all control and disease cases were 
stained with antibodies for COX4 (Abcam, UK) (1:200) and GRP78 (Abcam, 
UK) (1:2000) (using method described previously). Analysis was then 
performed using 2D densitometric analysis. In addition, the operator performed 
counts to assess the number of pyramidal neurons staining positive for each of 
the antibodies. To be counted, neurons must be large (as determined by 
operator), triangular, and show a nucleus.   
 Statistics 
Distribution analysis was performed using SPSS. Both GRP78 and COX4 data 
was found to be non-normally distributed and consequently, non-parametric 
data analysis tests; Kruskal-Wallis and Mann-Whitney U tests were used. 
Bivariate correlations were tested using Spearman’s rank coefficient. 
 Results 
 GRP78 staining in layers III and V of the dlPFC 
 Densitometric analysis of GRP78 
GRP78 revealed clear and specific staining of pyramidal neurons. The cortical 
ribbon was clear with layers III and V easily distinguishable due to the presence 
of large pyramidal neurons. The cell nucleus was visible within the soma and 
there was minimal non-specific background staining (Figure 6-2). GRP78 p/a 
revealed no significant difference between PSD and PSND subjects. (Figure 
6-3). PSND showed significantly reduced p/a staining when compared to 
controls in layer V. There were no significant differences between any other 
groups.  
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Figure 6-2 showing GRP78 staining of layer III of the dlPFC in PSND (a) and PSD (b). 
(scale bar = 20μm) 
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Figure 6-3 showing p/a staining of GRP78 in both layers III. Controls 
= aged controls, PSND = post-stroke non-demented, PSD = post-
stroke demented, VaD = vascular dementia, mixed = mixed vascular 
and Alzheimer’s disease, AD = Alzheimer’s disease. Blue = layer III, 
Green = layer V, * = Significant to controls. Control vs PSND (P = 
0.036) in layer V.   
 
  
 
 
Layer III 
Layer V 
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 GRP78 positive pyramidal neurons 
Data were found to be normally distributed in both layers ANOVA revealed 
significance in layer V (p = 0.002) but this was not repeated in layer III (p = 
0.226). There were no significant differences in GRP78 positive neuronal 
counts between post-stroke subjects in either layers III or V. Post Hoc testing 
revealed significance between Controls and PSND (p = 0.035), and PSND to 
AD (p = 0.005),  and VaD (p = 0.023). 
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Figure 6-4 showing GRP78 counts in layers III and V of the dlPFC Controls = aged controls, PSND = 
post-stroke non-demented, PSD = post-stroke demented, VaD = vascular dementia, mixed = mixed 
vascular and Alzheimer’s disease, AD = Alzheimer’s disease. Blue = layer III, Green = layer V, * = 
Significant to controls, ° = significant to AD, Ɨ PSND. Control vs PSND (p = 0.035), PSND vs AD (p = 
0.005), VaD (p = 0.023). 
 
  
Layer III 
Layer V 
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 COX4 immunoreactivity in pyramidal neurons  
 
COX4 revealed strong and specific staining, concentrated in the cell body of 
pyramidal neurons. When compared to GRP78 staining COX4 revealed a more 
granular staining pattern and it was evident that in several subjects that not all 
pyramidal neurons within layers III and V were positively stained. The nuclei of 
pyramidal neurons were readily visible, due to the absence of COX4. Cortical 
layers were easily identified as was the separation of GM and WM (Figure 6-7). 
Two dimensional densitometric analysis of COX 4 antibody in the dlPFC 
revealed no significant difference between PSND and PSD subjects (p = 0.086). 
In layer III all vascular based demented cases showed significantly reduced p/a 
staining when compared to controls (Figure 6-5). Interestingly, this pattern was 
similar in layer V with the addition of PSND showing significantly lower levels of 
stain when compared to controls. COX 4 positive pyramidal neuron counts in 
layer III revealed all diseased groups, with the exception of AD had significantly 
lower counts when compared to control cases. Layer V revealed significantly 
lower COX 4 positive neurons in all diseased cases when compared to controls 
(Figure 6-6). Additional analysis using IOD revealed similar findings.  
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Figure 6-5 showing cytochrome oxidase 4 (COX4) p/a staining. Controls = aged controls, PSND = 
post-stroke non-demented, PSD = post-stroke demented, VaD = vascular dementia, mixed = 
mixed vascular and Alzheimer’s disease, AD = Alzheimer’s disease. * = Significant to controls. 
Controls vs PSD (p = 0.019), VaD (p = 0.028), mixed (p = 0.034) in layer III. Controls vs PSND (p = 
0.019), PSD (p = 0.004), VaD (p = 0.049), and mixed (p = 0.004) in layer V. 
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Figure 6-6 showing average COX4 positive pyramidal neuron count in layers III and V of the dlPFC. 
Controls = aged controls, PSND = post-stroke non-demented, PSD = post-stroke demented, VaD = 
vascular dementia, mixed = mixed vascular and Alzheimer’s disease, AD = Alzheimer’s disease. * 
= Significant to controls. Ɨ = significant to AD. Controls vs PSND (p = 0.001), PSD (p = 0.013), VaD 
(0.001), and mixed (0.001) in layer III. Controls vs PSND (p = 0.002), PSD (p = 0.002), VaD p = 0.031, 
mixed (p = 0.002), and AD (0.019). Mixed vs AD (p = 0.044) in layer V.  
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Figure 6-7 showing COX4 positive pyramidal neurons in layer V of the dlPFC. a) aged-controls, b) 
PSND c) PSD, d) VaD, e) Mixed, and f) AD. Solid arrows indicate positively stained pyramidal 
neurons, hollow arrows indicate negatively stained pyramidal neurons. Size bar = 20μm. 
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 COX4 positive neurons as a percentage of total pyramidal neuron 
population.  
ANOVA testing revealed no difference between groups in layer III (p = 0.258), 
but did find significance in layer V (p = 0.002). There was no significant 
difference between post-stroke demented or non-demented subjects in either 
layer. However, both PS subject groups (PSND p = 0.006, PSD p = 0.043) VaD 
(p = 0.005), and mixed dementia (p = 0.010), showed significantly lower 
percentages of positively stained neurons when compared to controls. This 
finding was not repeated in AD (p = 0.608) (Figure 6-8).  
 Correlations between GRP78, COX4 and clinical variables 
Layer III GRP78 counts correlated significantly with COX4 p/a staining in both 
layers III (σ= 0.267, p = 0.039) and V (σ= 0.275, p = 0.035). In PSD total 
GRP78 positive counts significantly correlated with COX4 p/a staining in layer V 
(σ = 0.476, p = 0.039). GRP78 counts correlated with COX4 percentage counts 
in layer III (σ = -0.361, p = 0.005). 
In the PS cohort the percentage of COX4 positive pyramidal neurons in layers 
III and V correlated with both executive function (σ = -0.647, p = 0.004, σ = -
0.679 p = 0.002 in layers III and V respectively) and vascular pathology (σ = 
0.552 p = 0.010, σ = 0.568, p = 0.007 in layer III and V respectfully). Additionally 
attention (σ = 0.552, p = 0.010,) and calculation (σ= 0.568, p = 0.007) in layer 
V. 
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Figure 6-8 showing COX4 percentage differences of positively stained pyramidal neurons vs 
GRP78 total counts in layer V of the dlPFC. Controls = aged controls, PSND = post-stroke non-
demented, PSD = post-stroke demented, VaD = vascular dementia, mixed = mixed vascular and 
Alzheimer’s disease, AD = Alzheimer’s disease. * = Significant to controls. Controls vs PSND (p = 
0.006), PSD (p = 0.043), VaD (p = 0.005), mixed (p = 0.010). 
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 Co-localisation of COX4 and GRP78 
Fluorescent imaging revealed co-localisation (yellow) of COX4 and GRP78 in 
both control and AD subjects. Where the two antibodies did not co-localise 
vessels appeared red, indicating GRP78. There was noticeably less in co-
localisation in PSND, PSD, VaD, and mixed groups, though co-localised 
neurons were still present in these groups. Blood vessels appeared in auto-
fluorescence green, or attract un-specific staining from COX4 antibody (Figure 
6-9). Figure 6.9 demonstrates the increased COX4 staining (green) in aged 
controls, with minimal COX4 present in PSD subjects, though it is not absent. 
GRP78 staining appears clearly in both aged-controls and PSD subjects (Figure 
6-10).  
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Figure 6-9 fluorescent image showing the co-localisation of COX4 antibody (green), and GRP78 
(red) in pyramidal neurons in layer V of the dlPFC. Where antibodies are co-localised the image will 
appear yellow. Blue = DAPI. a) aged-controls, b) PSND,  c) PSD, d) VaD, e) Mixed, and f) AD. Open 
arrows indicate co-localisation of GRP78 and COX4 within pyramidal neurons. White arrows 
indicate GRP78 positive, COX4 negative pyramidal neurons. Red arrows indicate vessel auto-
fluorescence green. Size bar = 10μm. 
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  a b 
c d 
e f 
g h 
Figure 6-10 showing separate fluorescence images for DAPI (c, d), 
COX4 (e, f), and GRP78 (g, h) in control (left column) and PSD (right 
column) subjects. Images ‘a’ and ‘b’ show composite of images for 
control and PSD subjects, respectively. COX4 = green, GRP78 = red, 
DAPI = blue, co-localisation = blue Size bar = 10μm. 
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 Estimation of dendritic arbour 
The dendritic arbour is affected in stroke (C. E. Brown et al. 2007). To establish 
whether this vulnerability plays a role in the development of PSD it was 
necessary to investigate dendritic arbour in those with PNSD and PSD. Golgi 
staining techniques have been used previously to stain individual dendritic 
branches (Gabbott and Somogyi 1984; Dall'Oglio et al. 2010). The capricious 
nature of the stain results in isolated dendrites which are clear enough to study. 
Once the dendritic arbour of individual pyramidal neurons was highlighted, 3D 
stereological techniques would then be used to evaluate the length density 
(Burke et al. 2014; Foster et al. 2014) between PSND and PSD subjects 
Unfortunately, we were unable to repeat the results previously achieved by 
others and the Golgi staining proved too capricious and selective to allow for 
suitable and reliable analysis (Figure 8-1). Preliminary results are provided in 
the Appendix A. 
 
 Discussion 
 Analysis of GRP78 in the dlPFC 
 GRP78 analysis of the dlPFC 
 
GRP78 immunostaining revealed no significant difference between PSND and 
PSD in layer III of the dlPFC, however in layer V showed significantly higher in 
PSD when compared to PSND. GRP78 is expressed in all cell types, both on 
the cell surface and internally in relation to ER (Quinones et al. 2008), so any 
change would have to be rather profound in order to detect it using 2D 
densitometric analysis. Due to this high expression, the changes in cell counts 
would suggest fewer neurons were present in PSND subjects which was 
surprising as 3D analysis did not reveal any changes to pyramidal neuron 
density. Though increased GRP78 has been found in a range of disease states 
(Quinones et al. 2008; Yang et al. 1998), a more subtle method may be 
required. However, this method did confirm that GRP78 staining is ubiquitously 
present in all pyramidal neurons. It has however been reported that 
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endoplasmic reticulum associated GRP78 is increased in disease states such 
as tumour growth in an attempt to protect the cell against the undesirable 
environment the disease creates. The lower levels found in the two post-stroke 
subjects groups when compared to aged controls may suggest that perhaps 
this protective mechanism is not functional in these cases, increasing the 
burden of pathology. However, this would not explain the low levels of GRP78 
p/a staining in PSND. 
 It has been shown in cell culture that increased expression of GRP78 protects 
against oxidative stress and excitotoxicity (Yu et al. 1999), and GRP78 has also 
been associated with the up regulation of cytokines such as interleukin-6 and 
tumour necrosis factor-α as well as increasing the activity of microglia 
(Kakimura et al. 2001). The increased expression shown in PSND when 
compared to controls may be a result of this increased neuroprotective 
response, and possibly relates to why these subjects have not developed PSD. 
The PSD cohort expressed comparable levels to that of controls and therefore 
appears not to have developed an adequate enough response to starve the cell 
damage. 
 GRP78 positive pyramidal neuron counts 
Interestingly, individual neuronal counts did not follow the same pattern as that 
for p/a staining. PSND revealed significantly higher GRP78 positive neurons 
than controls and PSD, with VaD also significantly higher than AD within layer 
V. As it is understood that GRP78 is expressed in all cells in the human body, 
this data suggest that there are a higher number of pyramidal neurons present 
in the layer V of the dlPFC in PSND and VaD. This data was unexpected and 
contradicts our original findings regarding 3D stereological estimates of neurons 
in layer V. 
 
 COX4 analysis of pyramidal neuron metabolism 
 COX4 Immunoreactivity in pyramidal neurons.  
There were no significant differences observed between the PSND and PSD in 
COX4 immunoreactive neurons in layers III and V of the dlPFC despite quite 
marked differences observed between disease subjects and control groups. 
The smaller pyramidal neurons observed in demented subjects may explain the 
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reduced area expressing COX4, with neurons physically unable to express a 
higher degree of immunoreactivity, however, this does not explain why lower 
immunoreactivity was also observed in PSND, were pyramidal neuron volume 
was comparable to aged-controls. It has been put forward that COX4 is a 
reliable surrogate marker for decreased metabolic activity within a cell (F. N. 
Wong-Riley, Robert F. Hevner, Suyan liu 1998; M. T. Wong-Riley 1989). If this 
is the case it may suggest a potential mechanism for decreased pyramidal 
neuronal volumes within demented subjects, however, the findings in PSND 
does not support this. Though interesting, metabolism is a dynamic process and 
it is unlikely that COX4 expression within pyramidal neurons is the whole story. 
However, it does suggest a possible protein or structural change which may 
have some impact on the cells function.   
 COX4 counts 
The next step was to establish whether this apparent decrease in COX4 
immunoreactivity staining was representing changes in mitochondria within 
individual pyramidal neurons, or whether it was due to a reduction in the gross 
number of pyramidal neurons expressing the protein. To elucidate which, the 
number of individual pyramidal neurons expressing positive staining for COX4 
in each case were counted. COX4 positive pyramidal neuron counts revealed a 
similar pattern to immunoreactivity expression with all disease groups showing 
decreased positively stained pyramidal neurons when compared to controls 
(with the exception of AD in layer III). There was no significant difference 
between the number of COX4 positive pyramidal neurons between PSND and 
PSD, which again suggests that pyramidal mitochondrial dysfunction is not 
involved in the development of PSD, or the cause of decreased pyramidal 
neuronal volumes in the dlPFC. These data suggested that the lower 
immunoreactivity was due to fewer pyramidal neurons expressing COX4. There 
was no change in pyramidal neuron density in layers III or V as measured using 
3D stereology, so it would appear these neurons were present, but absence of 
COX4.   
 COX4 counts corrected with GRP78 total neuronal counts.  
This finding suggests the initial decreases in immunoreactivity are likely a result 
of decreased COX4 expression in individual neurons. However, it is unknown 
which proportion of the total neuronal population are COX4 positive. To 
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elaborate on these results, total pyramidal neuron counts were performed on 
GRP78 stained sections. GRP78 ubiquitously throughout the brain and will 
therefore mark each pyramidal neuron clearly (Quinones et al. 2008). By 
relating COX4 positive pyramidal neuron counts to the total pyramidal neuron 
population it may be possible to establish whether or not there is a decrease in 
healthy, metabolically active pyramidal neurons in the dlPFC.  
There were a significantly lower percentage of COX4 positive neurons in PSND 
(14%), PSD (25%), VaD (14%), and mixed subjects (17%) when compared to 
aged-controls in layer V of the dlPFC. This change was not apparent in layer III. 
These data directly contradicts those reported previously on decreases in AD 
but not CVD (Chagnon et al. 1995). However, studies in rat models have found 
that in ischaemic disease reduced COX activity in the CA1 and other brain 
regions is a predictor of neuronal damage, preempting damage to the cell soma 
(de la Torre et al. 1997; Cafe et al. 1994) and suggest that COX4 expression 
may play a role in neuronal soma volume changes, as those previously reported 
in the dlPFC. The current study found the percentage of pyramidal neurons 
expressing COX4 significantly correlated with vascular pathology in those who 
had suffered a stroke. This data provides evidence that CVD may have a 
profound effect on mitochondrial and cognitive function. It appears the 
dysfunction of mitochondria has a profound effect on pyramidal neurons, 
impacting cognitive decline. Indeed in post-stroke subjects COX4 expression 
correlated with executive function, suggesting that lower COX4 expression may 
be a marker of reduced pyramidal neuron activity in layer V in the dlPFC, 
influencing the clinical outcomes in those suffering a stroke.  
a) Only pyramidal neurons in layer V appear to be affected with dysfunctional 
‘power units’ in disease groups, suggesting that those neurons which are 
responsible for long range projections throughout the brain (Khundakar et al. 
2009; Tekin and Cummings 2002). It is plausible these neurons, have a very 
high metabolic demand (Attwell and Laughlin 2001) due to their crucial roles 
within the brain and would struggle to function correctly, if they have fewer, or 
less functional mitochondrial units. This stress may result in gradual dysfunction 
of the neuron, potentially affecting the dendritic arbour processes and other 
cellular processes 
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b) That only vascular based pathology appears to be affected in this way. This 
finding separates the vascular based pathologies from the neurodegenerative 
disease states and suggests a separate pathway, or disease progression 
between these diseases. In turn it reinforces the concept that different triggers, 
resulting from a arranged of pathologies, may have similar impacts on the brain 
(Wardlaw et al. 2003). In this case, this impact is shrunken pyramidal neurons.  
COX4 expression in AD was expected to follow a similar pattern to that of VaD 
and mixed, however it was more comparable to that of control subjects. As 
previously mentioned, AD has been shown to express significantly lower levels 
of COX4 when compared to controls (F. N. Wong-Riley, Robert F. Hevner, 
Suyan liu 1998). Given the findings in other disease groups, this omission is 
unexpected. Additionally, the previous findings reported in chapter 3 would 
have led to the assumption that COX4 would follow a similar pattern in AD 
subjects, as CVD subjects 
Interestingly, the correlation between GRP78 counts and COX4 counts in layer 
III suggest there is a distinct relationship between the two proteins, reinforcing 
the concept that COX4, like GRP78 is, under usual circumstances, active and 
present in the majority of pyramidal neurons. This finding was not repeated in 
layer V of the dlPFC, were not all pyramidal neurons appeared to expressed 
COX4, but did express GRP78. Together these correlations suggest GRP78 as 
a suitable marker for marking pyramidal neurons.  
 GRP78 and COX4 co-localisation.  
The above findings suggest that a population of pyramidal neurons in demented 
subjects express GRP78 but not COX4 and that a higher population of 
pyramidal neurons expressing both COX4 and GRP78 would be found in aged-
controls and AD subjects when compared to PSND, PSD, VaD, and mixed 
dementia. Immunofluorescence revealed a higher proportion of GRP78 and 
COX4 co-localisation in aged-control and AD subjects as suggested by the 
higher incidence of yellow fluorescence demonstrating a combination of both 
green (COX4) and red (GRP78). Figure 6.9 demonstrates the individual 
fluorescent staining of GRP78 and COX4 separately in aged-control (high levels 
of COX4 immunoreactivity) and PSD subjects (low COX4 immunoreactivity). 
GRP78 is comparable between the two groups which suggests its ubiquitous 
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nature. Though great effort went into suppressing the autofluorescing of 
lipofuscin (which can be an inherent issue when using human tissue) it is 
possible that some of this was picked up in the green and may have given the 
appearance of COX4 positive staining. However, the uniform nature of the 
green fluorescence does not support this theory (lipofuscin appears more 
granular and punctate). Though qualitative, this data does appear to support the 
notion that some pyramidal neurons within the dlPFC to in fact not express 
COX4, whilst GRP78 appears to be ubiquitous throughout the cortex.  
 Golgi analysis of the dendritic arbour 
Unfortunately the nature of the Golgi stain resulted in no reliable analyses with 
which to assess dendritic arbour in the dlPFC (Figure 8-3). The apparent 
random nature of the staining would have made unbiased analysis impossible, 
and the clustering nature of the stain compounded this issue by making the 
image to distorted, making the selection of individual dendritic limbs very 
difficult.   
 Conclusion 
GRP78 appears to be ubiquitously expressed in control and demented subjects 
and therefore a reliable cellular marker, though the unexpected lower 
expression in PSND subjects should be taken into account. Decreased COX4 
does appear to be markedly reduced in disease subject, suggesting it may be a 
potential marker for an underlying pathological process. Layer V appeared to be 
most impacted in CVD subjects, suggesting the long axonal projections of the 
dlPFC are most affected and vulnerable. COX4 counts did suggest that specific 
populations of pyramidal neurons appear to express the protein whilst others 
did not, and that this was the reason for lower immunostaining in VaD, Mixed, 
and AD cases. This data was supported by accompanying fluorescent staining. 
Unfortunately Golgi staining revealed sections which were inappropriate to 
analyses. However, the Golgi is a proven technique for staining dendrites and it 
is necessary for further work to be done to quantify dendrites and to establish 
their role in the development of PSD.
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Chapter 7. Discussion 
 Introduction 
The aim of this project was to establish the neuropathological substrates of 
post-stroke dementia (PSD), and what role the frontal lobe plays in the 
development of executive dysfunction.  Using clinically well characterised post-
mortem tissue, we investigated neuronal morphology and density, glial cell 
populations, and WM pathology to achieve a better understanding of the 
underlying causes of cognitive impairment including executive dysfunction 
which might be attributed to the frontal lobe in PSD.  The study involved the use 
of 88 brains from post-stroke subjects which have come to autopsy in addition 
to those collected from other dementias from out prospective clinical cohorts. 
The use of a large brain sample, including those from neurodegenerative 
disease, allowed for the comparison of disease processes and demonstrate 
specificity for changes relating to vascular aetiology. 
 Morphological changes in the dlPFC 
Three-dimension stereology revealed significant (about 30-40%) cell volume 
reduction of pyramidal neurons in the dlPFC of PSD subjects and in other 
dementias (AD, Mixed, and VAD) in both layers III and V, when compared to 
PSND and aged controls. This was not evident in the ACC or the OFC. These 
results suggest the decrease in neuronal volume is a regional specific 
pathological response to dementia in dlPFC. Investigations into cortical atrophy 
revealed that there was little or no atrophy with the dlPFC which would explain 
the neuronal shrinkage in these subjects. 
Pyramidal neuron atrophy correlated with global cognitive and executive 
dysfunction scores in the post-stroke group suggesting smaller, atrophied 
neurons may not be functioning normally and contribute to the cognitive 
impairment. Previous studies on PSD have also found reduced pyramidal 
neuronal volumes in the hippocampus (Gemmell et al. 2012). The hippocampus 
has a range of connections with the frontal lobe, with a strong interplay between 
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the two areas which may explain the reduced global function and reduced 
memory scores (Laroche et al. 2000; Tekin and Cummings 2002) which builds 
the complexity of the disease process. These connections may underlie the 
correlations between memory scores and pyramidal neuron changes in the 
prefrontal cortex. 
Damage to the frontal lobe has been previously related to executive dysfunction 
(S. W. Anderson et al. 1991), with stroke affecting fronto-subcortical circuitry (E. 
Burton et al. 2003; E. J. Burton et al. 2004; Pohjasvaara et al. 2002). Other 
disease states affecting the frontal lobes, such as FTD, (Huey et al. 2009) also 
result in executive dysfunction. There was no apparent relationship between AD 
type pathology and reduced pyramidal volumes in PSD, which was also evident 
in the hippocampus (Gemmell et al. 2012) suggesting either a) the neuronal 
volume reductions are the result of a common pathology between the demented 
groups, i.e. vascular disease pathology; present in all disease cases including 
AD (Jellinger 2002; Jellinger and Attems 2003; Kalaria 2003) or b) pyramidal 
volume changes are a common end point to multiple triggers (from stroke to 
Alzheimer-type disease (Wardlaw et al. 2003; Vaux 1993). Evidence suggested 
the latter b) is more likely, with similar findings amongst other disease types, 
such as depression, schizophrenia, and autism (Courchesne et al. 2011; Pierri 
et al. 2001; Khundakar et al. 2009). Indeed studies attempting to link the 
processes which precede the development of AD and schizophrenia have 
suggested that schizophrenia may be a form of premature dementia (Douaud et 
al. 2014), occurring at a different end of the age spectrum compared to AD, 
affecting younger individuals. 
The pathological complexity of diseases such as AD and vascular pathology 
make it very unlikely that the underlying mechanism which resulted in pyramidal 
volume reductions and cognitive impairments in PSD, VaD, mixed dementia, 
and AD are the same. A previous study (Regeur et al. 1994) has suggested that 
the neuronal volume reduction was an artefact resulting from the selective 
vulnerability of larger neurons to disease. Once these neurons succumbed to 
the disease state only smaller neurons were left, thus reducing the average size 
of the population. However, there were no changes in neuronal density in any 
disease group, an observation which suggests that at least in the dlPFC the 
majority of neurons are still present. These findings, along with previous 
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hippocampal data suggest that neuronal atrophy is not a global process with 
neurons in different areas of the brain responding differently to pathological 
stress.  
The lack of neuronal volume changes in the OFC or the ACC was surprising 
and unexpected. It is possible other factors prevent global deterioration, 
preserving some brain regions even when connected in the same frontal 
circuits. Further investigations into other components making up the cortex, and 
the cortical circuits are necessary to develop a greater understanding of the 
environmental factors which contribute to dementia, in PS subjects and other 
dementias.  
 
 The causes of cognitive dysfunction 
Overall, the above findings have some interesting implications: Firstly, that most 
neurons are preserved in dementia. Secondly, affected neurons appear to 
atrophy as detected by reduced volumes. Thirdly, that these atrophied neurons 
appear to dysfunction to such an extent that they result in cognitive impairment. 
This association of pyramidal neuronal volume with cognitive dysfunction may 
be key to deciphering why some post-stroke subjects develop cognitive decline 
in the form of PSD and others do not. In this respect, four hypotheses can be 
proposed that provide theories as potential links between pyramidal neuron 
atrophy and dementia; decreases in pyramidal neuron volume may represent:  
1.  The neurocentric hypothesis for the breakdown of the neurovascular unit. 
2. The degeneration of the white matter and disruption of cortical circuitry. 
3. Decreased metabolic output, dysfunctional ineffective neuron. 
4. The collapse of the dendritic arbour. 
These theories are explored below. 
 The neurocentric hypothesis for the breakdown of the 
neurovascular unit 
Traditionally, the theory behind cognitive impairment has been largely 
neurocentric, with pathology and dysfunction of the neuron at the centre of 
cognitive dysfunction and glial cells relegated to supporting roles (Verkhratsky 
et al. 2012). However, it is now well understood that the intricate nature of brain 
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function and cell survival is created in part through the cooperation between a 
wide range of cells, particularly the neurovascular unit (Giaume et al. 2007; 
Verkhratsky et al. 2012).  
Investigations into glial cell density suggested astroglial numbers were not 
significantly reduced in PSD and other dementias when compared with controls, 
in either layers III or V. Given that astrocytes have a role in controlling 
homeostasis within the CNS (Danbolt 2001; Walz 2000) it is surprising that 
there was not a more prominent change in their numbers post-stroke.  
Some subtle relationships between pyramidal neuron atrophy and glial cell 
density were detected. In PS cases, glial cell density positively correlated with 
pyramidal neuronal atrophy. These data suggest that though pyramidal neuron 
atrophy appears to play a role in executive dysfunction, glial cells appear to 
have some involvement. Though this finding is suggestive of glial cell 
involvement, supporting the glialcentric view to disease progression (Smith 
2010; LoPachin and Aschner 1993; Mutch 2010), further work into the role of 
astroglia, and other cells, needs to be embarked upon to shed light in this area. 
If the susceptibility of glial cells to excitotoxicity (Nedergaard and Dirnagl 2005) 
plays a significant role in cognitive decline, treatments targeted at the protection 
of these cells may be a viable treatment against the development of dementia. 
Indeed, it has been shown that the condition of neighbouring glial cells following 
a stroke can have a great impact on the outcome of the subject (Nedergaard 
and Dirnagl 2005). Astrocytes control synaptogenesis and synaptic pruning, 
shaping the architecture of connections within the GM during development and 
throughout adulthood (Nedergaard et al. 2003; Pfrieger 2009, 2010) which can 
be crucial in recovery following stroke (Nudo 2003), as previously mentioned, 
dendritic arbour may have a critical impact on pyramidal neuron volume 
(Harrison and Eastwood 2001). Though astroglia did not appear to be reduced 
in number it is possible that individual cell function and morphology is affected 
in dementia. Further study into the biochemistry and morphology of astroglia will 
shed more light on the role these cells play in the development of PSD.  
In addition to the neurovascular unit, the prefrontal cortex relies on an intricate 
arrangement of neurons known as minicolumns (Opris and Casanova 
2014).These minicolumns consist of neurons sending and receiving signals to 
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each other as they control executive and behavioural functions, with executive 
abilities arising from cortico-cortico interactions within the prefrontal cortex, in 
microcircuits. Damage to these circuits, which has been reported in AD may 
result in dysfunction of this intricate network (Opris and Casanova 2014). 
Breakdown of pyramidal neuron connection within this circuit in PSD may well 
contribute to the executive dysfunction observed in these subjects.  
 WM pathology and pyramidal volume change in the frontal lobe 
Previous imaging studies have found significant levels of WM hyperintensities in 
this post-stoke cohort (E. Burton et al. 2003; E. J. Burton et al. 2004; O'Brien et 
al. 2002). These are often indicative of underlying WM pathology, which, if 
present, would help explain the pyramidal neuronal atrophy. Both studies into 
axonal myelination changes, as well as direct axonal damage did not reveal any 
significant changes between PSND and PSD subjects. Some myelin pathology 
was observed in the vascular cohort, which agreed with previous findings (Ihara 
et al. 2010). These data were unexpected as it was hypothesised that WM 
damage may explain why pyramidal neurons in the dlPFC were atrophied 
through retrograde degeneration (V. H. Perry et al. 1991; Richardson et al. 
1982; Spoendlin 1975). However, changes in the WM which would just impact 
the dlPFC would have to be subtle, and specific, as to not also impact the 
pyramidal neurons in the OFC or the ACC. Axonal connections from each of the 
three pre-frontal cortices, though originating in different locations, eventually 
come together as they share similar circuitry as each other (Abeles 1991; 
Lichter and Cummings 2001; Tekin and Cummings 2002), so it is likely that any 
gross, non-specific pathologically changes, i.e. those occurring due to a stroke 
or breakdown of a nearby vessel within the WM, would result in unbiased 
damage to each of the axonal tracts. This in turn may then result in decreased 
pyramidal neuronal volume in both the ACC and the OFC. With this in mind, any 
potential WM changes which only affect the dlPFC may be too subtle to be 
picked up by this method, as any disease related pathology may be lost in the 
overall pathology resulting from age (Kalaria 1996). However, results on WM 
changes within the VaD subjects do not support this.   
The lack of correlation between axonal damage and myelin degeneration to 
morphological changes within the GM in PS subjects may suggest that there is 
indeed a minimal relationship between WM pathology and the GM neuronal 
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atrophy in PSD in this cohort. This would reinforce the concept of pathology 
originating within the GM. These data do appear to suggest little 
correspondence between MRI data and detectable WM changes at post-
mortem. However, if atrophy begins further down the circuit, for example the 
lateral dorsomedial aspect of the globus pallidus, this may result in retrograde 
damage, with connected areas of the circuit eventually being affected as well. 
The death of neurons in the globus pallidus would result in feedback to the 
connecting pyramidal neurons in the dlPFC, and not the OFC or the ACC (Tekin 
and Cummings 2002) 
 Mechanisms for pathology in the dlPFC and cognitive dysfunction 
The evidence so far argues a neurocentric view to pyramidal neuron volume 
changes and the subsequent progression of PSD. From the evidence obtained 
neither WM, nor glial cell pathology appear to have a strong impact on the 
neuronal changes observed through the different disease groups. Therefore, it 
is unclear how these volumetric changes may result in cognitive impairment or 
indeed how the morphological changes occur in the first place. Analysis showed 
no clear association between GM and WM pathology in PS subjects despite 
suggesting that both PSND and PSD exhibit significantly higher pathology than 
aged-control subjects, suggesting pathology originates in the GM, affecting 
selective neurons, particularly pyramidal neurons. COX4 immunoreactivity 
suggested reduced immunoreactivity in both PSND and PSD subjects 
suggesting the mitochondrial units in these subjects have undergone some 
chemical or structural change. This finding was compounded by similar findings 
in VaD, mixed, and AD subjects. Reduced COX4 immunoreactivity. However, 
the PSND showed a similar pattern of COX4 staining, and raising the question 
as to why these neurons are not, too, atrophied. 
It is unknown whether pyramidal neurons in demented cases are atrophied as a 
result of stroke, or that subjects begin life with smaller neurons than their non-
demented counterparts, and are thusly more susceptible to developing 
dementia. This is an important distinction, though one which may be very 
difficult to prove in human subjects as it is impractical to assess pyramidal 
neuron volumes in the living. However, COX4 immunoreactivity was reduced 
between PSND and PSD as well as VaD and mixed dementia, with mixed 
dementia expressing an even greater degree of change. Therefore, COX4 
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immunoreactivity may be reduced in all demented cases as a result of 
hypoperfusion, which would explain why AD subjects did not follow the same 
pattern. It is therefore possible that PSND subjects, had they lived longer, would 
have eventually succumbed to PSD. However, due to comorbidity factors, they 
died before cognitive dysfunction became apparent. 
COX4 expression was greatly reduced in diseased subjects. Though no 
correlation was found between pyramidal volume and COX4 staining, it can be 
suggested that smaller pyramidal neurons (those mainly present in the dlPFC of 
demented subjects) may have fewer fully functional mitochondria. Previous 
studies have found metabolic reduction in subjects following stroke, (Bruhn et 
al. 1989), VaD (Pascual et al. 2010), CVD (Kuczynski et al. 2009), and 
neurodegenerative diseases (K. Ishii et al. 1998; Blass 2001) suggesting a 
relation between metabolism and cognitive function, and may be related to the 
reduced COX4 staining reported here.  
 Cognitive brain reserve.  
The findings reported in this study suggest several other factors which could 
contribute towards the development of dementia. The volumetric changes 
suggest that neuronal atrophy may result in PSD. However, if it is assumed that 
those cases with PSD (and other subjects who go onto develop dementia) are 
not suffering from atrophy of the pyramidal neurons, but initially begin life with 
smaller neurons in the first place, then different theory become prominent. 
Cognitive brain reserve, as described previously regards the brain’s threshold 
capacity to resist pathology, and remain cognitively functional. Those with a 
higher cognitive reserve can withstand more than those with a lower reserve. 
With this in mind, those with smaller pyramidal neurons may only be able to 
withstand a specific level of CVD than those with larger neurons, and go on to 
develop PSD. Those with larger neurons starve of PSD until much later in life, 
and may well die before developing the syndrome. However, it is unknown 
whether all subjects would eventually go on to develop the disease or not.  
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 Strengths and limitations of the study 
 The CogFAST study 
The CogFAST study offered this study access not only to processed and well 
characterised post-stroke brains, but the clinicopathological detail which was 
collected during the last years of life offered unique insight into to the clinical 
and cognitive state of the post-stroke subjects allowing for the comparison 
between pathological findings which can only be investigated after death with 
cognitive changes during life. Additionally, the CogFAST study provided two 
well characterised groups. The longitudinal ascertainment of dementia status 
enabled us to compare the brains of those who did develop dementia after a 
stroke with those who did not develop dementia after a stroke, providing a 
unique insight into post-stroke processes and PSD development. However, with 
all human cohort based studies, every desirable and ideal variable cannot be 
assessed and often longitudinal studies are limited when it comes to post-
mortem analysis. The cut off age for inclusion in this study was 75 years old, 
with many much older. These subjects had all lived long, full lives, filled with 
varying degrees of risk factors, environmental factors, and personal factors. 
Each one of these factors is unaccounted for and may have an impact on our 
pathological findings.  
 Additional disease subjects and aged-controls 
The inclusion of aged-controls, VaD, mixed, and AD allowed insight into the 
complex processes which may be compared with PSD. By comparing the 
findings of the PS cohort to these groups it was possible to identify whether 
changes where pathologically distinct from CVD or neurodegenerative process, 
or if PSD shared characteristics with a range of disease types. Though the 
insight gained from these cases was invaluable, only limited information could 
be learned from the disease states themselves. Though it was possible to relate 
pathological changes within the dlPFC to executive and cognitive functions, 
these data were not available to make such comparisons in other disease 
groups. Additionally, VaD, mixed, and AD groups were recruited into other 
studies with strict pathological criteria, aged controls were not. Elderly brains 
can have varying degrees of pathological changes which may impact findings in 
this study. Though this makes the aged-controls a realistic cross section of 
society, the use of clinically ‘clean’ brains in future studies may provide more 
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insight into disease states. However, it is important to include aged-controls as 
it provides a baseline of age-induced changes from which are representative of 
the general population and can tell us a lot about the relationship between 
pathology, and normal ageing. Other characteristics of post-mortem tissue are 
issues such as post-mortem delay (PMD), and fixation time (FT), though these 
were taken into account and it was ensured that neither FT nor PMD were 
factors in this study.  
 Additional frontal pathology cases – Frontal temporal dementia  
In addition to the six groups analysed in this study, 3D stereology was also 
performed on the dlPFC of 4 subjects diagnosed with FTD. These subjects 
where analysed to investigate pyramidal neuron volumes in a disease group 
which specifically suffers from frontal pathology, and whether these subjects 
would follow a similar pattern to other dementia groups. The details of this study 
can be found in the appendix [Frontotemporal Dementia (FTD)]  
 
 Future directions 
 Morphological investigations 
This study has identified and outlined specific changes within the prefrontal 
cortex and related these changes to clinical occurrences and the outcome of 
dementia. Changes in dlPFC pyramidal neurons are clearly a relevant aspect of 
PSD, however, these changes can only ever be a small part of what must be a 
greater pathological process within the cortical circuits. It would be beneficial to 
our understanding of the prefrontal circuits in dementia to investigate further the 
components of the dlPFC. Whether the reported changes occur within cortex or 
whether the subcortical regions such as the caudate or the globus pallidus and 
thalamus (Tekin and Cummings 2002) is unknown. Further investigation would 
perhaps make the aetiology of the dlPFC GM changes, clearer.  
It is important to understand the progression of the circuit’s dysfunction. Are the 
pathological processes which originate and connect to the sub-cortical 
structures such as the globus pallidus of thalamus (critical areas in 
stroke)(Tatemichi et al. 1995) affected to the same extent as the cortical region 
of the dlPFC? As several sub-cortical regions are shared between the prefrontal 
circuits (Tekin and Cummings 2002) it would be interesting to establish at which 
200 
 
level the distinction between healthy and non-healthy circuits becomes 
apparent. Additionally, along the same vein, connections between the prefrontal 
circuits and the temporal lobe are potentially a key aspect to the development of 
dementia. With similar changes to pyramidal neuron morphology reported in 
PSD and other dementias within the hippocampus (Gemmell et al. 2012), the 
interplay between the two areas requires additional attention.  
Though this study included a large range of disease groups, it is important to 
establish the pathology present in groups which are not affected by the ageing 
process. The 3D stereology should be conducted on the dlPFC in CADASIL 
subjects. This disease of pure vascular aetiology, which largely affects younger 
individuals, will help to eliminate the effect of age-related CVD and AD 
pathology and aid in clarifying the role of pure vascular pathology in the 
development of dementia (Craggs et al. 2013). 
 Dendritic arbour and cognition 
The dendritic arbour is crucial in cellular communication within the CNS and is 
perhaps the most metabolically demanding structure of the neuron. Any 
changes to the metabolism within the brain may have a significant impact on 
these spines. Previous studies using Golgi methods have identified stunted 
dendritic arbour in those with dementia (Buell and Coleman 1979; Scheibel and 
Tomiyasu 1978), with decreased dendritic spines found on cortical pyramidal 
neurons (Catala et al. 1988). These findings, point towards an intricate 
relationship between dendritic arbour and cognition. Unfortunately, it was it was 
not possible to assess dendritic arbour in this cohort, as the Golgi stain was not 
sufficient to make accurate estimates of dendritic length, or condition. However, 
neuronal size has been linked to dendritic arbour (Harrison and Eastwood 
2001) and is a potential clue as to the state of neuronal connectively within the 
dlPFC. With this assumption, it would appear that dendritic arbour is 
significantly reduced in all demented subjects in this study, but perhaps most 
significantly; it appears to be intact in PSND and non-demented aged-controls. 
This distinction between the two PS cohorts perhaps highlights one of the most 
important findings which can be proposed, that the states of dendrites within the 
dlPFC may have a significant impact of the cognitive outcome of those suffering 
a stroke. However, further investigation will be required to confirm this 
hypothesis. It will be crucial to either establish a more effective Golgi-procedure 
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or develop a different technique to isolate the dendritic arbour in dementia. 
Once an effective method for dendritic staining has been established, 
quantification techniques such as 3D stereology can be used to accurately 
determine the state of the arbour between diseases.   
 Biochemical basis for neuronal dysfunction 
The importance of the prefrontal circuits as a whole cannot be over expressed, 
however this study has reinforced the significance of the pyramidal neuron as a 
key individual component in the development of PSD and other dementias. 
Early biochemical changes should be investigated. The mechanism of 
apoptosis, which incorporates both cell death and cell shrinkage (Majno and 
Joris 1995), and how cellular mechanism affect the neuron would be valuable to 
understanding underlying cause of the shrinkage. In addition, cellular 
autophagy, the controlled destruction of cells may also play a role in neuronal 
atrophy. If a common apoptotic or autophagic mechanism was established as 
the main cause for cell shrinkage and dysfunction it would explain why disease 
groups with different aetiologies have similar morphological traits. Apoptotic 
mechanisms may be triggered by a range of pathologies, and it would be 
important to decipher if this mechanism is in operation in PSD. 
 Genomics of the CogFAST cohort 
The CogFAST cohort, as a clinically well characterised post-mortem brains 
resource, has provided much information. There are still several factors and 
substrates which may be uncovered to explain how cognitive impairment occurs 
following a stroke. The next step may be to begin profiling the DNA of 
individual’s within the cohort, with the aim to isolate potential risk genes which 
may be present in those developing PSD. The identification of these genes 
would allow for more targeted analysis of proteins, if a particular mutation is 
identified, for example, tracing the regulated protein further downstream may 
highlight previously overlooked proteins which could play a crucial role in PSD 
development. Indeed it may be possible to uncover a common pathway which is 
affected by a range of disease types, from vascular pathology, AD, to autism, 
and through to schizophrenia and depression. If a common gateway protein can 
be discovered it may open the way for targeted therapies and drug treatments, 
open up the understanding between the different disease groups, and help take 
the mystery out of varying types of dementia. 
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 Conclusion 
This study has highlighted several novel findings which outline potential 
pathological substrates which may ultimately result in dementia post-stroke 
(Foster et al. 2014). Pyramidal neuronal volumes were reduced in the dlPFC in 
PSD and other demented groups in both layers III and V when compared to 
PSND and aged-controls. These findings provide an insight into the potential 
mechanism responsible for the disruption of the prefrontal circuits which 
ultimately leads to executive dysfunctions within demented subjects. The lack of 
relationship between neuron volume changes and Alzheimer type pathology 
suggests an underlying vascular basis for cognitive dysfunction. The presence 
of atrophied neurons and lack of neuronal density changes suggest neurons in 
demented subjects are not lost, but dysfunctional, leaving some potential 
opportunity for future therapeutic targets. 
Cortical glial cell densities were not significantly altered.  This suggests that 
dementia resulting after stroke is a largely neuronal phenomenon. However, 
previous literature is in contradiction to this finding and it remains likely that glial 
cells play a central role in this disease state. Though 3D stereology is perhaps 
the best method for assessing the density of glial cells, further investigation with 
immunohistochemical and protein based analysis is required to further clarify 
the role of glial cells within PSD. Astrocytes have been reported to express 
large numbers of processes which interact with neurons, following a stroke, as 
well as having an important role in controlling glutamate regulation (Nedergaard 
and Dirnagl 2005). It will be necessary to understand the role this processes 
may have in the development of PSD. 
Although some findings alluded to specific relationships between WM pathology 
in some disease states, it is not possible to link cognitive dysfunction and 
pyramidal neuronal volume changes in PSD. These data suggests PSD may be 
centred around pyramidal neuronal atrophy, with decreased neuronal 
connections potentially playing a large part in cognitive dysfunction following 
stroke. 
Future studies will need to investigate the mechanisms which result in individual 
pyramidal neuron dysfunction between disease groups and to investigate 
whether these mechanisms can be suitable targets for therapy. Additionally, 
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further work into the dendritic arbour with the dlPFC, and its association to 
pyramidal neuron volume may be crucial to understanding PSD. 
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Chapter 8. Appendix 
 Golgi staining  
 
 
Figure 8-2 demonstrating the clusterting nature of the golgi-kopsh technique. The 
section had been counterstained with nissl to demonstrate a specific sub-
population of pyramidal neurons within layer III of the dlPFC have been unaffected 
by the stain. Scale bar = 100μm. 
 
Figure 8-1 demonstrating the clustering nature of the Golgi-Kopsch 
technique on pyramidal neurons within layer III the dlPFC. Scale bar = 
100μm. 
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Figure 8-3 showing the Golgi techniques uniform staining of blood vessels within the frontal lobe. 
Scale bar = 100μm. 
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 Frontotemporal Dementia (FTD) 
 
Frontotemporal dementia is the second most common, early onset, dementia 
characterised by progressive behavioural changes, frontal executive 
dysfunction and language deficits (Ratnavalli et al. 2002). Frontotemporal 
dementia (FTD) is widely used to describe the clinical onset and 
characterisation of the disease, with the term frontotemporal lobar degeneration 
(FLTD) used to describe the pathological presentation and diagnosis. The 
disease classically presents with frontal and temporal atrophy and 
hypometabolism which can often be detected via MRI scans (Ratnavalli et al. 
2002; Pickering-Brown 2007, 2010).  
Relatively few studies have been conducted into the prevalence of 
frontotemporal dementia but it is thought that it affects between 15-22 per 
100,000 of the population aged between 45-64 (half the prevalence of AD in 
this age group) with an average age of onset between 50-60 years of age 
(Ratnavalli et al. 2002; Harvey et al. 2003; Borroni et al. 2010). 
Several variants for FTD exist: The behavioural variant (bvFTD), language or 
semantic variant (SD), and progressive non-fluent aphasia variant (PNFA). The 
progression of each FTD dementia presents with an insidious onset followed by 
a gradual decline in cognitive faculties with individual clinical syndrome 
indicative of different topographical cortical involvement (Ratnavalli et al. 2002; 
Pickering-Brown 2010): bvFTD with associated with symmetrical frontal and 
anterior temporal atrophy, PNFA with left frontotemporal dysfunction, and SD 
with anterior temporal deficits. The majority of FTD symptoms resolve around 
frontal lobe dysfunction. Despite this heterogeneity of cortical involvement each 
variant shares some similar symptoms: emotional blunting, apathy, loss of 
empathy and selfishness are symptoms shared by all variants though are 
indicative of bvFTC (Bathgate et al. 2001) making FTD an ideal clinical example 
of frontal lobe syndrome. Apathy has been associated with involvement of the 
anterior cingulate cortex (ACC), dis-inhibition with the orbitofrontal cortex 
(OFC), and executive dysfunction with the dorsolateral prefrontal cortex (dlPFC) 
(Huey et al. 2009) suggesting involvement of the three frontal cortical circuits. 
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When Theory of Mind (ToM) tasks are used to assess social cognition and 
empathy of early stage FTD, the test is thought to focus on deficits largely within 
the OFC. As the disease progresses additional frontal areas become 
increasingly involved. In late stage FTD ToM scores correlate with executive 
function deficits indicating increased pathology within the dlPFC (Libon et al. 
2009; Eslinger et al. 2007).  
MRI studies have shown involvement of both the frontal (including the Prefrontal 
circuits) and paralimbic areas in bvFTD with pathological studies finding high 
burdens of Tau in these areas(Pickering-Brown 2010). This atrophy spreads to 
more lateral frontal, more postural temporal and more anterior parietal areas as 
the disease progresses, though the tauopathy variant of FTD appear more 
symmetrical and is restricted to the frontal and temporal lobes (Whitwell et al. 
2007; Whitwell et al. 2009).  
FTD offers a useful model for investigating neuronal networks in the frontal 
lobes. Underlying pathologies of FTD are heterogeneous though a third of FTD 
suffers possess an autosomal dominant mutation (Pickering-Brown 2007). 
Mutations in the gene controlling microtubule-associated protein tau (MAPT) is 
thought to account for a high proportion of cases in which hyperphosphorylated 
tau builds up inside neurons of the frontal lobe, echoing AD (Pickering-Brown 
2010, 2007). Patients with MAPT mutations frequently present with the bvFTD 
variant of the disease with executive dysfunction and episodic memory deficits 
(Pickering-Brown et al. 2008; Pickering-Brown 2010).  
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 Three dimensional stereological analysis of the dlPFC in FTD 
subjects 
 
There were no apparent changes in pyramidal neuron densities in either layers 
III or V, separately or, when compared to control cases (p = 0.514, and p = 
0.433, respectively). In addition no significant changes in pyramidal neuronal 
volumes were detected when compared to control groups (p = 0.151, p = 0.151, 
respectively). However, when layer III and V were combined, total pyramidal 
neuronal volumes was significantly lower in FTD cases when compared to 
control cases (p = 0.044). Total pyramidal neuronal densities were not 
significantly different between the two groups (p = 0.708) (Figure 8-4, Figure 
8-5).   
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Figure 8-5 showing combined layer III and V pyramidal neuronal volume in the dlPFC in FTD subjects. * = 
significant compared to controls (p < 0.044). 
Figure 8-4 showing (a) pyramidal neuronal volumes, and b) pyramidal neuron densities in the 
dlPFC of FTD subjects in both layers III and V. 
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 Additional analysis of the FTD subjects  
The reduction in pyramidal neuronal volumes appeared to be a shared trait 
between several different types of dementia. It was unexpected to uncover such 
homogenous findings in range of disease states; from largely vascular based 
pathologies, to those suffering from the neurodegenerative effects of amyloid 
and tau. By analysing the dlPFC of a disease group characterised by frontal 
lobe tau-based pathology, perhaps some light could be shed on the direct effect 
of tau on pyramidal neurons. Interestingly, FTD cases showed no significant 
difference in pyramidal neuron densities when compared to controls, following 
the same pattern as other disease groups. Perhaps surprisingly, no significant 
difference was detected between neuronal volumes in the dlPFC of FTD cases 
when compared to controls. With FTD characterised by high levels of frontal 
pathology it was hypothesised that pyramidal neuronal volume would be 
significantly reduced, as those in other disease groups. This finding could 
suggest that pure tauopathies such as that suffered by this FTD cohort does not 
affect pyramidal neurons as those of vascular pathologies, however if this was 
the case one would expect similar findings in the dlPFC of AD cases, which was 
not found. It is therefore likely that this particular group was underpowered to 
detect significance. A total of 4 groups were analysed, compared to the 10 or 
more analysed in each of the other groups. This point is supported by the fact 
that when layers III and V are combined, effectively increasing the amount of 
neurons being analysed, FTD shows significantly lower volumes when 
compared to controls cases. 
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